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ABSTRACT 
 
Rheumatoid arthritis (RA) is the most common inflammatory arthritis and patients require 
appropriate information and education.  Cardiovascular disease (CVD) accounts for 50% of its 
mortality, due to both clustering of traditional risk factors and the novel role of systemic 
inflammation.  However, there are no educational materials about CVD designed specifically for 
people with RA; existing generic resources are likely to be inadequate as their advice is not set in 
the context of the physical and psychosocial constraints of RA.  Using a recommended 
framework for the design of complex interventions, qualitative stakeholder research was 
undertaken which informed the design of an eight week cognitive-behavioural education 
programme, underpinned by social cognition models and stages of change theory.  An 
appropriate outcome questionnaire was developed and psychometrically validated. A randomised 
controlled trial of this programme showed that, compared to controls, patients achieved 
significant improvements in knowledge, which translated into changing their psychological 
views, particularly intentions, to make behaviour change and, in turn, an improvement in diastolic 
blood pressure was observed. The implications of this study are that patient education has a 
significant role to play in CVD risk factor modification for patients with RA and furthermore a 
theoretically-driven process of developing patient education materials is the approach most likely 
to yield dividends. 
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CHAPTER 1: GENERAL INTRODUCTION; RHEUMATOID ARTHRITIS 
 
Rheumatoid arthritis (RA) is thought to have emerged as a condition in Europe in the early 19th 
century, although the disease had been prevalent for thousands of years in North America (1).  
Today, rheumatoid arthritis (RA) is the most common chronic inflammatory polyarthritis (1). 
 
Epidemiology 
 
Established in 1989, the Norfolk Arthritis Register recruited and followed up all adults presenting 
to primary care with recent onset inflammatory polyarthritis.  This cohort, recruited from a well-
defined population, revealed an annual incidence of RA of 36/100000 in women and 14/100000 
in men.  The peak age of onset in women was aged 65-74, whereas in men it was aged over 75 
(2).   A prevalence study, using the same cohort, showed the overall prevalence of RA in the 
adult population to be 0.8%; sex-specific prevalence estimates are 1.1% in women and 0.4% in 
men (3).  Geographically, interesting variations in occurrence of RA have been observed: South 
European countries possibly have lower incidence rates of RA than north European and North 
American countries (1;4).  Differences in genetic or environmental (for example, the 
Mediterranean diet) factors between these populations may explain these differences.  In 
developing countries, a lower prevalence of RA has been observed; this may reflect the shorter 
life expectancy or poorer access to medical care in developing countries (4).  Other studies have 
suggested that RA may be related to an industrialized lifestyle (1). 
 
Clinical features 
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RA is an inflammatory arthritis, characterized by synovial inflammation which manifests 
clinically as joint swelling, tenderness, warmth and functional loss.    The 1987 American 
Rheumatism Association (now the American College of Rheumatology (ACR)) classification 
criteria for RA require four or more of the following criteria: morning stiffness, arthritis of at 
least three or more joints for at least six weeks, arthritis of hand joints for at least six weeks, 
symmetrical involvement of joints, presence of rheumatoid nodules, positive rheumatoid factor, 
or typical radiographical changes (5).  Uncontrolled articular inflammation will result in bony 
erosions and subsequent joint damage, deformity and disability (6). Furthermore, RA is a 
multisystem disease; extra articular manifestations include rheumatoid nodules or rheumatoid 
vasculitis as well as organ specific involvement; rheumatoid lung disease includes pulmonary 
effusions, fibrosis or nodules, cardiac involvement includes pericarditis or conduction defects, 
ocular involvement includes episcleritis and scleritis as well as sicca symptoms with secondary 
Sjogrens syndrome, neurological involvement includes peripheral nerve entrapment syndromes, 
mononeuritis multiplex, peripheral neuropathy or cord compression.  Longstanding uncontrolled 
inflammation may cause renal amyloidosis (6).   
  
Aetiology 
 
The exact aetiology of RA is not clear but is likely to be multifactorial.  Determinants of the onset 
of RA include both genetic and environmental, such that when a genetically predisposed 
individual is exposed to certain environmental/host antigens an immune response occurs (7). 
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Clinical observation reveals a tendency for RA to run in families and indeed genetic factors are 
thought to explain 60% of the susceptibility to RA (8).  Multiple genetic factors are responsible.  
The major histocompatibility complex (MHC) is a large genomic region on chromosome 6 that 
encodes MHC molecules; class II MHC molecules are expressed on most immune system cells, 
specifically antigen presenting cells.  The best known genes in this MHC region are the human 
leucocyte antigen (HLA) genes.  Many alleles at the HLA locus DRB1 have been found to 
associate with the development and severity of RA, including HLA-DR4, the first allele to be 
associated with RA, discovered in 1978 (1).  These alleles share an amino acid sequence in the 
third hypervariable region of their DRB1 chain, and this is referred to as the shared epitope 
hypothesis (7).  In particular, the allele HLA-DRB1*0404 seems to be associated with the 
susceptibility of developing RA whereas only a modest association was found between the 
presence of other shared epitope alleles and recent onset inflammatory polyarthritis (9).  The 
other major susceptibility locus is the PTPN22 gene (10).  More recently other genetic loci have 
been implicated; a single nucleotide polymorphism in the STAT4 on chromosome 2 (11), the 
region of chromosome 9 containing TRAF1 and C5 genes (14) and a locus lying between the 
OLIG3 and TNFAIP3 genes on chromosome 6 (13) have been to found to associate with an 
increased risk of RA. 
 
Many environmental factors have been shown to have an aetiological role, including hormonal 
factors, lifestyle factors and the role of infection (1).  The incidence is higher in women; use of 
the oral contraceptive pill protects against the development of RA whereas subfertility and an 
adverse pregnancy outcome are associated with an increased risk of developing RA (14).  
Multiple studies have shown a positive association between cigarette smoking and RA (15;16), 
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and seropositive RA (15;17), including studies of recent onset inflammatory arthritis (18).  Only 
moderate intensity smoking was required to confer such risk and this risk remained for many 
years after smoking cessation (15).  An association between obesity and the development of RA 
has been observed (18).  Diet may also play a role in the aetiology of RA (19). There is some 
evidence that those consuming a low daily intake of antioxidants, such as vitamin C (20) or 
carotenoids, particularly β cryptoxanthin (21), were at greater risk of subsequently developing 
inflammatory polyarthritis; synovial inflammation is mediated by free radical activity, hence 
antioxidants, which scavenge reactive oxygen radicals and protect against oxidative damage 
would have a protective effect.  Red meat is a source of arachidonic acid, involved in the 
production of eicosanoids which can have proinflammatory activity (22).  Oils, such as olive oil 
or oil-rich fish may also have a protective effect via their anti-inflammatory properties; certainly, 
RA is less common in Southern Mediterranean countries where the diet is characterized by high 
quantities of fruit and vegetables, olive oil and oil-rich fish (19).   
 
Other environmental factors which may trigger the development of RA include a recent infection, 
with Epstein-Barr virus possibly implicated, (23) or immunization (24).  A history of a blood 
transfusion associates with developing RA (18).   
 
Predictors of severe rheumatoid disease 
 
The clinical course of RA may vary across a wide spectrum from mild to severe disease.   
As well as determining susceptibility, patients who are positive for the shared epitope are at high 
risk of severe RA (13;25).  Environmental determinants of poor outcome include older age at 
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onset (26) and female gender as well as smoking.  Smoking is associated with rheumatoid factor 
positivity and more severe rheumatoid disease (27) as well as a greater likelihood of developing 
extra-articular disease, such as rheumatoid nodules or vasculitis (28).  Disease-specific factors 
and measures of inflammation which have been shown to associate with adverse radiological 
outcome include autoantibody status (anti- cyclic citrullinated peptide (CCP) antibodies are 
associated with the development and extent of erosions (29)) as well as combined measures such 
as swelling of at least two large joints, disease duration of more than three months and a positive 
rheumatoid factor (30) or Larsen erosion score and swollen joint score (31).   
 
Treatment 
 
Perhaps the greatest determinant of RA outcome is treatment.  Historically, treatment was 
initially with non-steroidal anti-inflammatory drugs, progressing to sequential monotherapy with 
disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate or sulphasalazine, 
once erosions had developed (32).  However, since the early 1990s, when it became apparent that 
erosions and damage developed early in the disease course, treatment strategies have radically 
changed; the emphasis is now on early and aggressive treatment to achieve tight control of RA 
(33;34) . Initial combination DMARD therapy, rather than sequential monotherapy (35) or step-
up combination therapy (36) has been shown to result in significantly better outcomes. 
Corticosteroids are used to rapidly treat active disease, both early in the disease course, during a 
flare or as bridging therapy between DMARDs; occasionally corticosteroids are used long-term 
at a low dose if DMARDs are contraindicated (37).  The advent of anti-tumour necrosis factor 
alpha therapy (infliximab, etanercept and adalimumab) further revolutionized outcomes being 
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effective in patients who had not responded to traditional DMARDs, both in terms of improving 
symptoms and signs of RA as well as inhibiting structural damage (34).  Further biologic 
treatments have been licensed and the goal of treatment is remission. 
 
Inevitably, treatments may be associated with side-effects.  Non-steroidal anti-inflammatory 
drugs may cause upper gastrointestinal side-effects, and both these, as well as cyclo-oxygenase II 
inhibitors (coxibs) may induce or aggravate hypertension (38;39) as well as increase a person’s 
risk of cardiovascular disease (CVD) (40).  Furthermore, hypertension may also be a side-effect 
of the DMARDs leflunomide or ciclosporin or due to treatment with corticosteroids (38).  
Different DMARD treatments may also be associated with some of the following; rashes, nausea, 
diarrhoea, bone marrow suppression, renal or hepatic toxicity, pulmonary toxicity and others 
(41).  Other side-effects of corticosteroids include increased appetite with consequent weight 
gain, diabetes, osteoporosis, thinning of the skin and easy bruising and cataracts (42).  Biologic 
treatments associate with an increased risk of infection, demyelinating disorders, cardiac failure 
and although there is a theoretical risk of malignancy there is no evidence of an increased risk 
over that which would be expected of the general RA population (43).  
 
Importantly, medical treatments for RA must be provided within a multidisciplinary team setting 
whereby nurse specialists provide drug counselling and monitoring, occupational therapists 
provide joint protection advice, splints, assistive equipment, podiatrists assess for biomechanical 
foot deformities and provide insoles and shoes and physiotherapists improve muscle strength, 
manage pain, improve function and promote exercise (37;40).  Indeed exercise is particularly 
important for people with RA as it helps reduce RA-related inflammation and improves function, 
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pain, mobility and psychological well-being (44).  All these health professionals may contribute 
to patient education programmes which can promote self-management, positive health behaviours 
and concordance between health professionals and  patients (45). 
 
Co-morbidity 
 
Co-morbidities associated with RA include cardiovascular disease (CVD), infection, malignancy, 
depression, osteoporosis, lung disease and gastrointestinal ulceration (46).  These are not only 
serious but also frequent conditions; on average, a person with established RA has two or more 
such co-morbidities and these may have a significant effect on quality of life (47), disability and 
mortality (46;48).  Different comorbid conditions influence the different outcomes differently; for 
example, depression most commonly associates with work disability, whereas CVD and lung 
disease associate with mortality and hospitalization (46).  Indeed CVD accounts for about 50% of 
the excess mortality in RA (49).  Management of a patient with RA must therefore include 
screening, identifying, investigating and treating these comorbid conditions.   
 
Prognosis  
 
a) Function 
The self-report Health Assessment Questionnaire is the primary measure of functional ability in 
RA (50).  HAQ scores range from 0 (no disability) to 3 (severe disability).  A score of greater 
than one suggests a person is functionally disabled.  In a primary care based cohort, 29% of 
patients had a HAQ score greater than one, one year after presentation with inflammatory arthritis 
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(51).  Five years after presentation, 47% of patients in the same cohort had a HAQ score greater 
than 1 (52).  Thus, a conflict can be seen between the recommendation for people with RA to 
exercise and the practical issues involved.  Other measures of functional disability include use of 
home adaptations and/or wheelchair use by 10% of patients at 5 years (53), 58% of RA patients 
reported some limitation on their driving ability (54) and a considerable number of men and 
women report trouble with their joints during sexual activities (55).   
 
b) Employment 
Work disability is an important outcome for people with RA of working age.  Two English 
cohorts of patients with early RA have both shown that, at five year follow up, one third of 
(previously gainfully employed) people with RA had stopped working because of their RA (56) 
or ill health (57).  Manual work (56) and high baseline Health Assessment Questionnaire (HAQ) 
scores (56;57) were predictors of work disability.  Other studies in the USA and northern Europe 
have reported five year work disability rates between 29-50% (53).   
 
c) Mortality 
RA is associated with reduced life expectancy, and this has been noted in studies since the 1950’s 
(58).  A review of the main mortality studies since 1990 reveals a significant increase in 
mortality; this excess mortality is apparent within the first few years of the disease and increases 
with disease duration (58;59).  Examining cause-specific mortality reveals that most of the excess 
deaths are attributable to infection, cardiovascular disease and respiratory disease.  Non-
Hodgkins lymphoma and lung cancer also explain some of the excess mortality (58).   
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CHAPTER 2 (PART 1): GENERAL INTRODUCTION;  
CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS 
 
Medical care of patients with rheumatoid arthritis (RA) involves managing their joint disease but 
also addressing the co-morbidities associated with RA, such as osteoporosis, depression, 
cardiovascular disease (CVD) and malignancy (1).  Such co-morbidities may have a significant 
effect on quality of life, work disability or mortality (1).  Indeed, the increased mortality of RA 
(2) is most commonly due to co-morbidities such as infection, CVD or respiratory disease (3);  in 
particular, CVD accounts for almost 50% of the excess mortality (3;4).  Given the frequency and 
impact of CVD co-morbidity in RA, this chapter focuses exclusively on this.  We first summarise 
the epidemiological evidence for increased CVD morbidity and mortality in patients with 
established RA and discuss possible mechanisms for increased CVD risk in this group of 
patients.  We then focus on the evidence for concurrent CVD co-morbidity early in the RA 
disease process: we consider cardiovascular risk prior to the onset of RA, examine shared risk 
factors or predictors for both RA and CVD and discuss an overall framework of incorporating 
these into the current drive for early diagnosis and management of RA. 
  
Cardiovascular disease co-morbidity in established RA 
 
Rheumatoid arthritis is associated with heart disease.  Pericardial disease, including pericarditis 
and pericardial effusions, have long been identified as extra-articular manifestations of RA and 
were first described by Charcot in 1881 (5).  The true prevalence of pericardial disease in 
association with RA is difficult to determine as it often remains clinically silent.  
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Echocardiographic studies in established cohorts of RA patients have reported prevalence rates of 
pericardial disease between 1-30%.  Little is known about the prevalence of pericardial 
inflammation in the early years of RA.  In addition myocardial and endocardial disease have been 
described in association with RA.  Again, these cardiovascular complications rarely cause clinical 
symptoms and are often identified as coincidental finding on autopsy or imaging studies. Whilst 
extra-articular RA is associated with mortality (6), this does not appear to be due to 
haemodynamic consequences of structural rheumatoid cardiovascular disease. 
 
Many epidemiological studies have examined cardiovascular mortality in longitudinal cohorts of 
RA patients (tabulated in (7) and (8), also (9;10)).    Overall, the consensus is that CVD mortality 
is increased in RA, with standardized mortality rates (SMR) of between 1.13 and 5.15 (11).  
Studies that have explored cause-specific mortality in detail have highlighted that much of the 
excess CVD mortality is due to accelerated atherosclerotic CVD (12).  As expected, there is also 
evidence for increased CVD morbidity, namely myocardial infarction (MI), congestive heart 
failure (CHF) and stroke, in patients with RA (13-15), with their risk for MI or CVA being at 
least double that of the general population (15).  The relative risk for a CVD event is greatest in 
young adults, although in absolute terms the greatest difference in rates of CVD events was in 
older adults because CVD prevalence increases with age (15). 
 
Not only is ischaemic heart disease (IHD) more prevalent in patients with RA, but also the 
clinical presentation of IHD appears to be different to that in the general population. Symptoms 
of IHD may be silent (16), or angina may be unrecognized medically (17).  Patients with RA are 
less likely to report chest pain or symptoms of angina associated with ambulatory ECG evidence 
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of cardiac ischaemia, than  patients without RA (18). Comparing  clinical presentations in RA 
patients diagnosed with an acute coronary syndrome with age and sex matched non-rheumatoid 
controls showed that RA patients were less likely to present with chest pain and more likely to 
have an atypical presentation such as collapse or dyspnoea (19).  Other studies have demonstrated 
that patients with RA are more likely to experience unrecognized MIs or sudden death than non-
RA patients (14).  The Stockport inception cohort study in England in the 1980s and 1990s 
supports this: although the SMR for CVD was increased in this RA cohort, admissions to hospital 
with a CVD event were not, suggesting RA patients were less likely to seek hospital care, due to 
any of the above reasons (9).  After an index CVD event, Douglas et al. found that patients with 
RA were more likely to experience recurrent cardiac events or death (19).  The Stockport 
inception cohort revealed that, of those RA patients admitted to hospital, 70% only had one 
admission with a CVD event during the period of follow up (9), which may also suggest that 
patients with RA were more likely to die during or after their first cardiovascular admission; 
others have also observed an increased 30-day mortality after a CVD event (including both MI 
and stroke) (15;20).  Therefore, overall, not only is CVD more prevalent in RA but it also 
associates with a higher case fatality (20;21). 
 
a) Why is cardiovascular disease increased in patients with RA? 
Accelerated atherosclerosis in RA (8) is thought to be due to the interplay between classical risk 
factors for CVD, which may be adversely affected by RA, as well as novel risk factors, 
particularly systemic inflammation (11;22).  This is summarized in Figure 1.   
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Figure 1; Pathways leading to CVD in RA showing the role of traditional and classical risk factors  
 
RhF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide antibodies; NSAIDs = non steroidal anti-inflammatory drugs; COX II inhibitors = cyclo-
oxygenase II inhibitors; DMARDs = disease modifying anti rheumatic drugs; DM = diabetes mellitus 
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i) Classical CVD risk factors   
Classical risk factors, such as hypertension, dyslipidaemia, insulin resistance and obesity, appear 
to cluster in patients with RA and are highly prevalent (23).  A systematic review of hypertension 
in RA suggests the prevalence lies between 51.7% and 73% and discusses how factors pertinent 
to RA, namely, systemic inflammation, physical inactivity, obesity and medications (non-
steroidal anti-inflammatory drugs, cyclo-oxygenase II inhibitors, glucocorticoid and disease 
modifying drugs such as leflunomide or cyclosporin) may all contribute to the high rates and poor 
control of hypertension observed in RA (24).   
 
Dyslipidaemia in RA seems to relate to the inflammatory disease activity; greater disease activity 
associates with lower total cholesterol levels and particularly depressed levels of high density 
lipoprotein (HDL) leading to an unfavourable atherogenic index (25;26).  Pro-inflammatory 
cytokines, specifically tumour necrosis factor alpha (TNFα),  may explain this finding (25). 
Treatment of inflammatory joint disease may therefore lead to a rise in total cholesterol, but the 
disproportionate rise in HDL cholesterol leads to improvement in the atherogenic index (27).  
The effects of anti-TNF medications on dyslipidaemia have been explored in several studies. 
These have reported varied effects with some studies demonstrating improvement in 
dyslipidaemia whilst others have reported a more atherogenic lipid profile after treatment with 
prolonged TNF blockade (28). Pro-inflammatory cytokines also mediate the development of 
rheumatoid cachexia (29), the involuntary loss of skeletal muscle with progressively increased fat 
mass.  As a result, a patient with RA may have a higher percentage body fat when compared to a 
healthy control with the same body mass index; this increased body fat may contribute to the 
development of CVD (30).  Whilst the literature examining the prevalence of diabetes in RA is 
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conflicting (31), there is certainly evidence of insulin resistance associated with RA (32;33), 
related to systemic inflammation or glucocorticoid therapy (31).  Controlling systemic 
inflammation, using prednisolone or disease modifying drugs and dietary advice, has been shown 
to lead to improvements in insulin resistance (33).       
 
Smoking is common in RA and whilst it does not seem to confer the same relative risk of CVD 
events when compared to the general population (34), cigarette smoking certainly associates with 
more severe RA and with rheumatoid factor positive status; both these factors independently 
associate with increased CVD mortality (34).  Patients with RA may be at greater risk of physical 
inactivity if they have uncontrolled rheumatoid disease and/or chronic joint damage.  Physical 
inactivity in the general population has been shown to associate with an increased prevalence of 
risk factors for CVD such as increased body mass index, central adiposity, systolic hypertension 
and dyslipidaemia (35); these risk factors can however be modified by regular exercise (36).   
 
Despite the adverse effects that RA and systemic inflammation has on these classical CVD risk 
factors, analysis controlling for these risk factors still leaves RA patients with a twofold greater 
risk for IHD than controls (37).  The Rochester, Minnesota, incidence cohort of RA patients 
demonstrated that the prevalence and incidence of traditional CVD risk factors was similar 
between RA patients and age and gender matched non-RA subjects. However, some traditional 
risk factors including male gender, smoking and prior cardiovascular disease, appear to have a 
weaker association with CVD events in patients with RA (38). Thus novel cardiovascular factors 
are thought to play a pivotal role in the CVD morbidity and mortality associated with RA.  These 
novel risk factors relate to the vascular and metabolic effects of systemic inflammation. 
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ii) Novel CVD risk factors 
Understanding the vascular effects of systemic inflammation requires an appreciation that 
atherosclerosis per se is an inflammatory disease (39).  Factors such as free radicals from 
cigarette smoking, hypertension and diabetes mellitus, alongside high levels of low density 
lipoprotein cause endothelial cell dysfunction which sets up a chronic inflammatory process in 
the artery with procoagulant properties and migration of inflammatory cells .  Fatty streaks, 
consisting of foam cells and T lymphocytes and migrated smooth muscle cells, progress to 
intermediate and advanced lesions, ultimately developing a fibrous cap walling off the lesion, 
which has the potential to occlude the arterial lumen (39).  Local inflammatory phenomena not 
only drive this development of the atherosclerotic plaque but also their rupture and subsequent 
clot formation that causes the acute events (8).  Further evidence supporting the central role that 
inflammation plays in the pathogenesis of atherosclerosis is provided from studies in the general 
population using high sensitivity assays of CRP (hsCRP); high hsCRP values have been shown to 
be a moderate predictor of future coronary heart disease (40).  Such high hsCRP values would be 
considered normal by routine assays suggesting that low-grade systemic inflammation is 
sufficient to potentiate atherosclerosis (8).  Thus it has been argued that high levels of systemic 
inflammation, as seen in RA, are pivotal to the accelerated atherosclerosis observed in RA 
(37;41).  Potential mechanisms for inflammation induced vascular damage include,  a) the 
development of endothelial dysfunction via excessive production of nitric oxide, b) activation of 
the coagulation cascade and c) induction of secondary dyslipidaemia with an atherogenic profile 
(42). In support of this hypothesis that systemic inflammation promotes atherosclerosis in RA are 
observational studies and reviews of the literature that show reduced CVD event rates with use of 
DMARDs (43;44)  and anti TNF agents (45;46).  
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Other novel risk factors for atherosclerosis include hyperhomocystinaemia, as well as adversely 
effected thrombotic markers (7).  Hyperhomocystinaemia has been shown to be an independent 
risk factor for atherosclerotic disease (7;11) with higher levels observed in patients with RA and 
significantly higher levels in patients with RA and CVD (7).  Methotrexate may increase 
homocysteine levels but this needs to be balanced against its effectiveness in reducing systemic 
inflammation (11).  Thrombotic markers, such as elevated fibrinogen or factors that impair 
fibrinolysis, are independent predictors of CVD mortality and higher levels have been found in 
patients with RA compared with healthy controls (7;47).     
 
Cardiovascular disease in early RA 
 
a) What is early RA? 
The definition of early RA is not always easy as the 1987 ACR classification criteria were 
derived from study of patients with established disease (48) and have not been found to be 
discriminatory at symptom onset (49).  For patients presenting with recent-onset inflammatory 
polyarthritis (IP) or undifferentiated inflammatory arthritis, it has been suggested that the patient 
should not be immediately classified but observed (50). Experience in early arthritis clinics, such 
as the Leiden early arthritis clinic where patients whose symptoms are for less than two years 
duration are intensively investigated and followed up (51), suggests that a third of such patients 
remit, a third of patients become diagnosed with RA and the others remain undifferentiated or 
develop other rheumatological diagnoses (52;53).  Thus, while some disagree with the concept of 
‘early RA’ (preferring either undifferentiated inflammatory arthritis or established RA) (50) 
others find it helpful to emphasise the need for speedy referral to secondary care, prompt 
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diagnosis and intervention to suppress inflammation (54).  In practice, randomized clinical trials 
use a definition of disease duration of either less than two (55) or three (52) years to describe 
patients with early RA . 
 
b) What is the evidence for CVD co-morbidity in patients with early RA? 
In patients with early RA, there is both surrogate evidence for co-morbid CVD (for example, 
carotid intima media thickness studies) as well as evidence from cohort studies of patients with 
recent-onset inflammatory polyarthritis.  This evidence is summarized in Tables 1 and 2.  
 
Carotid intima media thickness (cIMT) measured using ultrasound shows early subclinical 
atherosclerosis and has been shown to predict CVD events in the general population (56).  In 
patients with established RA, case-control cross sectional studies have also shown increased 
cIMT which independently associates with duration and severity of RA (57), and which is 
significantly reduced following anti-TNF therapy (58), although no long term studies exist to 
show whether cIMT can predict future CVD events in RA (56).  Hannawi et al examined cIMT in 
40 patients with early RA (less than 12 months disease duration) and in 40 control patients 
matched for age, sex and CVD risk factors (59).  Patients presenting with early RA were found to 
have both increased cIMT as well as increased carotid arterial plaque indicating an increased 
atherosclerotic burden (59).  Similarly, Georgiadis et al examined cIMT in 40 non-smoking 
patients with early RA (again, defining this as disease duration less than one year) and no past 
medical history of a CVD event.  This case-control study involved age and sex matched controls 
with no history of CVD events.  At baseline, patients with early RA had statistically significant
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Table 1: Surrogate evidence for CVD in early RA 
 
Author Year  
published 
Type of 
study 
Number of 
subjects 
Definition of 
early RA 
Surrogate marker for 
CVD used 
Result 
Georgiadis et al 
(60) 
2008 Case- 
control 
40 ERA 
45 controls 
Disease 
duration < 1 
year 
cIMT 
carotid plaque 
- cIMT statistically higher in ERA subjects than 
controls 
- No difference in prevalence of carotid plaque 
between groups 
Hannawi et al (59) 2007 Case- 
control 
40 ERA 
40 controls 
Disease 
duration < 1 
year 
cIMT 
carotid plaque 
- cIMT statistically higher in ERA subjects than 
controls 
- Statistically increased prevalence of carotid 
atherosclerotic plaque in RA patients compared to 
controls 
Park et al (61) 2002 Case-
control 
53 RA  
(unspecified 
how many had 
early RA) 
53 controls 
Disease 
duration < 1 
year 
cIMT - cIMT greater in patients with RA than controls; 
those with ERA had greater cIMT than controls, but 
not as great as those with RA of a longer duration 
Kumeda et a (57) 2002 Case 
control 
138 RA 
94 controls 
Not 
specified 
cIMT 
carotid and femoral 
artery plaque 
- cIMT significantly higher in RA patients than 
controls; this associated with the duration of RA 
- No difference in the prevalence of carotid or 
femoral artery plaque between groups 
Chung et al (62) 2005 Case-
control 
70 ERA 
71 established 
RA 
86 controls 
Disease 
duration < 5 
years 
Electron beam CT to 
measure coronary 
calcification 
- coronary calcification significantly increased in 
patients with established RA, compared to controls, 
but not in those with ERA 
Bergholm et al 
(63) 
2002 Case-
control 
10 ERA 
33 controls 
Disease 
duration < 
18 months 
Vasodilatory 
responses to intra-
arterial endothelium-
dependent and -
independent 
vasodilators 
- significantly impaired vasodilatory responses in 
ERA patients compared with controls 
RA = rheumatoid arthritis; ERA = early rheumatoid arthritis; cIMT = carotid intima media thickness; CT = computed tomography 
 
 
24 
 
Table 2: Epidemiological evidence for CVD in early RA  
 
Author Year  
published 
Country Type of 
study 
Criteria to enter 
cohort 
Number of 
subjects in 
cohort 
Length of 
follow up 
Result 
Goodson et al 
(64) 
2002 Norfolk,  
England 
Inception 
cohort 
Inflammatory 
polyarthritis (2 
or more swollen 
joints for four 
weeks or longer) 
1,236 Median 6.9 
years 
Overall no increase in 
mortality; those 
seropositive RA 
patients however had an 
increased risk of death 
from all causes, and 
CVD was the most 
common cause of death 
(SMR for CVD was 
1.34 for men and 2.02 
for women) 
Young et al 
(65) 
2007 Multi-centre,  
England 
Inception 
cohort 
RA symptoms 
less than 2 years 
1,429 Median 9.1 
years 
Survival was lower than 
expected in the first 7 
years from diagnosis.  
IHD was the most 
common cause of death 
(SMR 1.49).  
Maradit-
kremers et al 
(66) 
2008 Rochester, 
Minnesota, 
USA 
Incidence 
and 
control 
cohort 
First date of 
fulfilment of 4 
out of 7 ACR 
criteria 
553 RA 
subjects 
574 control 
subjects 
Median 
14.7 years 
for RA 
patients. 
Median 
16.1 years 
for non-RA 
subjects 
Ten years after a 
diagnosis of RA, the 
absolute CVD risk in 
RA patients was similar 
to non-RA subjects 5-10 
years older. 
RA = rheumatoid arthritis; CVD = cardiovascular disease; IHD = ischaemic heart disease; ACR = American College of Rheumatology 
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greater cIMTs’ than controls, although the prevalence of plaques in the carotid artery did not 
differ between the case and control groups.  After one year of treatment with methotrexate and 
prednisolone the cIMT in the patients with early RA had significantly decreased.  This change in 
cIMT was independently associated with changes in inflammatory markers and serum lipids (60).   
 
Another surrogate measure of vascular disease is evidence of endothelial dysfunction, which 
predates the development of atherosclerotic plaques. Endothelial dysfunction has been shown in 
patients with cardiac risk factors as well as in patients with rheumatoid arthritis and systemic 
lupus erythematosus (67;68).  In a small study of 10 patients with early RA (defined as disease 
duration less than 18 months) all disease modifying drug naïve, blunted vasodilatory responses 
were observed (both endothelial–dependent and endothelial–independent mechanisms) compared 
to control subjects without RA, suggesting early abnormalities in vascular function in patients 
with early RA (63).  There is, therefore, some evidence that the pathophysiological processes of 
vascular injury are occurring early in RA.  Not all studies, however, have shown this pattern (62) 
and clearly further research is required.   
 
Epidemiological studies also provide evidence of CVD co-morbidity occurring early in the 
disease process.  Between 1964 and 1978 a cohort of patients with established RA was developed 
and subjects were followed up until 1990.  The proportion of excess deaths due to CVD was not 
related to length of disease duration (2).  More recent epidemiological studies of patients with 
recent-onset inflammatory polyarthritis provide evidence of CVD co-morbidity occurring in early 
RA.  The Norfolk Arthritis Register (NOAR) is a primary care inception cohort of all patients 
aged over 16 years living in what was the former Norwich Health Authority, with two or more 
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swollen joints lasting for four weeks or longer with an onset since January 1st 1989 (69).  
Between 1990 and 1994 1,236 patients were recruited, followed up and tracked for notification of 
death.  It should be noted that this cohort therefore included patients subsequently diagnosed with 
RA, psoriatic arthritis, inflammatory polyarthritis or post-viral arthritis.  After a median follow up 
of 6.9 years, although mortality was not increased in this group of patients compared to annual 
death rates for the Norfolk population, those patients with seropositive inflammatory polyarthritis 
had an increased risk of death from all causes; the majority of this excess mortality was due to 
CVD, with SMRs for CVD being 1.34 for men and 2.02 for women (64).  Further analysis of this 
cohort has shown that this increased mortality from CVD in seropositive patients with early 
inflammatory arthritis was apparent after five years from symptom onset and was greatest in 
women younger than aged 55 years at symptom onset (70).  CRP level at baseline (41) and 
Health Assessment Questionnaire (HAQ) score after 1 year (71) are important independent 
predictors of CVD death in patients with new onset inflammatory polyarthritis.  Another multi-
centre inception cohort which has studied mortality in patients with early RA is the Early 
Rheumatoid Arthritis Study (ERAS).  Established in 1986, 1429 patients newly diagnosed with 
RA (less than 2 years of symptoms) were recruited.  Mortality was greater than expected for the 
first seven years of follow up, and the main cause for this increased mortality was ischaemic heart 
disease (IHD) (65).  In America, using the resources of the Rochester Epidemiology Project, 
newly diagnosed patients with RA were identified (defined as fulfilling 4 of the 7 ACR criteria).  
These patients, and non-RA matched controls, were followed longitudinally.  After 10 years, the 
absolute risk of a CVD event in a RA person was the same as a non-RA subject 5 to 10 years 
older (66).   
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Not only has CVD mortality been shown to be increased in early RA, but also CVD morbidity.  
Since 1985, Kroot et al. recruited 186 patients with recent onset RA (diagnosed less than 1 year) 
to participate in a prospective longitudinal cohort study.  After a mean period of follow up of 4.3 
years, 27% of patients reported a co-morbid condition, the most common of which was a 
cardiovascular condition, particularly hypertension or angina (72).    
 
These studies showing evidence of atherosclerosis or CVD mortality or morbidity in early RA 
support the hypothesis that atherosclerosis is part of the disease itself, exacerbated by adversely 
affected traditional CVD risk factors, rather than simply related to the cumulative side effects of 
medication and decreased physical mobility accrued with increasing disease duration (67).  
Therefore, interventions to address CVD risk factors should be implemented in patients with 
early RA.   This should include not only traditional risk factors, as has been recommended by the 
British Society for Rheumatology (73), (and there are guidelines on the management of 
hypertension specific to patients with RA (24;74)) but theoretically also requires rapid and 
effective control of systemic inflammation (22).  Trials of intensive disease modifying drug 
treatment and biologic therapy on CVD outcomes in early RA are required.   
 
c) What is the evidence for CVD risk factors in early RA? 
There is a growing body of evidence showing dyslipidaemia is present in early RA, likely related 
to the untreated systemic inflammatory burden in those with early disease (25).  Georgiadis et al 
examined the lipid profile of 58 treatment naïve patients diagnosed with RA in the past year, and 
with no past history of CVD events or conditions or concomitant medications known to affect the 
lipid profile.  Their mean disease activity score from 28 joints was 5.8 indicating active disease.  
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These patients had evidence of a mild dyslipidaemia with higher levels of total cholesterol, low 
density lipoprotein (LDL) and triglycerides (TG) and lower levels of HDL compared to healthy 
controls; the atherogenic index (TC/HDL) was therefore less favourable.  After 1 year’s treatment 
with methotrexate and prednisolone, levels of HDL were significantly higher, despite no dietary 
modification or weight change, hence the atherogenic index was reduced (75).  This increase in 
HDL inversely correlated with improvements in the inflammatory indices CRP and ESR 
(erythrocyte sedimentation rate).  Similar findings of low total cholesterol, low HDL but elevated 
atherogenic index have also been reported in patients with early, untreated, active RA from 
several early arthritis studies in The Netherlands.  The atherogenic ratio improved with 
antirheumatic treatment (27).  Of note, one of these studies was the COBRA study whereby 
patients with active RA and median disease duration of 4 months were randomized to 
combination treatment including corticosteroids versus sulphasalazine alone; the atherogenic 
index improved faster in those patients taking combination treatment.  However, the authors 
acknowledge that longer term studies are required to evaluate the role of corticosteroids on the 
breadth of cardiovascular risk factors in the longer term (27).   
 
The role of novel risk factors for CVD, particularly systemic inflammation, has also been 
explored in patients with recent onset inflammatory polyarthritis in the NOAR cohort.  One 
hypothesis to explain why these rheumatoid factor positive patients have increased CVD 
mortality (64) is that they have more severe disease with increased levels of inflammation (34) 
contributing to accelerated atherosclerosis.  The combination of other markers of severe disease, 
namely smoking, presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies and 
possession of 2 copies of the shared epitope (SE) also associate with CVD mortality (76).    
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Risk of cardiovascular disease prior to the onset of RA 
 
a) What is the evidence for CVD events or CVD risk factors prior to RA? 
Retrospectively exploring medical records back to aged 18 years of all 603 patients in the 
Rochester RA incidence cohort revealed that in the two year period prior to fulfilling the 
diagnostic ACR criteria for RA, these participants were significantly more likely to have been 
hospitalized for an acute MI or to have experienced an unrecognized MI compared to non-RA 
subjects (14).  The previously discussed study examining co-morbidities in patients with early 
RA also revealed that for many patients with RA their co-morbidities were present before the 
diagnosis of RA (72).  These observations may be explained by studies that reveal the presence of 
several risk factors for CVD in the pre-RA period; specifically, there is evidence of 
dyslipidaemia, an acute phase response and the production of autoantibodies prior to a diagnosis 
of RA (42).  van Leuven et al therefore suggest that the pathological processes initiating 
atherogenesis may initiate years before the diagnosis of RA is made (42).   
 
Although there is evidence regarding dyslipidaemia prior to a diagnosis of RA (blood donors who 
subsequently developed RA have been shown to have a more atherogenic lipid profile up to 10 
years before they developed RA (77)) there is also conflicting research; namely, a prospective 
case control study found no difference between blood pressure readings, cholesterol levels and 
obesity between participants who did, and those who did not, subsequently develop inflammatory 
arthritis (78).  Additionally, as smoking is a shared risk factor for both RA and CVD (see below), 
this is another CVD risk factor present in the pre-RA period. 
 
30 
 
b) Are there any shared risk factors for the development of both CVD and RA? 
Smoking is certainly a risk factor for the development of both RA (34;78) and CVD (79).  
Moreover, smoking is also associated with more severe RA, for example, more erosive disease or 
extra-articular features (53).  Serologically, smokers are more likely to be RF positive as well as 
positive for anti-CCP antibodies.  In non-RA smokers, smoking causes citrullination of cells; in 
patients with RA this citrullination of cells is particularly important as anti-CCP antibodies 
predict more aggressive RA (53). 
 
There is evidence for diet also having an aetiological role in the development of RA (80) and 
CVD.  Both atherosclerosis and synovial inflammation are mediated by free radical activity; 
hence antioxidants, which scavenge reactive oxygen radicals and protect against oxidative 
damage are thought to have a protective effect.  Certainly, levels of CRP and oxidized LDL, both 
linked to the development of RA and CVD, are inversely related to serum concentrations of 
circulating antioxidants (81).  In studies involving both a Norfolk population-based prospective 
study, which included baseline diet diaries, and the NOAR cohort, the pre-morbid diets of those 
who subsequently developed IP could be analysed.  People with a lower daily intake of fruit and, 
particularly, foods containing the antioxidant vitamin C were at greater risk of subsequently 
developing IP (82) as were those whose diets were low in the antioxidant dietary carotenoids, 
particularly β cryptoxanthin, (81), and those who consumed high levels of red meat (83).  Dietary 
red meat is a source of arachidonic acid, involved in the production of eicosanoids which can 
have proinflammatory activity (83).  The Mediterranean diet, comprising a high intake of oily 
fish, white meat, olive oil, fruit and vegetables is advocated for primary and secondary prevention 
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of CVD, and as these studies suggest may also have a protective role in the development of RA, 
although further work is required (80).   
 
As already discussed, dyslipidaemia has been observed many years prior to the onset of RA.  
However, the novel concept of dyslipidaemia as an aetiological agent for both RA and CVD has 
been considered by van Halm et al. (77).  In their study, changes in CRP only explained a small 
part of the differences in the lipid profile between those who subsequently developed RA and 
controls.  Therefore they postulate that either an unfavourable lipid profile renders a person more 
susceptible to inflammation, or, is related to the development of RA by a linked background, 
either genetic or socioeconomic. 
 
There are also genetic predictors for both RA and CVD.  The gene HLA-DRB1 is a susceptibility 
gene for RA and also is associated with severity of RA (84).  However, there is evidence that this 
gene also appears to confer risk of CVD: using evidence of endothelial dysfunction as a surrogate 
marker for CVD, it has been shown that endothelial dysfunction was greater in RA patients with 
certain HLA-DRB1 genotypes (85).  Mortality data also supports this finding.  Carrying two 
copies of shared epitope alleles at the HLA-DRB1 gene, particularly certain genotype 
combinations such as HLA-DRB1*0101/*0401, gave an increased risk of CVD death in patients 
with IP, compared to patients with 0 or 1 copy of shared epitope alleles (76;86).  Other gene 
polymorphisms relating to thrombotic factors and inflammation are also currently being explored 
with regard to increased frequency of CVD in RA patients (87;88).   
 
Conclusion 
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In summary, there is well established evidence for CVD mortality and morbidity in patients with 
RA.  The more recent evidence that CVD morbidity and mortality occurs early in the disease 
process, and the suggestion that pathogenic processes for atherosclerosis may be in place even 
before a diagnosis of RA, however, represents a new development in our understanding of CVD 
co-morbidity.  Further research is required to explore CVD in early RA, particularly to elucidate 
the relative contributions of both traditional and novel CVD risk factors, as well as the effect of 
their modification early in the disease course, including the effect of early immunosuppressive 
treatment (including corticosteroids and biologic therapy) on CVD outcomes.  Importantly, these 
findings will need to be translated into direct clinical practice with CVD risk management being 
an integral part of the care of every patient with RA, in both primary and secondary care, from 
the point of diagnosis.  This will require including RA as a risk factor multiplier in CVD risk 
calculators as well as providing sufficient resources to support patients making necessary lifestyle 
changes to modify traditional CVD risk factors, such as prescribed physical activity, weight loss 
programmes and smoking cessation. 
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CHAPTER 2 (PART 2): GENERAL INTRODUCTION; 
IS RHEUMATOID ARTHRITIS A CORONARY HEART DISEASE EQUIVALENT? 
 
The archetypal disease considered a coronary heart disease (CHD) equivalent is type 2 diabetes 
mellitus (DM2), as people with DM2 have the same risk for future CHD events as non-diabetic 
patients who have had a previous myocardial infarction (MI) (1).  This review addresses the 
question whether rheumatoid arthritis (RA) is also a CHD equivalent and discusses the 
implications of this.   
 
Epidemiology 
 
RA is associated with an increased mortality with standardised mortality ratios (SMR) ranging 
from 1.3 to 3.0 (2).  Cardiovascular disease (CVD) accounts for up to 50% of this excess 
mortality (3); several epidemiological studies and recent meta-analyses clearly show that RA 
patients have an SMR for CVD of 1.5-1.6 compared to the general population (2;4).  The 
increased CVD risk of RA has specifically been compared with that of DM2 in both cross-
sectional (5) and longitudinal (6) studies.  Three groups of subjects were studied: i) patients with 
RA and normal fasting glucose levels from the Dutch Cardiovascular and Rheumatoid arthritis 
(CARRE) cohort; ii) patients with DM2; iii) non-diabetic controls; these latter two groups of 
patients were drawn from another Dutch cohort, the Hoorn cohort, (5;6).  The prevalence of CVD 
was 12.9% in patients with RA (n = 294), 12.4% in patients with DM2 (n = 194) and 5.0% in 
control patients (n = 258), giving an age- and gender-adjusted prevalence odds ratio for CVD of 
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2.3 for patients with DM2 and 3.1 for patients with RA in comparison to the non-diabetic control 
group (5).  These patients were followed longitudinally until the occurrence of a fatal or nonfatal 
CVD event, death of any cause or the cessation of the study.  The mean follow-up period was 
nearly 3 years; age- and gender-adjusted hazard ratios of CVD events was 2.16 for non-diabetic 
RA patients and 2.04 for patients with DM2 compared to the non-diabetic control patients (6).  
Thus, both studies show a two-fold higher risk of CVD in patients with RA and the magnitude of 
this increased risk is comparable to the risk associated with DM2.  Similar findings were seen in 
a, soon to be published, study of a Danish nationwide cohort comparing incident RA with 
incident DM2 (Lindhardsen J, personal communication). 
 
Independently, another research group cross-sectionally compared a group of non-diabetic RA 
patients (n=48), with a disease-duration, age- and sex-matched group of patients with DM2 
(n=48) and a matched control group (n=48).  Assessments of vascular function and morphology 
were used to identify prevalent preclinical atherosclerosis.  There was a significantly higher 
prevalence and severity of preclinical atherosclerosis in patients with RA compared to healthy 
controls, which was similarly found in the DM2 patients (1).  Whether such vascular assessments 
are good surrogates of future CVD events in patients with RA remains unclear, however, this 
study again suggests that RA confers approximately the same risk for CVD as DM2 (1). 
 
Mechanisms of atherosclerosis development 
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The development of atherosclerosis is thought to be related in part to the accumulation of 
“classical” risk factors for CVD.  However, over the last 2 decades, it has emerged that 
atherosclerosis is an inflammatory disease per se (7) whereby systemic and local inflammatory 
phenomena drive the development of the atherosclerotic plaque, as well as its instability and 
rupture, with consequent clot formation causing an acute ischaemic event (3).  There is also an 
appreciation of a complex interplay between “classical” and “novel” CVD risk factors, including 
inflammation (Figure 1, Chapter 2 (part 1)).   Below, we consider both classical and novel risk 
factors and their interaction, and the relative contributions each group of risk factors plays in 
atherosclerosis development in DM2 and RA. 
 
a) Classical CVD risk factors 
Classical risk factors for CVD namely smoking, hypertension, insulin resistance, physical 
inactivity, dyslipidaemia and obesity are highly prevalent, tend to cluster and may frequently be 
undertreated in people with RA (3;8;9).  Several of these risk factors may be affected by RA 
itself or its treatment: for example, joint pain or structural joint damage may contribute to 
physical inactivity (10), while non-steroidal anti-inflammatory drugs and cyclo-oxygenase II 
inhibitors, glucocorticoids, some disease-modifying anti-rheumatic drugs such as leflunomide or 
cyclosporine, and other factors such as obesity, physical inactivity or systemic inflammation per 
se can all contribute to hypertension in patients with RA (11). Some epidemiological studies 
suggest occasional paradoxical associations between RA and some CVD risk factors (12);  body 
composition and dyslipidaemia are classical examples of this.  Undesirable types of body 
composition in RA include obesity (which in cross-sectional studies associated with low levels of 
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physical activity or being an ex-smoker (13)) but also rheumatoid cachexia (a state of apparent 
normal or low weight, in which pro-inflammatory cytokines mediate the involuntary loss of lean 
body mass (muscle) which is progressively replaced by body fat, thus also representing a ‘high 
fat’ state (13-15)).  Whilst obesity is widely appreciated as a risk factor for CVD in both the 
general population and people with RA (16), rheumatoid cachexia may provide an explanation 
for the paradoxical finding that a low body mass index (BMI) in people with RA associates with 
a threefold increase in CVD death (14).  Further research also suggests the distribution (visceral 
or subcutaneous) of abdominal adiposity may be of relevance, with visceral adiposity associating 
with cardiometabolic risk factors and CVD in people with RA (17).   
 
Lipid levels are another excellent example of paradoxical associations found in RA.  Contrary to 
the general population, in RA, decreased lipid levels have been associated with increased CVD 
risk (12).  This is thought to be because lipid levels are inversely associated with inflammation; 
specifically, pro-inflammatory cytokines, particularly tumour necrosis factor α (TNFα), 
associated with high levels of inflammation depress the total cholesterol (TC) level but 
particularly depress the high-density lipoprotein (HDL) cholesterol level leading to an 
unfavourable atherogenic index (TC:HDL ratio) (2;18;19).  Using the CARRE cohort of patients 
described earlier, Peters and colleagues showed in 289 RA patients (not taking lipid-lowering 
medication) that indeed C reactive protein (CRP) correlated negatively with TC, more so with 
HDL and correlated positively with the TC:HDL ratio.  These associations were predominant in 
patients whose CRP was greater than 10mg/l (20).  These CARRE cohort patients were followed 
up prospectively as described above; TC:HDL ratio was positively related to risk of CVD event, 
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whereas TC alone was not (20). We have also observed that whereas individual lipid components 
(TC, low density lipoprotein, HDL, triglycerides) are influenced to a greater or lesser extent by 
inflammation, lipid ratios did not correlate with CRP (21); both studies therefore suggest that 
lipid ratios may be more robust and appropriate for CVD risk stratification in people with RA. 
 
Insulin resistance has also been described in patients with RA (22) and appears to relate to 
systemic inflammation or glucocorticoid therapy (3). We have recently demonstrated that insulin 
resistance in RA has 2 main components: one that relates to active inflammation and appears to 
be reversible with its adequate control; and another that relates to adiposity and appears to remain 
unaltered with potent anti-inflammatory therapy, at least in the short and medium term.  
Furthermore, the risk (incidence ratio) of developing DM2 in a cohort of nearly 49 000 patients 
with RA has been calculated as 8.6 compared to 5.8 per 1000 person-years in non rheumatic 
controls (23).   
 
It is clear that in terms of the classical CVD risk factor burden, there are several parallels between 
RA and DM2, including obesity, hypertension, dyslipidaemia and insulin resistance (1;24;25).  
However, it remains unknown whether these confer a proportionally similar CVD risk in the two 
disease groups, and whereas systematic screening and identification of such risk factors in routine 
clinical practice is now imperative in both conditions, it is not known whether primary prevention 
strategies applied successfully in DM2 would be equally easy to implement and demonstrate 
similar benefits in people with RA.  
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b) Novel CVD risk factors 
Novel risk factors implicated in CVD risk in RA relate to both RA activity (ie level of 
inflammation) as well as other characteristics of the RA phenotype.  In the general population, 
modest increases in circulating CRP (detected using high-sensitivity CRP (hsCRP) assays) have 
been associated with CHD risk (26).  Thus high levels of inflammation observed in patients with 
RA are thought to contribute to accelerated atherosclerosis (12); potential mechanisms include 
the development of endothelial dysfunction, activation of the coagulation cascade and induction 
of secondary dyslipidaemia (27;28).  Active RA disease has been shown to associate with an 
atheromatous plaque more vulnerable to rupture (1) as well as a greater prevalence and extent of 
coronary artery calcification (29).  Having adjusted for classical risk factors and co-morbidities, 
RA characteristics which independently associate with an increased risk of CVD death include 
small and large joint swelling, destructive changes on joint radiographs, rheumatoid nodules, 
vasculitis, rheumatoid lung disease and corticosteroid use (30).  Additionally, being positive for 
rheumatoid factor (RF) or anti-nuclear antibodies has been shown to be a significant predictor for 
CVD morbidity or mortality, supporting the theory that immune dysregulation may play a role in 
the aetiology of CVD in RA (31).   
 
Comparing DM2 and RA with regard to novel risk factors reveals differences as patients with 
DM2 do not exhibit such high levels of systemic inflammation.  However, patients with DM2 
have “low grade” systemic inflammation; adiposity, insulin resistance, hyperglycaemia, 
hypertension and dyslipidaemia are some of the factors associated with low-grade systemic 
inflammation in the general population and these are prevalent in patients with DM2 (32).  
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Shared novel mechanisms have been proposed where the proinflammatory cytokine TNFα 
appears to be central. TNFα is the pivotal cytokine driving the inflammatory cascade in RA (33).  
However, TNFα also arises from adipose tissue and during chronic hyperglycaemia has harmful 
effects on insulin signalling, may cause insulin resistance and may impede the insulin-mediated 
disposal of glucose in the skeletal muscle (5).   
 
A further consideration is the role that chronic kidney disease (CKD) is known to play in causing 
CVD. After adjusting for traditional CVD risk factors, patients with CKD have an increased risk 
of CVD death, and this risk extends to patients with mild CKD as well as those with end stage 
renal failure (34).  Non-traditional risk factors have been implicated such as hyperactivity of the 
renin-angiotensin-aldosterone system, volume overload, dyslipidaemia other than LDL levels, 
inflammation, coagulopathy, oxidative stress and sympathetic hyperactivity, which lead to 
histomorphological alterations of the heart and vessels (34;35).  CKD is a well known 
complication of DM2 (36) but is also prevalent in patients with RA; in our cohort of 400 RA 
patients, 67.75% of patients had a reduced glomerular filtration rate (GFR) of less than 90 
ml/minute per 1.73m2 and 12.75% had a GFR of less than 60ml/minute per 1.73m2(37).  The 
aetiology of renal impairment in RA has been hypothesised to include nephrotoxic medications, 
reactive amyloidosis, metabolic factors, levels of systemic inflammation or the role of serum uric 
acid (37).  However, multivariate analysis in our cohort revealed renal dysfunction in RA 
associated with classic CVD risk factors such as advanced age and dyslipidaemia, levels of serum 
uric acid and the presence of extra-articular rheumatoid disease; RA duration and activity, 
disability and past or present use of nephrotoxic medications were not associated (37).  
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Interestingly serum uric acid has been shown to independently associate with hypertension (38), 
renal dysfunction (39) and CVD (40) in patients with RA and may be a common 
denominator/predictor for CVD and CKD in RA; indeed serum uric acid may be another novel 
risk factor, alongside systemic inflammation, for CVD in RA (41). 
 
A comparison between the classical and novel risk factor burden in RA and DM2 is provided in 
Table 1. 
Table 1: A comparison between “classical” and “novel” risk factors in RA and DM2 
Risk factors RA DM2 
Classical 
risk factors  
 
• Smoking Prevalent Prevalent 
• Hypertension prevalent; affected by RA and 
its medications 
Prevalent 
• Insulin resistance prevalent, related to RA or its 
medications (glucocorticoids) 
100% prevalence 
• Physical inactivity prevalent; affected by RA 
activity and previous damage 
Prevalent 
• Dyslipidaemia paradoxical association related 
to systemic inflammation 
Prevalent 
• Abnormal body composition both obesity and rheumatoid 
cachexia prevalent; related to 
RA or its medication 
(glucocorticoids) 
obesity highly prevalent 
Novel risk 
factors 
• Systemic inflammation high grade inflammation low grade inflammation 
 • Chronic kidney disease prevalent, related to age, 
dylipidaemia, serum uric acid 
and extra-articular disease  
Prevalent 
 
 
c) Relative contribution of classical versus novel risk factors in RA and DM2  
A population-based incidence cohort from Rochester, USA, of 603 patients with RA was 
compared to an age and gender matched control cohort of 603 people without RA; both groups 
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were followed up longitudinally for 15 and 17 years, respectively.  The baseline prevalence of 
classical CVD risk factors was similar between groups, but the relative impact of several classical 
risk factors (male gender, current smoking and personal history of ischaemic heart disease) on  
CVD outcomes, appeared to be significantly less in those with RA compared to those without 
(42).  These authors hypothesise this may be observed if a novel RA-specific risk factor results in 
a dilution effect making the relative contribution of classical risk factors appear smaller in RA 
(42).  The same authors sought to estimate the proportion of CVD risk that could be attributed to 
classical risk factors.  Using heart failure as the outcome measure, they identified that all classical 
CVD risk factors explained 80% of the risk for heart failure in non-RA subjects but only 40% of 
the heart failure risk among RA subjects, again suggesting that other, novel, risk factors make a 
significant contribution to the overall heart failure risk that RA patients have (30).  Other groups 
have similarly concluded that in RA both classical and novel risk factors predict CVD outcomes.  
Solomon and colleagues examined baseline data from a prospective longitudinal cohort study of 
10,156 patients with RA who were followed for a median of 22 months observing primary CVD 
events.   Models predicting CVD events increased in accuracy when both classical and novel risk 
factors (markers of disease severity, namely, longer disease duration, radiographic joint erosions, 
subcutaneous nodules, prior total joint replacement, seropositivity, high Health Assessment 
Questionnaire score and a high clinical disease activity score) were included; increasing numbers 
of both types of factors were associated with greater risk (43).   
 
The relative contribution both classical and novel risk factors play in CVD has been compared in 
patients with DM2 and RA using measurements of preclinical atherosclerosis (such as flow-
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mediated dilatation, pulse wave velocity or ultrasound measures of carotid intima media 
thickness) as surrogate markers for CVD events (1).  Different vascular assessments can be used 
to assess different aspects of the atherosclerotic process (44).  Diabetic patients had a worse 
classical CVD risk factor profile compared to patients with RA, yet there were no differences in 
vascular assessments between both groups, suggesting other RA-specific novel risk factors 
played a significant role in atherosclerosis development in RA.  Further analysis looked at 
individual vascular measurements; in DM2, endothelial dysfunction, an early indicator of 
atherosclerosis, appeared to be mediated via classical risk factors, whereas it was independent in 
RA.  Early aggressive risk factor control may therefore be sufficient in DM2 but not in RA.  In 
contrast, measurements of arterial stiffness, representing functional and structural deterioration in 
the vessel wall, were independent of classical risk factors in DM2, but not in RA (1).   
 
Implications for practice 
 
Patients considered at high risk for CVD should receive appropriate lifestyle advice and 
medication.  High risk patients are defined as those who have had a previous CVD event, those 
whose 10 year risk of a CVD event is greater than 20% and those who have diabetes, as this is 
considered a CHD equivalent (45).  If RA is a CHD equivalent, similar to DM2, then should 
similar preventative strategies be considered for patients with RA (5)?  Whilst there is a strong 
evidence base for primary CVD prevention in DM2 (46), there is currently no evidence base to 
confirm/refute whether similar strategies should be applied in RA.  RA patients have been 
excluded or reflect a very small number of the participants to all large primary (or secondary) 
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prevention trials performed to date.  Large randomised controlled trials with hard CVD endpoints 
are urgently required specifically in RA, to inform clinical practice. 
 
a) CVD risk management in RA   
Education must underlie all strategies to decrease CVD risk.  This includes not only patients, 
where education about relevant lifestyle modifications needs to be provided within the context of 
any physical and psychosocial constraints related to RA (47), but also of health professionals. 
The excess CVD risk conferred by RA has been shown to be under-recognised and under-
assessed in primary care (48); appropriate education of both primary and secondary health care 
professionals is required so that a consistent message is given to the patient (49).   
 
Recently the European League Against Rheumatism (EULAR) published recommendations for 
CVD risk management in patients with RA (50), stating that both classical and novel risk factors 
need to be addressed.  Adequate treatment to control RA activity and systemic inflammation is 
essential and certainly effective treatment with disease modifying drugs, especially methotrexate 
has been suggested to decrease CVD risk (30) and the risk of mortality following an acute 
myocardial infarction (51).  Anti-TNFα agents have also been shown to both improve lipid 
parameters and levels of inflammation, (52), measures  of aortic stiffness (53), as well as actual 
CVD events (54-56).  With regard to managing classical risk factors, pragmatic recommendations 
by EULAR include that all classical risk factors need to be regularly systematically screened for, 
as part of routine care, and included in a CVD risk score calculation.  Using CVD risk calculators 
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to determine whether a patient falls over the 20% threshold to receive preventative treatment 
requires the calculation to be accurate and validated in the target patient population.  Despite 
several risk calculators currently available (9), a specific calculator designed for and validated in 
the RA population does not exist, although a multiplier for RA is incorporated in QRISK2, a UK 
primary care CVD risk calculator (57).   Current advice is therefore to use the nationally 
recommended risk calculator and apply a multiplication factor of 1.5 to the result, if 2 out of 3 of 
the following factors are present to take account of the novel risk factors likely increasing the 
risk; disease duration of more than 10 years, sero-positivity for RF or anti-cyclic citrullinated 
peptide antibodies, presence of severe extra-articular manifestations.  Specific medical 
interventions should be implemented as per national guidelines (50).  The impact of this approach 
remains unknown and needs to be prospectively evaluated.   
 
Other guidelines have similarly recognised the importance of novel risk factors for CVD.   
Canadian guidelines list inflammatory biomarkers (alongside other classical risk factors) as a risk 
factor for CVD and emphasises the importance of screening for classical risk factors in patients 
with chronic autoimmune inflammatory diseases such as RA; more specific details are not 
provided as these guidelines are written by their Cardiovascular Society rather than from a 
rheumatologists perspective (58).   
 
b) Future research 
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There are several key research questions needing answering to inform the ongoing debate about 
CVD risk management in RA.  They include: (a) the development and validation of an RA-
specific CVD risk calculator; (b) RA-specific prospective primary prevention trials of different 
interventions with hard clinical end points, such as the UK-based TRial of Atorvastatin for the 
primary prevention of Cardiovascular Events in Rheumatoid Arthritis (TRACE RA) trial (see 
www.dgoh.nhs.uk/tracera) (59).  This study follows the promising results of a short-term smaller 
study in RA patients whereby atorvastatin effected a positive lipid-lowering effect of a magnitude 
in keeping with the findings in the non-RA population as well as mediating modest but clinically 
apparent anti-inflammatory effects, suggesting statins may attenuate both inflammatory and 
vascular risk parameters (60);  (c)  development and validation of imaging or biomarker 
techniques as surrogates of future CVD events specifically in patients with RA.  Current imaging 
techniques such as carotid intima media thickness (cIMT) (61;62) or coronary arterial 
calcification measured by computed tomography (29) have been used in research settings in RA 
patients; however, as yet, they have not been validated as surrogates of CVD outcomes 
specifically in RA.  Encouragingly, measures of carotid plaque using high-resolution ultrasound 
have recently been shown to strongly associate with future acute coronary syndromes in a RA 
cohort (63). 
 
Conclusion 
 
Current epidemiological evidence suggests that RA is a CHD equivalent similar to DM2.  
However, the mechanisms behind this increased risk of CVD may be different in the 2 
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conditions: classical CVD risk factors appear important in both cases but high-grade systemic 
inflammation may be particularly important in RA.  Therefore, CVD risk management in RA 
may require effective management of systemic inflammation as well as classical CVD risk 
factors; the results of primary prevention trials in RA will hopefully provide definitive evidence 
to guide future recommendations.  
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CHAPTER 3 (PART 1): GENERAL INTRODUCTION; 
CARDIOVASCULAR EDUCATION FOR PEOPLE WITH RHEUMATOID 
ARTHRITIS; WHAT CAN EXISTING PATIENT EDUCATION PROGRAMMES 
TEACH US? 
 
Introduction 
 
Rheumatoid arthritis (RA) is a chronic disabling inflammatory arthritis (1) and patients require 
long term patient-centred care; concordance between patients and health professionals will help 
the patient commit to necessary complex medication regimes, self-management and lifestyle 
behaviour modifications (2).  Patient education, defined as ‘any set of planned educational 
activities designed to improve patients’ health behaviours and/or health status’ (3), is at the heart 
of patient-centred care.  Education can be provided verbally during the outpatient appointment, 
using leaflets, such as those by Arthritis Research UK (4), audio-visual material, or as 
specifically developed patient education programmes (5).  The generic chronic disease self 
management programme (6) and arthritis specific version (7) are well known examples of patient 
education programmes and, additionally, a wealth of RA-specific programmes have been 
developed, published and reviewed (8;9).  Broadly, these have aimed to improve bio-clinical 
features of arthritis such as pain or disability, self management skills or psychosocial status; 28 of 
the 37 studies (involving 9955 patients in total) reviewed by Albano et al reported positive results 
(9).  Specifically, the Cochrane review found that RA patient education effected, when compared 
to no intervention at first follow up, a 10% improvement in functional disability, measured using 
the Health Assessment Questionnaire, a 12% improvement in the Arthritis Impact Measurement 
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Scales arthritis impact subscale and a 12% improvement in depression (8). Although depression 
has been included as a topic/outcome measure (8), other co-morbidities of RA have been largely 
neglected.  This is particularly pertinent as these co-morbid conditions not only affect quality of 
life (10), but also account for the excess morbidity and mortality associated with RA (1).   
 
CVD accounts for about 50% of the excess mortality in RA (11).  This is thought to be due to 
accelerated atherosclerosis occurring due to “classical” CVD risk factors, such as hypertension 
(12), dyslipidaemia (13), obesity (14) and physical inactivity (15), which may be adversely 
affected by RA or its medications (16;17), as well as more recently implicated risk factors, 
particularly high-grade systemic inflammation (18-20).  Guidelines, therefore, suggest that 
patients with RA should have an annual cardiovascular risk assessment (21;22).  A shared care 
approach to CVD risk management seems sensible; when surveyed, only 5% of general 
practitioners (GPs) felt CVD risk management in people with RA should occur in secondary care 
suggesting their perceived ownership (23).  Local protocols defining explicit but integrated roles 
for primary and secondary physicians will be important.   Education for people with RA is 
required to compliment these clinical consultations about CVD.  However, no patient education 
about CVD exists specifically designed for people with RA, and this has been identified as an 
unmet need (24).  Experience from CVD education initiatives for the general population and 
other high risk patient groups is valuable, but may not be wholly transferable to the RA 
population.  For example, advice about increasing exercise or achieving a normal weight must be 
provided within the context of any physical and psychosocial constraints from having RA.  Fear 
of causing joint damage or the requirement for some medications, especially corticosteroids, may 
affect a patient’s perceptions of these as realistic goals (24).  These patient beliefs need to be 
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acknowledged and explored before patients are receptive to current medical evidence 
emphasising the contrary, and committing themselves to substantial lifestyle changes.   
 
In this review we appraise existing patient education programmes for patients with RA and 
identify which specific features are characteristic of successful interventions.  Similarly, we 
examine patient education programmes used in primary and secondary prevention of CVD.  We 
then integrate the findings to provide a theoretical framework on how novel patient education 
addressing CVD in RA could be constructed.    
 
Patient education in rheumatoid arthritis  
 
There have been four systematic reviews/meta-analyses (8;25-27) of the RA patient education 
literature, (summarised by Christie et al (28)), which relate to studies published up until 2002.  In 
addition, we have identified a further ten randomised controlled trials (RCTs) of RA patient 
education programmes published since 2002; 5 were self management programmes (29-33), one 
aimed to improve drug adherence (34) and four were therapeutic education programmes(35-38).  
We review these programmes in order to identify common patterns of structure and delivery as 
well as which aspects are most effective (39).   
 
a) Fundamental design 
The Cochrane systematic review (8) compared the results of information-only (9 studies; 687 
patients), counselling (5 studies; 430 patients) or behavioural interventions (24 studies; 2493 
patients) versus control groups.  Pooled analysis revealed no significant effects for information 
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and counselling interventions, whereas behavioural interventions did show significant effects for 
scores on functional disability, patient global assessment and depression.  Similarly, Niedermann 
and colleagues observed that purely educational programmes were not associated with 
improvements in health status whereas some psychoeducational programmes benefited both 
physical and psychological health (27).  This concurs with the principle that the aims and content 
of an education programme must be congruent with the intended outcome: if the aim is to 
improve knowledge then information may suffice; if it is to change behaviours, which may 
subsequently confer clinical benefits, then the programme needs to include a behavioural 
component. 
 
b)  Robust theoretical underpinning 
Psychoeducational programmes are more likely to be successful if they also address the 
psychology behind why we adopt or maintain certain behaviours (40).  Indeed, a theoretical 
underpinning is thought to be instrumental to an intervention’s success (41;42). RA patient 
education programmes, particularly in the last decade, do tend to be based upon theories of 
human behaviour, most notably Social Cognition Theory (29;32-36).  This has, as a central tenet, 
the concept of self-efficacy (the belief in one’s own ability to succeed in a certain situation) (43).  
Such interventions have aimed to enhance a patients’ self-efficacy, e.g., using motivational 
interviewing, and have included specific skills-training in relation to encouraging behaviour 
change, e.g. goal-setting.  As inaccurate health beliefs may undermine health professional efforts 
to encourage behaviour change, another theoretical consideration is to provide the opportunity to 
explore patients’ beliefs about RA or its management (44).    
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c) Structure 
A variety of formats of patient education programmes have been described, such as group 
sessions (29-33;35;37;38), one-to-one sessions (34) or a combination (36); it has been suggested 
that group formats are more successful (45).  Telephone calls have been used to support 
participants (33); others have included subsequent booster sessions (29;32), although Riemsma 
and colleagues concluded that their booster sessions had little effect (29).  Previous programmes 
have been facilitated by various members of multidisciplinary care teams but nurses have been 
the most common educators (9); none of the programmes were lay-led.   Programmes ranged in 
duration from several consecutive days (37), to weekly sessions over several weeks (29-
33;35;38), to a year-long programme (36). Programmes lasting more than six weeks are 
considered to be more effective (26;41), although it must be remembered that increased 
programme length may affect attrition (46). Shorter programmes have also produced successful 
outcomes, for example, Abourazzak described an intensive course which delivered 18 hours of 
education and group workshops over 3 days to 39 patients who were compared to a control group 
of 38 patients (37).  Several programmes involved partners; one study was designed to analyse 
the effect of partner participation by comparing two groups receiving the same group self-
management intervention, one group attending with a partner and the other without; contrary to 
expectation, partner participation was found to decrease self-efficacy (29).   
 
d) Efficacy 
A wide range of outcome measures have been employed to assess the efficacy of these 
programmes.  The measures chosen should be congruent with the aims and content of the 
programme (47).  Measures of knowledge, such as the Patient Knowledge Questionnaire, have 
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been used (38).  However, if the education programme is seeking to encourage behaviour change, 
measures that reflect successful behaviour modification are essential, as well as consequential 
clinical outcome measures, for example, pain scores, tender and swollen joint counts or measures 
of disability (36).   
 
Outcome measures have usually been assessed immediately after completing an educational 
intervention and also after a follow up period, ranging from 6 months (30;35) to 3 years (37).  
The Cochrane review showed a beneficial effect on clinical outcomes immediately post 
intervention, but these benefits were not maintained at the final follow up visit (8).  Some studies 
have, however, been able to demonstrate longer term clinical benefits. For example, 43 patients 
were recruited to a study comparing a 1-year programme designed to improve self-reported 
disability using active learning strategies focusing on real life situations against a control group.  
The programme involved individual education sessions every three months, as well as two group 
sessions with full written information provided.  After 18 months, 59% of participants in the 
intervention group achieved an ACR20 response (48) compared to 10% of the control group (36).   
Another successful study randomized 85 patients with moderate to severe RA treated with 
infliximab to either a 9-week programme or a control group.  The programme comprised four 
three-hour group sessions aiming to improve pain, disability and health status.  Activities 
included a detailed home-exercise programme, written programme brochure and home guide, as 
well as monthly supportive telephone calls.  Seventy patients completed the trial and were 
included in the analysis.  Significant benefits on pain and disability in the intervention group 
persisted up to the final follow up visit at eight months compared to the control group (33).   The 
intensive three day course discussed earlier (37) followed up its intervention participants for three 
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years.  Disease activity was significantly lower in the intervention group 3 years later, but no 
benefit on functional impairment or quality of life could be demonstrated; however, the control 
participants were not followed up at 3 years so between groups analysis was not performed.   
 
Patient education in cardiovascular disease  
 
The majority of modifiable “classical” CVD risk factors are over-represented in people with RA 
(14;18;49).  We reviewed the literature specifically to identify studies using a multifactorial 
educational approach (‘Healthy Heart Programmes’) including both primary and secondary 
prevention programmes.   
 
a) Fundamental design 
Most CVD education programmes are behaviour-based.  Primary prevention programmes  
include techniques, such as goal-setting or motivational interviewing (50).  Most secondary 
prevention programmes comprise a comprehensive lifestyle programme to address health risk 
behaviours via behaviour change techniques, lifestyle coaching and psychosocial support; there is 
usually a particular emphasis on exercise (51). 
 
b)  Robust theoretical underpinning  
Although few secondary prevention programmes indicate an underpinning theoretical model, 
some primary prevention programmes do; the Stages of Change Model is the most common 
model used (52-54).  Some studies describe preceding research to explore patients’ expectations 
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of CVD patient education (53) or health beliefs (55) in order to inform their subsequent CVD 
education programme; this approach is advocated by the literature (56).   
 
c) Structure 
CVD prevention programmes vary in terms of group or individual sessions and several included 
follow up telephone calls (50;57-59) or booster sessions (54;60).  They were facilitated by 
various members of the multidisciplinary team rather than lay-led.  Interestingly, some secondary 
prevention programmes relied entirely on telephone calls (61) or were delivered via the internet 
(including e-mail communication with a case manager) (62).  Primary prevention programmes 
vary in duration from a few hours (63) to, for example, a programme involving 28 two-hour 
meetings over a ten month period (58).  Most secondary prevention programmes lasted several 
weeks or months; for example, the Vestfold Heartcare Study Group lifestyle intervention 
programme involved six weeks of ‘heart school’ including supervised physical exercise and twice 
weekly group meetings (addressing dietary advice, smoking cessation, physical activity 
counselling, risk factor management, psychosocial management, medication and reduction of 
mental stress) followed by nine weeks of twice weekly supervised gym exercise with group 
meetings every three months (64).  The value of longer programmes is unclear; distributing a 3-
month programme over a year was found to make no difference to its impact (65). Further, a 2-
year programme was associated with fewer clinical events (66), whereas a 3-year programme was 
not (51).   
 
d)  Efficacy 
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Outcome measures did not usually include measures of knowledge but instead were behavioural 
(smoking status, physical activity, weight) and clinical, including changes in individual risk 
factors. Framingham 10-year CVD risk, or subsequent rate of CVD events.   
 
Both primary and secondary CVD prevention programmes showed improvements in CVD 
behaviours ((50;54;63) and (51;64) respectively) as well as CVD risk factors ((53;57;60) and 
(59;66;67) respectively).  Some primary prevention programmes showed reductions in 10-year 
CVD risk (57;58).  In terms of translating risk factor modification into hard clinical endpoints, 
primary CVD prevention programmes have had mixed success.  The large multiple risk factor 
intervention trial (MRFIT) involving 12 966 patients was successful in modifying diastolic blood 
pressure, serum cholesterol levels and smoking status, and maintaining this over a 6 year period; 
the effect on coronary heart disease mortality rate was favourable although not significantly 
different from a usual care control group (68).  Similarly, the Cochrane review (reviewing the 
literature up until 2001) found modest improvements in risk factors following counselling and 
education programmes but no significant impact on mortality (10 trials reported CVD event data 
comprising 903 000 patient years of observation; for total mortality there was a pooled odds ratio 
of 0.96 (95% CI 0.92 to 1.01) favouring intervention) (69).  However, Rachmani and colleagues 
were able to demonstrate a significant reduction in CVD events over an eight-year follow up 
period in 165 patients with diabetes, hypertension and dyslipidaemia (70). A key feature of this 
particular programme (70) was that, as well as lifestyle advice and a fitness programme, patients 
were given their risk factor measurements as well as defined target values and were encouraged 
to urge their general practitioner to change their medication if target values were not met.  
Participants in this intervention programme had 52 CVD events compared to 80 CVD events in 
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the control group; the relative risk, over 8 years, for the combined CVD event index in the 
intervention compared to the control group was 0.65.  This strategy whereby patients are 
empowered to request to be ‘treated to target’ by their doctors highlights the successful results 
that can be achieved when concordance in the patient-health professional partnership is achieved.  
A similar strategy was used as part of the COACH (Coaching patients On Achieving 
Cardiovascular Health) programme which aimed to improve CVD risk factors in people with 
coronary heart disease (61). 
 
Secondary CVD prevention programmes have also shown an improvement in clinical events 
(62;66).  For example, Giallauria and colleagues recruited 52 post-infarction patients, who had 
just completed a standard 3-month cardiac rehabilitation programme, and randomised them either 
to a further 2-year multifactorial educational and behavioural programme or a control group.  The 
programme entailed monthly hospital visits providing dietary advice, lifestyle reinforcement and 
exercise; families were invited to help sustain the patient long term.  Supportive written material 
was provided.  This study observed CVD events in 27% of patients in the control group 
compared to 11% in the intervention group, although the study was not powered to detect CVD 
morbidity and mortality.  Furthermore, the Cochrane systematic review of exercise-based cardiac 
[secondary] rehabilitation (involving 8440 patients) observed that cardiac mortality was reduced 
by 31% in exercise-only interventions and 26% in comprehensive cardiac rehabilitation schemes 
when compared to usual care (71).  The pooled effect estimate of secondary cardiac rehabilitation 
on combined mortality, non-fatal myocardial infarctions and revascularisation procedures was 
0.81 (71).   Can specific features be identified to explain this improvement in clinical status in 
secondary prevention programmes?  Most obviously, these programmes involve patients who 
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have had a cardiac event or procedure.  For them, CVD is a ‘real’ rather than a potential event; 
this is likely to considerably increase motivation to engage in preventative behaviours, which will 
translate into increased self-efficacy (72;73).  To similarly enhance motivation in primary 
prevention schemes will require skilful communication about the seriousness and implications of 
future risk (74).  Alternatively or additionally, it may be the prominent role that exercise plays in 
secondary prevention schemes, which contributes to their greater general effectiveness.   
Certainly, exercise has a major beneficial effect on the likelihood to develop, become 
symptomatic or die from CVD, through ameliorating multiple risk factors including obesity, 
dyslipidaemia, hypertension and diabetes mellitus (15).  
 
A comparison of the successful components of patient education programmes in RA and CVD is 
provided in Table 1.  
 
Table 1: Successful components of patient education programmes 
Component 
 
RA patient education programmes CVD patient education programmes 
Fundamental design Behavioural based Behavioural based 
Theoretical underpinning Social Cognition Theory  Stages of Change Theory 
Structure • Group meetings 
• Participants attend individually 
• Duration of more than 6 weeks 
• Written information provided 
• Supportive follow up telephone calls 
• Duration of several weeks/months with 
frequent meetings 
Content • Skills training in behaviour change 
techniques 
 
• Skills training in behaviour change 
techniques 
• Compulsory exercise 
• Accurate and skilful communication of 
CVD risk to enhance motivation 
• Empowering participants to urge doctors 
to ‘treat to target’ their risk factors 
Outcome measures Measures of behaviour and clinical outcomes Measures of behavioural and clinical 
outcomes, including hard clinical endpoints if 
follow up is long enough 
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Conclusion: Developing novel patient education to address CVD in RA; what have existing 
programmes taught us?  
 
The principle of specifically designing patient education programmes to address a significant co-
morbidity is novel in itself; this design process may be transferable, both to other RA co-
morbidities but also other chronic diseases, with specific adjustments on a case by case basis.   
 
There is significant common ground between successful RA and CVD education programmes 
(Table 1), which can be integrated to provide a framework for designing education for RA 
patients about CVD.  
   
a) Fundamental design 
A behavioural approach, rather than solely the provision of information, should be provided by 
the intervention.   
 
b)  Robust theoretical underpinning 
Research will be required to ascertain which health psychology models may be pertinent, but the 
existing literature suggests that Social Cognition Theory is likely to be particularly important, 
combined with the Stages of Change model (75).  Preceding research is also required to identify 
patients’ expectations of the intervention.  
 
c) Structure 
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The evidence suggests that a programme lasting several weeks or months would confer greatest 
benefit, providing the time for participants to learn and implement skills in behaviour change.  A 
group format is recommended; the use of follow-up telephone calls could be a possible strategy.  
A relationship between the nature of the facilitator and the outcome of the programme was not 
observed; the facilitator should therefore be the person most suitable for the role who is 
adequately trained and educated.  As this programme is providing cross-disciplinary education, 
training the facilitator will be particularly important; for example, the DESMOND (Diabetes 
Education and Self Management for Ongoing and Newly Diagnosed) primary prevention 
education programme in people with diabetes (63) describes providing two days of 
multidisciplinary training for the programme educators (55). 
 
The actual content of the CVD education programme for people with RA will require appropriate 
modification to suit a rheumatoid population.  Inaccurate health beliefs about CVD need to be 
corrected and skilful communication of the magnitude of the risk of CVD and its relevance to 
them must be included at the outset to enhance motivation for behaviour change (76;77).  
Cognitive-behavioural strategies (such as counselling, motivational interviewing (78) or lifestyle 
coaching) need to be deployed to change maladaptive ways of thinking and feeling about CVD 
and enhance participants’ perceived control over CVD lifestyle behaviours (79), combined with 
specific skills in how to actually implement a desired behaviour change (80), such as smoking 
cessation, eating a low fat diet, weight control or increasing exercise.  The benefits of 
corticosteroids and non-steroidal anti-inflammatory medications for a person with RA need to be 
provided alongside their potential adverse effects on weight or blood pressure; it should be 
emphasised however that these adverse effects are not inevitable or fixed and may be modified 
74 
 
through dietary control and exercise.  Empowering patients with the skills to monitor their own 
progress with CVD risk factor reduction, and seek further advice or treatment if they fail to reach 
target values has been shown to be a useful strategy.  Existing shared care booklets for blood test 
monitoring related to drug therapy could be modified to incorporate RA patients’ CVD risk factor 
results as well as target values for body mass index, smoking status, blood pressure or lipid 
profile (81).  Exercise should be a core component.  Both physical (pain, mobility) and 
psychological (low levels of self efficacy) factors are reported by RA patients as barriers to 
exercise (82).  Therefore, advice is required to reassure patients that exercise will not only 
improve their cardiovascular risk (15) but may also reduce RA-related inflammation and improve 
function, pain and mobility (82;83) without damaging their joints (84).  Strategies that foster self-
efficacy and improve intrinsic motivation (85), and tailored advice from a healthcare professional 
(86), have been recommended to promote exercise participation.   
 
d)  Efficacy 
Evaluation of the efficacy of a new intervention is essential.  Knowledge of CVD can be 
measured using a questionnaire specifically designed and validated for people with RA (87).  
Alongside measuring actual behaviours, self efficacy measures (88-91) and Stages of Change 
measures for the different lifestyle behaviours could be used (92). Clinical outcomes could 
include risk factors, 10 year CVD Framingham risk or other risk algorithms (22), and, if follow 
up is long enough, rates of CVD events.   
 
These suggestions for developing a successful CVD education programme are summarised in 
Figure 1. 
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Figure 1: Schematic representation of a theoretically-informed CVD education programme in 
people with RA, making explicit how recommended theoretical models relate to the content and 
outcomes of the programme. 
 
 
+ represents enhanced results expected due to interventions theoretically driven 
 
e) Other considerations 
There are other practical factors that need to be considered in delivering CVD education to 
patients with RA (9;93) (Table 2).   
 
 
 
 
• What is CVD 
• Risk of CVD in RA 
• Current perceived control over 
CVD lifestyle behaviours 
• Strategies to enhance 
perceived control 
• Goal setting 
• Exercise 
• Self-monitoring of risk factors 
• Increase knowledge of 
CVD 
• Explain relevance of 
CVD 
• Explain role of risk 
factors 
• Emphasise importance of 
lifestyle modification 
• Encourage 
implementation of long 
term relevant behavioural 
modifications 
• Improved knowledge 
• +Improved behaviours
 ↑ Self efficacy 
Improved Stages of 
Change 
• +Improved clinical 
results 
Risk factors  
10 year risk of CVD 
CVD events 
AIMS CONTENT OUTCOMES 
congruency  congruency 
SOCIAL COGNITION THEORY 
STAGES OF CHANGE THEORY 
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Table 2: Additional factors to consider in designing CVD education for people with RA 
• When is the appropriate time, in relation to participants’ disease duration, to deliver such an intervention? 
• Is the written material suitable for the reading age of the target audience (many RA patients have limited 
health literacy (94))? 
• Is the reading material available in large text, Braille and appropriate ethnic languages? 
• Would it be helpful to have the written material available in an on-line format?  
• Does the intervention take into account potential cultural barriers? 
• Is the educational intervention held in a convenient venue for participants, that is accessible by the disabled? 
• Is the intervention available at different times of the day to be convenient for those in employment/ those who 
are retired/ those with small children? 
• Have financial costs to the participants attending been minimised? 
 
When would be the optimum time to deliver this intervention?  Patients interviewed suggested 
once initial control of RA had been established, rather than at diagnosis (44).  However, 
behavioural and cognitive-emotional adaptations have been shown to manifest early in RA (95), 
so education is required early enough to ensure appropriate behaviours are implemented and/or 
maintained.  Inclusion of patients from ethnic minorities is particularly important as South Asians 
are at increased risk of CVD (96).   How these barriers could be overcome will be an important 
component in the design of the intervention (93).   
  
Only future implementation and evaluation of an education programme underpinned by these 
recommendations will allow us to judge how effective this process has been in providing a 
theoretical framework on which a novel education intervention may be constructed. 
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CHAPTER 3 (PART 2): GENERAL INTRODUCTION; 
PATIENT EDUCATION ON CARDIOVASCULAR ASPECTS OF RHEUMATOID 
DISEASE: AN UNMET NEED 
 
Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis affecting nearly 1 
in 100 adults (1).  Cardiovascular disease (CVD) occurs at rates higher than expected in the 
general population, is the most prevalent co-morbidity and most common cause of death in RA 
patients (2-5).  The exact reasons remain unclear, but both classical CVD risk factors (such as 
hypertension and dyslipidaemia) and novel mechanisms (such as systemic inflammation), and 
their interplay, appear to be important (6;7).  Classical risk factors may be fixed (e.g. age, sex, 
family history) or modifiable (e.g. smoking, hypertension, dyslipidaemia, obesity, sedentarity).  
The latter are an obvious target for identification and intervention (7;8), neither of which appears 
to be happening systematically in the current rheumatology health care environment (3;9).  This 
is partly due to lack of sufficient awareness of health professionals and information/education of 
patients on this aspect of their disease.  Interestingly, many of the medications used for the 
management of RA may have a significant impact upon these factors, with the clearest example 
being the potential cardiovascular effects of the commonly used non-steroidal anti-inflammatory 
drugs (NSAIDs) and coxibs (10), the hypertensive effects of some disease-modifying anti-
rheumatic drugs (DMARDs) such as cyclosporine and leflunomide, or potential beneficial lipid 
effects of others, such as hydroxychloroquine (7).  Non-pharmacological interventions are of 
equal, if not more, importance:  for example, there is excellent quality evidence to suggest that 
exercise provides significant functional benefits in RA patients, together, of course, with 
important cardiovascular benefits, such as improvements in lipid profile and insulin sensitivity, 
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reduction of prothrombotic states and body fat content, and diminished risk of death from CVD 
in the general population and high risk groups therein (11).  The importance of systemic 
inflammation is more controversial: there is clear evidence that atherosclerosis is an 
inflammatory disease (12) and that RA appears to associate with premature peripheral 
atherosclerotic changes (13); there is also evidence that better control of systemic inflammation 
leads to survival benefits in RA (14-17).  However, it remains unclear whether this is a direct 
effect or whether it operates through amelioration of the multiple metabolic and vascular effects 
of inflammation (18;19).  Uncertainties also remain as to the best way to achieve sufficient 
control of high-grade inflammation without adverse effects to the vasculature.   
 
Within the general population it is possible to estimate an individual’s likelihood to sustain an 
acute CVD event in the next 10 years, using validated risk algorithms based on the presence and 
severity of classical CVD risk factors (20).  On the basis of this, informed decisions can be taken, 
as to whether this individual would be suitable for primary prevention therapy, according to 
existing accepted guidelines (20).  Communicating future risk and the need for therapy to prevent 
it (as opposed to the need for treatment to control symptoms or problems that a patient is already 
experiencing), is one of the most challenging education/communication tasks in the patient/health 
professional interaction (21). Despite such difficulties, patient education has been placed right at 
the heart of prevention strategies in cardiovascular medicine, and has been shown to be effective.  
Important examples include the PREMIER trial, where behavioural interventions improved 
multiple lifestyle factors and resulted in significant improvements of blood pressure control (22).  
Further studies in high-risk groups with diabetes and (for secondary prevention) in patients with 
confirmed previous cardiovascular events have shown that increased knowledge of CVD risk 
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factors correlated with improved adherence to medication, successful and sustained lifestyle 
modification, and improvement in individual CVD risk factors (23;24).  More importantly, 
participation in education programmes has been shown to result in improved clinical outcomes, 
including statistically significant reduction in 10-year CVD risk (25) as well as actual CVD 
events in the long term (8 year follow up) (26). 
 
Research in the cardiovascular aspects of rheumatic disease is increasingly being translated into 
clinical practice.  Management of cardiovascular risk is becoming an integral component of the 
long term care of patients with RA.  Every day practice indicates, and British Society for 
Rheumatology (BSR) guidelines state, that controlling co-morbidities such as ischaemic heart 
disease (IHD), hypertension and dyslipidaemia are already important aspects of rheumatology 
care provision (27).  This has been operationalised in the “Arthritis and Musculoskeletal 
Alliance” (ARMA) standards of care for patients with inflammatory arthritis in the inclusion of 
an updated cardiovascular health check in the annual specialist review appointments (28).  A 
recent Arthritis Research Campaign (arc) report also states that all patients with RA should be 
screened annually for CVD risk factors (29).  However, a patient survey of the ARMA standards 
in 2006 by the National Rheumatoid Arthritis Society (NRAS) has revealed that monitoring of 
cardiovascular health was infrequent (30).   Even with increasing awareness amongst health 
professionals about CVD risk identification and management in RA, effective implementation of 
such an important and ambitious change of practice requires appropriate and timely education of 
the patients themselves, in order to achieve concordance.  Concordance, the informed interaction 
in the decision making process in the patient-professional partnership, promotes shared 
responsibility for care (31) and is particularly important for lifestyle modification interventions 
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and for prevention therapy.  A survey of more than 2000 patients with diabetes in 2002 revealed 
that two thirds of respondents did not consider CVD a serious complication of diabetes, 
suggesting that their education on, and communication of, CVD risk had been inadequate (32).  
Such shortcomings are likely to be more pronounced in RA patients, where research evidence has 
only recently started to reach the medical, let alone the patient, communities.  Indeed, previous 
work in our unit has shown that only a quarter of patients with RA and confirmed CVD recorded 
the latter as a co-morbidity when listing their other illnesses (33).  Therefore, a combination of 
research findings, management imperatives, observations and experience from other conditions 
and from RA, as well as common sense, place patient education on the cardiovascular aspects of 
rheumatoid disease right at the centre of any successful prevention strategy. 
 
In general, patient education is defined as “any set of planned educational activities designed to 
improve patients’ health behaviours and/or health status” (34) and has a vital role to play 
particularly in the management of chronic disease.  Its main purpose is to facilitate desired health 
outcomes (35), which can be achieved by increasing self-efficacy, decreasing helplessness and 
thus increasing the ability to make health-related decisions (36).  Written information (such as the 
multiple arc-funded leaflets), when used to complement verbal information, has been shown to 
improve patient satisfaction (37) and disease knowledge (38).  However, it has been suggested 
that knowledge alone, whilst it may be a pre-requisite, is rarely sufficient for behaviour change 
(39-41).   Social cognition theory, developed by Bandura (42), examines the different factors that 
contribute to behaviour change.  Several models have been developed, including the Theory of 
Planned Behaviour, developed by Ajzen and colleagues: this proposes that behaviours are a result 
of a persons attitude towards a behaviour (both beliefs and evaluation of the outcome, which may 
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be affected by gaining knowledge), but social norms and perceived behavioural control (self-
efficacy) are also very important (43).  Thus educational interventions developed to include 
knowledge, behavioural and psychosocial components have been found to be the most effective 
in behaviour modification (39).  In patients with RA, such cognitive-behavioural educational 
interventions addressing articular symptoms have shown improvement in knowledge, self-
efficacy to cope with chronic arthritis (44),  exercise and joint protection, disability and pain (45).  
A systematic review of RA patient education analysed the effectiveness of different types of 
educational intervention, namely information only, counselling or behavioural treatments (46).  
Only studies involving behavioural interventions showed significant effects (improving outcomes 
for functional disability, patient global assessment and depression) but this was limited to 
immediately after the intervention.  Perhaps the best known example of such a multifaceted 
education programme is the Arthritis Self-Management Programme (ASMP), pioneered by Lorig 
in the late 70s in the USA (47) and successfully run in Australia (48) and Europe (49) for many 
years.  In the UK the ASMP is delivered through Arthritis Care under the name Challenging 
Arthritis (50), and significant improvements in self-efficacy, health behaviours and health status 
have been shown (51).  A generic chronic disease self-management programme (CDSMP) is also 
established.  In patients with heart disease, lung disease, stroke or arthritis, participation in the 
CDSMP reduced hospital visits and health distress and improved self-efficacy (52). 
 
However, the systematic review of rheumatoid arthritis patient education mentioned above failed 
to show long-term benefit from patient education interventions (46).  This may be because many 
of the existing interventions failed to explore the patient’s previous level of knowledge (which 
may be low), or the patient’s own model of illness and its management.  More specifically, the 
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interventions may not have assessed the patient’s needs beforehand (we have found through work 
in the Birmingham Arthritis Resource Centre (BARC) that, despite the ever-increasing 
availability of both educational material and format, formal ‘needs assessments’ continue to 
identify unmet needs (53)) or the intervention may have failed to explore the divergence of 
opinions between healthcare professionals and patients regarding the importance of various 
aspects of disease or management (41;54).  For example, we have previously shown that, 
compared to health professionals, patients are more interested in information pertaining to 
medication side effects, diet and alternative treatments (53).  This suggests that the quality of the 
analysis prior to designing an educational intervention will determine its subsequent effectiveness 
(55).  Specifically in relation to CVD risk, research has also shown that patients’ recall of blood 
test results may be susceptible to self-enhancement bias, wherein people with high cholesterol 
recall a lower figure (56): this may explain the lack of change in health behaviours even after 
personally relevant risk information.  Overall, these observations would suggest that educational 
material and interventions are more likely to be successful if they are developed specifically for 
the purpose and evaluated for their effectiveness prior to application. 
 
Patients’ preferences for educational interventions are also important to consider, as this is central 
to their design.  Qualitative research in RA patients has shown they found a one-to-one format 
helpful for learning about very specific information such as medications, whereas a group format 
was better for learning about self-management techniques and exercise due to the motivation 
factor a small group can offer (57).  This will be particularly pertinent if one wants to promote 
lifestyle changes for cardiovascular benefit.   Leaflets were viewed as helpful and a useful 
memory aid, but insufficient alone to address the breadth of concerns there may be, e.g., 
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surrounding the value and safety of exercise (57).  A comparison of group education with 
supporting self-help guide versus supporting self-help guide alone showed improvement in self-
efficacy in the former group, whereas no changes from baseline were observed in the latter group, 
or, interestingly, in those participating in the group education session with their partner (58).  
Conversely, questionnaire research has shown the preferred format for learning about arthritis 
was in writing (59). 
 
There has been a small pilot study in Glasgow of 22 RA patients who also attended a nurse-led 
clinic to address CVD lifestyle factors with modest (but promising) benefit as a result (60).  Other 
than that, to the best of our knowledge, no educational interventions have been developed and 
evaluated for communicating the increased CVD risk and relevant requirements for 
pharmacological prevention therapy and lifestyle modification to people with RA.  Our 
anecdotal, but significant, experience from the first combined rheumatology/cardiology clinic in 
the UK that has been running in Dudley for the last 3 years, is that there is a thirst and need for 
such material, which has to be developed specifically for the purpose.  The approaches used in 
the general population or other high-risk groups, e.g. diabetics, may not be sufficient for people 
with RA, because they present several additional challenges.  Some of these challenges relate to 
the healthcare community, for example the lack of consensus about the exact magnitude of 
additional CVD risk conferred by having RA, because this cannot yet be accurately calculated (as 
it can be for other conditions, such as diabetes or hypertension).   Other challenges are of more 
personal nature.  The RA patient presents with disabling joint symptoms yet rheumatologists also 
discuss cardiovascular disease, which may seem to the patient unrelated, unimportant if it is 
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currently asymptomatic or even overwhelming as we ‘break bad news’ twice about both RA and 
CVD.  Potential adverse cardiovascular effects of medications needed for sufficient relief of RA 
symptoms, the possible need for even further medications on an already significant background 
of polypharmacy (61) and the potential drug interactions need to be outlined and put in 
perspective.  Lifestyle changes, e.g. exercise, may seem daunting in the presence of significant 
joint discomfort.  There are currently no “off the shelf” resources to address sufficiently this 
specific need. 
  
In summary, patient-focused education on the cardiovascular aspects of rheumatoid disease is a 
very important yet neglected area of current RA patient education programmes.  There is an 
urgent requirement to address this unmet need and develop properly designed and evaluated 
educational interventions, which will specifically address the complex lifestyle and 
pharmacological measures required to optimise the cardiovascular health of every person with 
RA. It is likely that a combination of appropriate written information with a psycho-educational 
behavioural approach will be the most effective means for this.  Such programmes could be 
delivered through already existing infrastructure, for example the excellent network of 
rheumatology clinical nurse specialists (62), possibly with initial help by health psychologists 
(63), where available.   It is now up to us, the wider rheumatology clinical and scientific 
community, to rise to this challenge.  
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OVERVIEW OF THESIS 
 
Having identified CVD education for patients with RA as a currently neglected area of patient 
education, this thesis describes the development and evaluation of an educational programme 
designed to meet this need.  The Medical Research Council provides a framework on how 
complex non-pharmacological interventions should be developed and evaluated (1).  The pre-
clinical or theoretical phase has been provided in the Introduction, where both the scientific 
rationale for focussing on CVD co-morbidity in RA (Chapter 2), as well as existing patient 
education interventions in both RA and CVD (Chapter 3), are discussed. 
 
Phase I, or the modelling phase, aims to identify or improve understanding of the various 
components of the proposed intervention and qualitative research is recommended as a useful 
tool in this setting.  In order to develop patient education about CVD in RA it is important to seek 
the views of key stakeholders, namely relevant health professionals and patients.  Chapter 4 
describes a qualitative exploration of the perceptions of health professionals and how these could 
influence the subsequent content, timing and delivery of a programme whereas Chapter 5 
similarly explores RA patients’ existing health beliefs and perceived needs from a future 
intervention.   
 
Phase II, or the exploratory phase, defines components of the proposed trial, including outcome 
measures to be used, the nature of the control arm of the intervention and the precise nature of the 
trial itself.  As there was no extant measures of RA patients’ knowledge of CVD in RA, a new 
questionnaire had to be both constructed and psychometrically validated.  This is described in 
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Chapter 6.  The proposed complex education intervention will need to be compared to a control 
arm, whereby patients are provided with basic knowledge about CVD in RA, akin to existing 
leaflets about RA or its other co-morbidities.  The development of this leaflet, as well as its 
evaluation is described in Chapter 7.  Chapter 8 describes the exact nature of the complex 
education intervention developed, explaining how information gained from Chapters 4 and 5 was 
integrated to inform the design, structure, and duration of the programme. 
 
Phase III is the randomised controlled trial of the education intervention and is described in 
Chapter 9.  The final MRC framework phase IV explores the practicalities of long term 
implementation.  Chapter 10 discusses the issues that emerge from this thesis, as well as 
considering its possible limitations and future research directions.   
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CHAPTER 4: “ALL SINGING FROM THE SAME HYMN SHEET”: HEALTHCARE 
PROFESSIONALS’ PERCEPTIONS OF DEVELOPING EDUCATIONAL MATERIAL 
ABOUT THE CARDIOVASCULAR ASPECTS OF RHEUMATOID DISEASE 
 
Abstract 
 
Objective: Cardiovascular disease (CVD) is the leading cause of death in Britain and its 
prevention is a priority.   Rheumatoid arthritis (RA) patients have an increased risk of CVD and 
management of modifiable classical risk factors requires a programme with patient education at 
its heart.  Before a programme for RA patients is implemented it is important to explore the 
perceptions of patients and relevant healthcare professionals and consider how these could 
influence the subsequent content, timing and delivery of such education.  Here, we assess 
healthcare professionals’ perceptions. 
Methods: Qualitative focus group methodology was adopted.  Four group meetings of healthcare 
professionals were held using a semi-structured interview schedule. The focus group transcripts 
were analysed using Interpretative Phenomenological Analysis. 
Results: Three superordinate themes emerged: professional determinations about people with 
RA, including their perceptions about patients’ priorities and motivations; communication about 
CVD risk, including what should be communicated, how, to whom and when; and responsibility 
for CVD management, referring to patients and the healthcare community.  
Conclusions: Although healthcare professionals agree it is important to convey the increased 
CVD risk to patients with RA, there is concern they may be less proactive in promoting risk 
management strategies.  There was uncertainty about the best time to discuss CVD with RA 
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patients.  Maintaining a close relationship between primary and secondary care was thought to be 
important, with all healthcare professionals ‘singing from the same hymn sheet’.  These findings 
can inform the development of novel education material to fulfil a currently unmet clinical need. 
 
Introduction 
 
This paper describes the first in a pair of studies addressing opinions on the development of 
patient education to address knowledge and management of cardiovascular disease (CVD) risk 
among people with rheumatoid arthritis (RA).  CVD is the leading cause of death in Europe (1), 
and its prevention, diagnosis, treatment and rehabilitation is a priority (2).  Rheumatoid arthritis 
(RA) is a chronic inflammatory disease associated with an increased risk of CVD, which 
predominantly accounts for the excess mortality in patients with RA (3;4).  Comprehensive care 
of the person with RA therefore needs to focus not only on management of articular symptoms 
and prevention of joint damage but also on managing their cardiovascular risk.   
 
The increased risk of CVD in RA is attributed to accelerated atherosclerosis due to both classical 
risk factors for CVD and novel mechanisms such as systemic inflammation, and their interplay 
(5-7).  Classical risk factors may be fixed (e.g., older age, male sex, positive family history) or 
modifiable (e.g., smoking, hypertension, dyslipidaemia, sedentarity, obesity) and appear to be 
highly prevalent in patients with RA (8).  Although further research is required to elucidate the 
relative contributions these different factors make to overall CVD risk, management of 
modifiable classical cardiovascular risk factors is an obvious target.  This requires active 
identification and proactive intervention (5), which does not currently appear to be happening 
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systematically (8;9).  Recommendations by the British Society for Rheumatology suggest that all 
individuals with RA should have an annual assessment of all co-morbid conditions (10) and the 
Arthritis and Musculoskeletal Alliance standards of care for people with inflammatory arthritis 
specifically suggest an annual cardiovascular health check (11).  A similar approach is advocated 
in France (12).  To implement such a cardiovascular screening and intervention programme 
requires patient education to be at its heart in order to address such integral issues as patient-
professional concordance with both lifestyle and behavioural modifications as well as 
polypharmacy and primary prevention therapy (13).  Patient education programmes are well 
established in rheumatology (14).  However, no cardiovascular educational material or 
programme exists, designed specifically for patients with RA.  This has been recognised as a 
clinical oversight that should be addressed (13). The present paper is the first of a pair of 
manuscripts considering the design of such a novel educational programme; this endeavour will 
require input from both patients and healthcare professionals.  Patients needs and health beliefs 
must be explored and reacted to (15-17) and this is addressed in the accompanying paper (18).  
However, it is also important to explore the perceptions of healthcare professionals and consider 
how these could influence the subsequent content, timing and delivery of a CVD risk education 
programme for patients with RA.  It is these healthcare professionals who will be the source of 
referral to such programmes. Understanding the assumptions that healthcare professionals may 
bring to the design or structure of any patient education material is as crucial as understanding 
those of patients, especially as many education programmes include little or no patient 
involvement in the planning stages (15).   
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In order to fully explore healthcare professionals’ perceptions of CVD education for RA, a 
variety of opinions needs to be canvassed and explored in-depth providing the opportunity for 
ideas, not initially anticipated, to emerge.  Accordingly, a qualitative approach was adopted (19).  
Focus group methodology harnesses group interaction and allows discussion of each other’s 
experiences and should prove an appropriate and effective technique for exploring healthcare 
professionals’ attitudes (20).  The aim of the present study, therefore, was to explore, 
qualitatively, healthcare professionals’ perceptions of how to develop patient education regarding 
CVD risk for patients with RA.   
 
Methods 
 
a) Participants 
Participants consisted of 12 healthcare professionals who were considered to have relevant 
experience, including doctors and nurses from both primary and secondary care, specialising in 
rheumatology, cardiology and management of cardiovascular risk factors (Table 1).  Purposive 
sampling was used to recruit participants, from the pool of local healthcare professionals, with 
international, national and local expertise and to ensure a broad mix of participants in the sample. 
 
b) Procedure 
Local research ethics committee approval was granted and all participants provided informed 
written consent.  Four focus groups were held with, on average, 3 healthcare professionals 
attending each (range 2-5); the number of participants in each group was related to the pragmatics 
of convening clinical staff at mutually convenient times.  A semi-structured interview schedule 
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Table 1: Composition of the health professional focus groups 
 
Profession Focus  
group  
number 
Sex Age Specialty Special interest Years of  
relevant  
experience 
Medical doctor 1 Male 47 Rheumatology Cardiovascular 
disease 
20 
Medical doctor 1 Male 56 Chemical Pathology Obesity and 
dyslipidaemia 
20 
Director of 
Action Heart 
1 Male 45 Cardiac Rehabilitation  15 
Clinical nurse 
specialist 
1 Female 52 Community Cardiology Community 
Cardiac Liaison 
Nurse 
20 
Clinical nurse 
specialist 
1 Female 48 Cardiology Patient education 
and cardiac 
rehabilitation 
27 
Medical doctor 2 Female 57 Cardiology Patient education 
nationally 
28 
Medical doctor 2 Male 41 Cardiology Cardiac disease 
in rheumatoid 
arthritis 
12 
Clinical nurse 
specialist 
3 Female 45 Rheumatology Annual review 
clinics (including 
CVD risk 
assessment) 
21 
General 
practitioner 
3 Male 52 Primary Care CVD risk 
assessment 
23 
Medical doctor 4 Male 42 Rheumatology Medical 
education 
13 
Medical doctor 4 Male 47 Diabetes CVD primary 
prevention 
18 
Clinical nurse 
specialist 
4 Female 43 Diabetes Patient education 5 
 
was created (by HJ) based on a review of the existing literature (13) and discussed among all 
authors, who include rheumatology clinicians and qualitative researchers, prior to the interviews.  
The schedule contained core open-ended questions (Table 2), which were employed, along with 
probes and prompts, in all four focus groups in no set order.  The questions were non-directional 
and designed to stimulate in-depth discussion among participants.  Opinions that emerged but 
were not anticipated were followed up with more probing questions.  The focus groups were led 
105 
 
by HJ and facilitated by EDH. Each group discussion was audio-recorded and transcribed 
verbatim by a sole professional typist. 
 
Table 2: Semi-structured interview schedule for all focus groups 
Core open-ended questions       Relevant probes and prompts 
Could you please introduce yourself to the group, what job 
you do and the relevant experience you have for this focus 
group? 
 
What are your thoughts about cardiovascular education for 
patients with RA? 
• Is it the same as other patients with CVD? 
• Is it different to other CVD patients? 
• Are there different approaches to management of 
CVD risk factors if a patient has RA? 
• When should such education be given? 
What do you think are the important messages to convey 
to patients with RA about the increased risk of CVD?  
• Increasing awareness of associated CVD risk 
• Generic education on CVD 
• Discussion of risk factors 
• Lifestyle advice 
What do you think should be a priority for the doctor in 
managing cardiovascular risk for a patient with RA? 
• Primary prevention 
• Managing individual risk factors 
• Explaining relevance 
• Assessing compliance 
• Referrals to services that can support lifestyle 
modifications e.g., smoking cessation 
What do you perceive are the priorities of a patient with 
RA? 
 
• Managing arthritic pain 
• Optimising analgesia 
• Polypharmacy 
• Medications interacting 
• Worrying they may make their arthritis worse if 
they exercise 
• Needing a support group to motivate them for 
lifestyle modification 
• Do doctor and patient priorities clash and/or 
where do they match? 
• Do you perceive a patient wants to take 
responsibility for managing their disease 
themselves or do they want the doctor to take 
responsibility and treat everything with tablets? 
What are your experiences of suggesting medication or 
lifestyle changes to patients at risk of CVD? 
 
• Which do you feel most comfortable suggesting? 
• Which is easiest to suggest? 
• Which are patients most interested in? 
• What resources do you use to support lifestyle 
changes? 
How successful do you perceive we are currently in 
educating patients about CVD risk? 
• Primary prevention 
• Post MI 
• In high risk groups e.g. diabetics 
• How effective are we at supporting patients in 
lifestyle modification? 
What educational methods have you found helpful for 
patient education on CVD risk management? 
• Behaviour-orientated programmes 
• Written information 
• How do we engage people who don’t want to 
know? 
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c) Qualitative analysis 
Focus group transcripts were subjected to Interpretative Phenomenological Analysis (IPA).  IPA 
is a method of qualitative analysis that has become established in health research as an effective 
approach for exploring participants’ experiences.  IPA follows established yet flexible 
methodology (21;22) with two levels of analysis; the descriptive (phenomenological), which 
explores the participants’ personal perception of an event, and the explanatory (interpretative), 
whereby the researcher interprets the data in order to make sense of the personal experience of 
participants.  These interpretations were subsequently presented to participants to check that their 
views were not being misrepresented.  Thus, IPA can facilitate understanding of how individuals 
perceive illness and healthcare services (23), and may be used to learn from both the healthcare 
professional (24;25) and patient perspective (26).  The transcripts were primarily analysed by HJ.  
Subsequently EDH and GJT read the transcripts to confirm that the interpretation was reflective 
of the content of the original discussions.  Transcripts were analysed ideographically  
 (individually) and returned to in an iterative process as later focus group discussions informed 
the analysis.  Superordinate (overarching) themes were identified that represented a cohesive 
interpretation of the healthcare professionals’ opinions across all focus groups. 
 
Results 
 
Three superordinate themes emerged from the analysis: (i) professional determinations about 
people with RA; (ii) communication about CVD risk; and (iii) responsibility for CVD 
management.  Verbatim quotations are used to illustrate these three themes and square brackets 
are employed, where required, to provide context for the quotes. 
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The first theme describes the suppositions that the participants held about patients with RA.  
These healthcare professionals perceived that CVD risk would not be high on their agenda; 
rather, patients would be more concerned with management of their painful joints.  Furthermore, 
symptom relieving drugs were considered to be more of a priority than cardiovascular prevention 
medication: 
 
“Because the rheumatoid is painful and disabling, they’re not going to see the coronary 
disease side at all.” (focus group 2, participant 1) 
 
Healthcare professionals presumed that patients with RA would find various aspects of CVD risk 
management more difficult than patients without RA, particularly implementing lifestyle 
changes, such as exercise or coping with increasing polypharmacy.  It was also assumed that 
patients with RA, who may not yet have had a cardiac event, would be less motivated to engage 
in preventative healthy behaviours: 
 
“They’re not going to give up smoking, they’re not going to eat properly, they’re not 
going to do anything until we’ve got their disease under control.” (focus group 3, 
participant 1) 
 
“Patients do not have the motivation because they don’t feel the ill effect – you’re trying 
to prevent something in the future.” (focus group 1, participant 2) 
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The second superordinate theme concerned communication about CVD risk.  When considering 
the design of a patient education programme, issues such as what, how, when and with whom 
should these healthcare professionals communicate emerged as important considerations.  
Essentially, any education programme must convey the increased risk of CVD in patients with 
RA: 
 
“… putting on the agenda that arthritis is more than just the joints…” (focus group 4, 
participant 1) 
 
Participants also discussed how to convey the, sometimes difficult, concept of future risk: 
 
“They [patients] are saying ‘What is he talking about? I am feeling well’.” (focus group 4, 
participant 2)  
 
An important sub-theme that emerged unprompted in all focus groups was the importance of 
conveying adequate information to allow patients to make informed choices; participants 
discussed how patients should be given the opportunity to negotiate their specific priorities with a 
healthcare professional.  For the participants, the dual benefits of lifestyle modification for RA 
and CVD were regarded as an important message to get across: 
 
“... lifestyle modifications… make sense from both the rheumatoid point of view and the 
cardiovascular point of view.” (focus group 1, participant 1) 
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How information should be communicated to patients was also viewed as critical to such an 
education programme.  Participants perceived that raising the issue of increased CVD risk to 
patients with RA was akin to breaking further bad news: 
 
“… when you’re dealing with people with rheumatoid arthritis I guess you also have to 
break the news to them that they’re potentially at added risk of cardiovascular disease…” 
(focus group 1, participant 3) 
 
“… it’s not a very palatable conversation to have though, is it…” (focus group 2, 
participant 2) 
 
The matter of who multidisciplinary rheumatology teams should communicate with emerged.  
Beyond communication with patients, dialogue between healthcare professionals in primary and 
secondary care was considered essential.  Primary care professionals regularly calculate CVD 
risk scores; good communication with general practitioners could prompt sharing of this 
information and avoid duplication.  Importantly, educating general practitioners about the CVD 
risk associated with RA will mean a consistent message is given to patients by all healthcare 
professionals: 
 
“If they’ve [the patient] got all groups [of healthcare professionals] saying the same thing, 
we’re all singing from the same hymn sheet… then they might actually think, well, maybe 
I should…” (focus group 3, participant 1) 
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The timing of an educational intervention provoked mixed opinions from the healthcare 
professionals; their dilemma was that: 
 
“… what we need to do is get over to them [patients] the priority of this [CVD] as an 
important issue… or do we do that once we’ve got them [i.e. their disease] under 
control?” (focus group 3, participant 1) 
 
Some participants felt that education about CVD should be included in all interactions with 
patients from the moment of diagnosis because: 
 
“… the new diagnosis of rheumatoid arthritis is one of those golden opportunities for 
people to stand back and look at their lifestyle and be at a motivated stage where they can 
take control of their health condition.” (focus group 1, participant 3)  
 
This was considered to be because:  
 
“If you leave it too long… they will say ‘Oh, what’s he doing? I’ve been fine for the last 
year and now he’s telling me about cholesterol, he’s telling me about blood pressure.’” 
(focus group 4, participant 2) 
 
Other participants stated they would delay patient education: 
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“If you tell them too much in one go, you’ll either frighten them to death and they won’t 
come back or they’ll switch off.” (focus group 4, participant 3) 
  
Further, patients’ priorities were judged to change over time: 
 
“… in the beginning it is the rheumatoid arthritis [that patients are most concerned with] 
and probably this may not be the best time to tackle everything… after you’ve controlled 
the pain… then they are probably more receptive to other areas.” (focus group 1, 
participant 2) 
 
This issue of priorities links into the third superordinate theme: responsibility for CVD 
management.  Participants judged that patients themselves have a responsibility to take advantage 
of the opportunities offered and to engage with services available: 
 
“I think as long as patients, all of them, are equally informed… each person has to take 
responsibility for their own actions.” (focus group 1, participant 2) 
  
The responsibilities that healthcare professionals identified for themselves included both 
provision of resources and further research to answer clinical questions.  To support patients 
implementing lifestyle changes, adequate resources were deemed to be required and should be 
accessible to all cultural and other minority groups, as well as being available in different 
formats, and facilitated by different types of professionals and the patients themselves: 
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“It’s easy to give out information and to give booklets but what really is needed is some 
support to carry through those messages.” (focus group 1, participant 3) 
 
Equally important is that such resources should remain available for patients to access, even if 
initially they do not feel able or ready to participate: 
 
“… they [patients] should know that the offer is still there if they want to engage at any 
time...” (focus group 1, participant 1) 
 
Participants identified a clear need and responsibility to increase research in certain areas.  Issues 
such as being able to include RA as a risk factor in cardiovascular risk calculators to help more 
accurately determine CVD risk was highlighted: 
 
“I’d want to be able to quantify the risk.” (focus group 3, participant 2) 
 
“The difficult bit is can you fit your rheumatoid patients into those risk registers… 
because they’re [the risk registers] rather crude… they don’t look at other risk groups.” 
(focus group 2, participant 2) 
 
Further, participants wanted a set of targets for risk factor management agreed with primary care 
and long term studies on both adherence to primary prevention and the effects of lifestyle 
modifications: 
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“Do we begin to set targets for patients that they can work with us together on?” (focus 
group 3, participant 2) 
 
Discussion  
 
Exploring healthcare professionals’ perceptions of developing novel education material has 
identified assumptions currently held.  This will inform how CVD risk messages are delivered.  
There was a clear presumption that patients with RA would not view CVD as a priority.  
Unfortunately this may afford a rationale for failing to inform patients about the clear association 
between RA and unfavourable CVD outcomes.  Healthcare professionals have been reported to 
find ‘breaking bad news’ stressful (27), and so may unwittingly exploit the presumption of 
patients’ priorities as a reason for not informing or delaying informing patients of CVD risk.  
This potential ‘gatekeeping’ of information may deny the patient the opportunity to make 
informed decisions about their lifestyle and could be considered to reflect a type of medical 
paternalism that constrains patients opportunities to act with autonomy; in developing novel 
education material, this defensiveness will necessarily have to be both acknowledged and 
challenged.    
 
Healthcare professionals interviewed also presumed that implementing lifestyle changes would 
be harder for patients with RA than for others.  As a consequence, they might be reluctant to 
encourage patients to initiate beneficial lifestyle changes.  For example, some healthcare 
professionals stated that those in pain may find it more difficult to stop smoking.  However, 
people in pain report that they are just as likely to feel ready to quit smoking than those without 
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pain (28) and, indeed, some of patient participants, in the accompanying paper, describe the 
motivation they had to quit smoking (18).  Accordingly, it would seem important to actively 
encourage smoking cessation, despite the scepticism of professionals.  In addition, healthcare 
professionals may ‘excuse’ patients from undertaking behaviour change.  Some doctors believe 
that they need to empathise with overweight patients to maintain a good patient-professional 
relationship (25).  However, empathising or excusing a patient from addressing unhealthy 
behaviours may inadvertently be giving the patient permission to persist with their current 
behaviours, which the patient could interpret as tacit approval.  The assumption that patients will 
be less motivated to engage in healthy lifestyle behaviours prior to a cardiac event may similarly 
result in healthcare professionals not promoting lifestyle modifications with sufficient vigour.  
Motivation for behaviour change is complex, and is not simply a function of a previous adverse 
health event.  It has been shown that women are more motivated than men, whereas perceiving 
oneself to be too old or too young, as well as finding medical advice conflicting at times, 
undermines motivation to change (29).  The Theory of Planned Behaviour proposes that 
behaviour depends on a person’s attitudes, based on beliefs of risk and evaluation of the outcome, 
toward the behaviour (30).  It also posits that social norms and perceived behavioural control, i.e. 
self-efficacy, are very important.  Indeed, perceived behavioural control has been shown to be the 
most influential component of the theory when it comes to predicting future lifestyle changes 
after a diagnosis of coronary heart disease (31).  Therefore, instead of assuming that patients with 
RA will be poorly motivated to modify their lifestyle, healthcare professionals could consider 
how they can enhance and support their patients’ self-efficacy for changing unhealthy 
behaviours.  This should be an intrinsic component of any new education material.  This is 
discussed further in our accompanying patient-centred analysis (18). 
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Given the preconceptions that healthcare professionals appear to hold about CVD risk-related 
behaviour change among RA patients, the development of education programmes is a challenging 
task (32;33).  Nevertheless, it is an important pre-requisite for patient participation in an informed 
decision-making process, as part of the patient-professional partnership.  This concordance is 
particularly critical for lifestyle modifications (34).  Indeed, the concept of shared responsibility 
was addressed again in the third superordinate theme on responsibilities.  Discussions 
surrounding the timing of a patient education programme proved interesting.  There was 
consensus about identifying a ‘golden moment’, i.e., that point in time when a patient will 
objectively self-assess their health status and lifestyle and commit themselves to a specific 
behaviour change.  Healthcare professionals need to capitalise on this moment. The 
Transtheoretical Model of behaviour change describes pre-contemplation, contemplation, 
preparation, action and maintenance as five stages through which patients pass (and may relapse 
and cycle through) to achieve permanent behaviour change (35).  The preparation stage is when 
patients take preliminary steps towards making a specific change (36) which could be considered 
analogous to the ‘golden moment’.  Clearly, this point will be reached by different patients at 
different times, and by some it will not be reached in time.  The challenge for healthcare 
professionals is not only to identify this point in different individuals but also to use this 
opportunity to encourage definitive action to modify behaviour and to provide adequate resources 
to support this commitment to change. The arthritis-specific and generic self-management 
programmes that have been set up and tested over the past decades (37;38) provide several 
important lessons about locally and individually tailored delivery of such education. 
 
116 
 
A salient finding from the present study is the perceived importance of maintaining and 
improving a close relationship between primary and secondary care.  Mutual guidelines, 
electronic patient records, and transfer of information across the primary/secondary care interface 
will help to develop seamless care (39).  This not only prevents duplication (e.g., cardiovascular 
risk scores) but, importantly, also allows all health professionals to be “singing from the same 
hymn sheet”.  Conflicting information from a general practitioner and consultant could prevent a 
patient from making progress and decrease the patient’s confidence in the healthcare system (40).  
We would argue that the responsibility lies with secondary care, as well as the research 
community, to disseminate guidance to primary care highlighting the relationship between CVD 
and RA.  As the present study revealed, this guidance will inevitably need to include specific 
information, such as how to ‘fit’ patients with RA into existing CVD risk calculators, as well as 
identifying specific targets for risk factor management that both primary and secondary care can 
work towards co-operatively.  Cardiovascular risk charts based on the Framingham risk 
algorithms do not include some CVD risk factors, such as family history, being of South Asian 
origin, or having RA (41).  Further research is clearly needed here and it is pertinent that this was 
identified as a priority in this study. 
 
Strengths of the present study are that it addresses a currently neglected clinical issue, and that it 
highlights preconceptions and presumptions which, when challenged and addressed, will impact 
directly on the quality of patient care.  A broad range of people with relevant expertise were 
recruited from primary and secondary care and a robust qualitative analytical methodology was 
employed.  The sample size was necessarily small but it conformed to the norms for IPA research 
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(21).  In qualitative research, the sample is selected primarily to illuminate the phenomena of 
interest (42), and it is “not the amount of data but rather the richness of the data” which is 
important (43).  Purposive sampling of participants who could provide detailed narratives 
allowed the generation of an in-depth analysis to enable the phenomena to be understood; simply 
selecting more participants would have diluted the interpretation of the phenomena (44).  The 
participants recruited have been involved in the first combined rheumatology/cardiology clinic in 
the UK; hence their narratives offered the necessary excellent insight.  The views expressed here 
reflect those of a specific group of healthcare professionals from one region of the UK rather than 
those of the worldwide community of relevant rheumatology and cardiology healthcare 
professionals.  Generalization is a secondary concern with all qualitative research (42), although 
this does not mean that it is not possible to theoretically or conceptually generalize from such 
research (45).  It is suggested that as long as the clinical problem is the same, then the theoretical 
findings will also probably apply, even in different settings (44) thus comparisons can be made 
between similar people in similar circumstances (46;47).  It is more than likely that the emergent 
themes from the present interviews will have international resonance. Future studies, however, 
could involve healthcare professionals from other regions and also involve other members of the 
multidisciplinary team, such as physiotherapists and occupational therapists, to broaden 
knowledge of the wider team input. 
 
In summary, this study has revealed that currently healthcare professionals may be less proactive 
in promoting CVD risk management strategies to patients with RA than to patients without RA.  
In terms of timing, there was some uncertainty as to when CVD risk strategies should be 
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incorporated into patient education programmes but the need to maintain close relationships with 
primary care was evident.  These findings, complemented by an examination of RA patients’ 
perspectives in our accompanying paper (18), can be directly translated into clinical practice by 
informing the design of novel health educational material.  This material needs to address the 
CVD co-morbidity associated with RA, actively encourage necessary lifestyle modifications, 
support patients’ self-efficacy to implement behaviour change and signpost patients to helpful 
resources.  Ultimately, this should improve the quality and length of RA patients’ lives. 
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CHAPTER 5: “EXTRA INFORMATION A BIT FURTHER DOWN THE LINE”: 
RHEUMATOID ARTHRITIS PATIENTS’ PERCEPTIONS OF DEVELOPING 
EDUCATIONAL MATERIAL ABOUT THE CARDIOVASCULAR DISEASE RISK 
 
Abstract 
 
Objective: There are no patient education programmes addressing the increased risk of 
cardiovascular disease (CVD) associated with rheumatoid arthritis (RA).  This is the second in a 
pair of studies exploring stakeholder perceptions of developing such educational material.  
Healthcare professionals’ perceptions were explored in the first study; here we explore the 
perceptions of people with RA.  
Methods: Semi-structured interviews were held individually with 18 people with RA, 
purposively sampled to include participants with no co-morbid history of CVD, those with CVD 
risk factors, and those who had experienced a CVD event.  The interview transcripts were 
analysed using Interpretative Phenomenological Analysis.  
Results: Four superordinate themes were identified: experiences of living with RA; reactions to 
learning about co-morbid CVD; implementing lifestyle changes; and expectations of education.  
Participants found being diagnosed with RA a devastating experience and were mostly unaware 
of their increased risk of CVD co-morbidity.  They explained how information about CVD would 
be overwhelming and irrelevant at diagnosis, but they would have coped with “extra information 
a bit further down the line.”  
Conclusion: There is a need to develop educational material or programmes.  Their design must 
consider factors which facilitate lifestyle change, such as motivation or receiving personalised 
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advice, and factors that inhibit change, such as depression or fatalism.  Emphasizing the positive 
effects that some CVD lifestyle changes may have on RA symptom control may be particularly 
persuasive. Group education would be a popular format. These findings can be directly translated 
into clinical practice. 
 
Introduction 
 
This paper describes the second of a pair of studies addressing the important and pressing 
requirement to provide patient education designed specifically for people with rheumatoid 
arthritis (RA) that addresses their risk for co-morbid cardiovascular disease (CVD).  CVD mainly 
accounts for the excess mortality in RA patients (1).  New CVD screening programmes for 
patients with RA have been advocated recently (2;3) and patient education is an important 
corollary (4).   
 
In the general population, controlled studies of CVD patient education programmes versus usual 
care have shown relative improvements in behaviours, risk factors and actual cardiac events in 
both primary (5;6) and secondary (7;8) prevention settings.  The only published study of CVD 
patient education intervention in patients with RA was a small non-controlled trial where 
participants attended an additional nurse specialist clinic to identify and address CVD lifestyle 
factors; the intervention led to modest improvements (9).  The authors acknowledged the 
challenge in trying to change these patients’ behaviours.  An approach to developing new 
educational material in this context takes as its starting point the involvement of the key 
stakeholders.  In our accompanying paper we explore the perceptions of healthcare professionals 
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(10); the other stakeholder group is the patients themselves.  Any educational intervention must 
address both patients’ health needs and health beliefs (11;12). 
 
Patients’ needs may not be the same as those presumed by healthcare professionals (13-15).  In 
addition, patients’ beliefs about illness or disability, which are likely to underpin their behaviour, 
may not be congruent with a healthcare professionals’ medical model of disease (11;16).  
Educational interventions that do not take account of any divergence of opinion may be less than 
optimally effective.  The evidence also supports the involvement of patients in designing services 
and resources.  Patient information leaflets developed by healthcare professionals in conjunction 
with consumers compared to those developed by healthcare professionals alone were judged 
more relevant, understandable and readable to patients (17).  Patient involvement in service 
development highlighted their specific health needs and suggested strategies to address them 
(18;19).  Certainly, the benefits of consumer involvement in the NHS has ensured that it is now a 
prominent feature of government health policy and its importance at all levels of the health 
service is widely recognized (20).  
 
There has been a call for more qualitative research with patients in order to understand their 
health needs and to inform the development of educational material (21).  A qualitative approach 
allows the researcher to explore the full breadth of patient experiences and may reveal concepts 
that were not predicted, but may be central to understanding the patient perspective (22).  Group 
dynamics may constrain personal disclosure and discussion of the full breadth of an individual 
patient’s experiences. Thus, individual interviews, which maintain confidentiality, were 
considered the most effective manner to explore patients’ perceptions (23).  The aim of this paper 
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is therefore to explore qualitatively RA patients’ perceptions about developing novel educational 
material to address their associated CVD risk. 
 
Methods 
 
a) Participants 
Eighteen participants with a diagnosis of RA were recruited.  Purposive sampling was used to 
include participants from three groups; those with no co-morbid history of CVD or CVD risk 
factors, those with CVD risk factors, and those who have had a CVD event.  Both men and 
women were recruited and the age range was deliberately broad (Table 1).  All participants had to 
be able to read, understand and speak English.  Patients with severe mental illness or terminal 
physical illness were excluded.   
 
Table 1: Demographic details of the participants interviewed 
Participant Sex Age CVD co-morbidity or risk factors 
HG Female 45 - 
EB Female 56 - 
MR Male 70 - 
AB Male 33 - 
KW Female 31 - 
AH Male 51 - 
MD Male 67 Hypertension; Hypercholesterolaemia 
SE Male 62 Hypertension; Obesity 
EC Female 31 Obesity; Smoker 
EL Female 54 Diabetes; Hypercholesterolaemia; Obesity 
MH Female 67 Diabetes; Hypercholesterolaemia 
FB Male 67 Angina 
 MW Male 59 Coronary artery bypass graft 
TH Male 66 Myocardial infarction 
IP Male 58 Angina 
PH Female 68 Angina; Coronary stents inserted 
BC Male 64 Myocardial infarction 
PC Female 72 Angina 
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b) Procedure 
Ethical approval was obtained and written informed consent was gained from all participants.  A 
semi-structured interview schedule was created by HJ and its content and probes were agreed by 
all authors (Table 2).   
 
Table 2: Semi-structured interview schedule used in the individual patient interviews 
Core open-ended questions Relevant probes and prompts 
Would you please introduce yourself describing where 
you live, how old you are and how long you have had 
rheumatoid arthritis? 
 
Could you tell me what you understand by the expression 
‘heart attack’? 
 
Could you tell me what you understand by the term 
‘stroke’? 
 
Have you any experience, either yourself or a friend or 
family member, of heart attacks or strokes? 
 
Have you heard about any link between rheumatoid 
arthritis and heart attacks and strokes? 
  
If I confirm that there is a link and that patients with RA 
are more likely to have heart attacks and strokes, would 
you like to ask me any questions? 
 
Is there any other information you would want to know?  
 
• Why are these associated?  
• How much more likely is a patient with RA to 
have a heart attack or stroke?  
• What can be done to decrease this risk of a heart 
attack or stroke?  
• Is this due to the medications a patient with RA 
takes?  
Would you want to try and decrease this chance of heart 
attacks and strokes?  
• By making changes yourself? 
• Would you prefer the doctor to treat you with 
tablets? 
Stopping smoking, controlling your weight, lowering your 
cholesterol and exercising are important things that help 
to decrease the likelihood of heart attacks and strokes. 
How easy would you find it to do these things?  
 
What do you think might it take to persuade or motivate 
you to start to do more of these healthy lifestyle 
activities? 
• Understanding why or how doing these healthy 
activities actually makes a difference 
• Having an actual heart attack or stroke 
• Partner or close family member asking them to 
make healthy changes to their lifestyle 
• Partner or close family member doing it with 
them 
• Believing in themselves that they really can do 
it 
• Tried doing these healthy lifestyle changes 
previously and they felt better for it 
• Joining a group to help ‘kick-start’ a new 
healthy lifestyle 
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Many people know that stopping smoking, taking more 
exercise etc is good for their health, but they still don’t do 
it. What reasons might stop you from taking more 
exercise or improving your diet for example? 
 
• Not believing these things really makes a 
difference to their health 
• Doing it on their own 
• Would be hard to do because the rest of the 
family smoke, for example 
• Having close family who wouldn’t support 
them 
• Have tried stopping smoking before but failed 
and don’t think they can do it again 
• Too busy/ too stressed/ not a ‘convenient’ time 
to make these changes 
• Don’t believe they have the inner strength to 
make these changes 
• Worried that there may be consequences of 
taking up a healthy lifestyle e.g., exercise may 
make their arthritis worse. 
What things might help you maintain this healthier 
lifestyle? 
 
• Ongoing support of family 
• A partner who does it with you and to whom 
you are accountable 
• Local support group 
• Facilities available to help e.g. with exercise 
What facilities would you find most helpful to support 
you making these changes to a healthier lifestyle 
 
• Written information 
• Internet resources 
• Opportunity to attend a talk about why you need 
to make these changes  
• Attending a small group session to discuss 
practical advice in how to make these changes 
• Availability of smoking cessation group/ 
nicotine replacement therapy 
• Having a ‘buddy’ scheme to support you with 
these changes 
• Availability of exercise facilities to use 
• Advice from their doctor and nurse to make 
these healthy lifestyle changes 
 
The ethos and approach of the semi-structured interview has been described elsewhere (10).  
Initial interviewees were happy with the interview schedule and process and so the interview 
schedule was not amended following this patient-involvement.  All interviews were conducted by 
one author (HJ); they were held in a private room in the hospital and lasted between 32 and 63 
minutes each.  The interviews were audio-recorded and the recordings transcribed verbatim by a 
sole professional typist. 
 
c) Qualitative analysis 
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Interview transcripts were analysed using Interpretative Phenomenological Analysis (IPA) (24).  
The theoretical basis and practical application of IPA to generate superordinate themes has been 
described in our accompanying paper (10) and in detail elsewhere (25).  Transcripts were initially 
analysed by HJ; GJT and EDH also read the transcripts to confirm the representativeness of the 
resultant themes.  Interpretation was also confirmed with the participants individually by 
telephone; all participants were happy with our interpretation of their interview. 
 
Results 
 
Four superordinate themes were identified from the analysis: (i) experiences of living with RA; 
(ii) reactions to learning about co-morbid CVD; (iii) implementing lifestyle changes; (iv) 
expectations of education.  Verbatim quotations illustrate these themes.  Square brackets are 
employed, where necessary, to provide context for the quotes. 
 
The theme highlighting experiences of living with RA includes patients’ reactions to being 
diagnosed with RA.  For most participants this was a devastating experience, for some because it 
represented the onset of ill-health whereas for others it was the disabling effects of RA that were 
so worrying: 
 
“… when you’re younger, you think you’re invincible... and you’re never going to get ill, 
but then when you actually think it might happen to me…” (HG) 
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“It felt as though my life was virtually ended.  Everything I loved to do was stopped and 
then what have I got in life?  What’s life worth living for?  I can’t do anything…” (MH) 
 
Controlling their joint pain, unsurprisingly, emerged as the most important consideration for 
participants and any lifestyle changes initiated were with the aim of controlling their RA 
symptoms: 
 
“I know it’s [smoking] not good for the rheumatoid… so that’s why I decided I wanted to 
cut down and that’s what I have done.” (EB) 
 
For many participants, living with RA involved taking personal responsibility for their health: 
 
“Part of the rehabilitation of having rheumatoid arthritis, along with the brilliant drugs… 
is you’ve got to help yourself.  ” (AB) 
 
This was often motivated by wanting to minimise the risk of further adverse functional health 
outcomes in the future and to allow them to fulfil future roles: 
  
 “I don’t want to be…incapacitated in any way when I’m older” (AB) 
 “… my grandson… I want to be here to see him.” (MW) 
 
Conversely, other participants described taking much less personal responsibility for their health 
and had a more fatalistic outlook of the future: 
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“Why shouldn’t I enjoy it [smoking] now when potentially in 20 years I’m stuck in a 
wheelchair… and I don’t really care if I have a heart attack and drop down dead.”(EC) 
 
The second theme concerned participants’ awareness of co-morbid CVD.  Essentially, the vast 
majority were unaware of the association between RA and CVD: 
 
“… rheumatoid to me, it’s all in the bones… I didn’t think that would have affected your 
heart.” (BC) 
 
This generated several questions from the patients.  Firstly, why is RA associated with CVD? 
  
 “Is it the arthritis or... the drugs?”(EC) 
 
Exploring participants’ beliefs about the aetiology of CVD revealed that some attributed CVD to 
powerful external factors, rather than their own lifestyle: 
  
“… if [the government] do a full survey on all the nitrates and phosphates and everything 
else that’s thrown on the land in order to grow stuff, they’ll find out that all them 
chemicals have a lot to do with heart attacks… But… that ain’t never going to happen.  
So they come up with a theory that… smoking is a big contributor…” (TH) 
 
Such views were in the minority, however, and most participants listed some of the classical risk 
factors when describing their understanding of a heart attack and stroke. 
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Patients were also interested in what could be done to address cardiovascular risk: 
 
 “Is there anything you can do to prevent it? I’m very keen on prevention.” (HG) 
 
When would patients with RA feel most receptive to education about CVD?  Patients with 
established RA felt, retrospectively, that discussing CVD risk at the same time as making a 
diagnosis of RA would not only have been overwhelming, but also irrelevant: 
 
“I’d have topped myself… Do they need to know all the information in one go?” (EB) 
 
“I’d have thought, yeah and? I think I’ve got bigger things to worry about at the moment.” 
(EC) 
 
Interestingly, patients felt that, given time to adapt to their diagnosis of RA, they would then feel 
ready and able to cope with information about co-morbid CVD: 
 
“Maybe when it’s [RA] got controlled a bit more, so you stop having the tunnel vision of 
arthritis, arthritis, arthritis, my joints hurt, my joints hurt.  Once it’s controlled… I think I 
certainly would have been better able to deal with extra information a bit further down the 
line.” (EC) 
 
The theme that centred on implementing lifestyle changes describes both reasons why 
participants have, or have not, made behavioural changes already.  They articulated a number of 
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factors to explain why they had changed their behaviour, including being proactive and taking the 
initiative, being personally motivated to make changes, being inspired by seeing the benefits of 
lifestyle modification, receiving personal advice and having an actual cardiac event: 
 
“I think with smoking I think it’s got to come from within.  It’s no good just saying… 
we’ve got to give up smoking.  It don’t work like that, it never will work for a smoker.  
It’s got to come from within here – you really want to give up.” (TH) 
 
Researcher: “How easy did you find it to stop smoking?” 
MW: “Quite easy when somebody tells you it’s a warning, you’re going to have a heart 
attack if you don’t stop smoking – I just stopped.” 
 
Conversely, some participants had felt unable so far to implement lifestyle changes.  Reasons 
here included denial, depression, feeling self-conscious (about their weight or disability), lack of 
motivation or underestimating their cardiac risk: 
 
“I’ve thought about it [joining a gym] for months and months and I keep thinking I ought 
to really try and join… I think it’s just the thought of starting… it’s like the unknown and 
just sort of thinking, well, I’d really like to have a go but what would it be like?” (EL)  
  
“… if I had a serious heart attack, then I would probably change my ways a lot but touch 
wood, I haven’t really had a serious one.” (BC) 
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The final theme on expectations of education reflects what patients asked for, namely, common 
sense advice that addresses their uncertainties: 
 
“I don’t know what sort of exercise to do.  So like some sort of exercises which could 
help my heart but not hinder the rheumatoid arthritis.  Because it’s no good me doing the 
exercise to help my heart if it’s going to make my arthritis worse because that’s a vicious 
circle isn’t it really?” (EL) 
 
How healthcare professionals communicate information was considered important by all patients: 
 
“… a leaflet just sometimes poses questions that they can’t often have answered.  I think 
talks are the way forward… people begin to have more of an understanding and they’re 
not alone really.” (MH) 
 
The idea of group education was popular, particularly because participants valued the opportunity 
to meet others with the same condition and to learn from their experiences: 
 
“…you feel so isolated - when you’re on your own… but talking in a group and you 
suddenly realise there’s other people in the same situation as you and you can talk things 
over… so in a group session I think it’s far better.” (PC) 
 
Importantly, there was a plea from patients for staff to not only communicate information to them 
but also to listen to their concerns: 
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“…[healthcare professionals] don’t really show any interest because they listen but they 
don’t hear.” (MR) 
 
Such clear expectations of an education programme will guide the healthcare professional when 
developing novel patient education. 
 
Discussion  
 
This study offers rheumatology healthcare professionals a valuable insight into the perceptions 
that people with RA hold about developing a novel CVD education programme. Gaining a deeper 
understanding of a patients’ personal experience of living with RA allows us to appreciate the 
context in which further decisions about their health will be made.  The emotional impact of a 
diagnosis of RA has, similarly, been described in other studies (19;26).  This study adds that 
potential improved control of their RA is the primary reason why patients have implemented 
behaviour change.  Addressing patients’ symptom control must be achieved before other health-
related interventions, such as CVD risk education, could seem personally relevant; this is again 
reflected in the quotes relating to the timing of an educational intervention.  Some lifestyle 
measures intrinsic to cardiovascular risk management, such as smoking cessation, also benefit 
management of RA (27). Such dual benefits were also identified by the healthcare professionals 
(10).  These patient interviews suggest that emphasizing the positive effects such lifestyle 
measures may have on the management of RA may be more persuasive. 
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Patients with RA appear to be unaware of their risk of CVD co-morbidity.  This most likely 
reflects the lack of current patient education (4).  Poor levels of awareness of CVD co-morbidity 
have also been found in other at-risk patient groups, such as people with diabetes (28).  
Leventhal’s Common-Sense Model suggests that how a person will react and cope when 
confronted with an(other) illness will depend on their beliefs or cognitions about that illness 
(informed by considering the identity/label, the perceived cause, the time-line, the consequences 
and the curability/controllability  of the illness) as well as their emotional response (29).  The 
model then proposes that an individual will develop coping strategies, either ‘approach coping’ 
techniques such as taking necessary medication or making relevant behavioural changes, or 
‘avoidance coping’ techniques, such as denial (29).  In this study, participants did describe being 
able to take on board the realisation they were at added risk of CVD provided they were informed 
about CVD at an appropriate time.  The role of healthcare professionals is to then encourage the 
adoption of helpful ‘approach coping’ techniques. 
 
Given the lack of awareness, it was not surprising to discover that few patients appear to have a 
good knowledge about CVD, with some participants describing quite complex, but incorrect, 
aetiological models of disease (30).  Lack of relevant knowledge has been documented not only 
in patients undergoing primary prevention (31) but also secondary prevention of CVD (32).  
Additionally, it is not uncommon to uncover patients’ health beliefs incongruent with those of 
healthcare professionals; such health beliefs may be formed from a wide variety of sources 
(including political or economic factors or the wider natural or man-made environment) and link 
ill-health to surrounding circumstances to generate personal theories of disease causation or ‘lay 
epidemiology’ (33).  The implication, however, of misconceptions about CVD is that they will 
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inform illness cognitions which may then afford a rationale for poor motivation to make long-
term lifestyle changes.  An example is regarding myocardial infarction as an acute event, rather 
than as a symptom of chronic atherosclerotic disease (34).  Conversely, improving knowledge 
and understanding about the aetiology of CVD, by exposing patients to educational material, 
should theoretically provide the framework for patients to understand why specific lifestyle 
changes or pharmacological interventions are required (32;34).  In practice, however, knowledge 
alone does not always result in behaviour change (35;36).  Other social cognitive factors need to 
be invoked to explain why behaviour change is, or is not, implemented.  An individuals attitude 
to a behaviour, social norms and their self-efficacy for that behaviour, are examples of such 
factors proposed by the Theory of Planned Behaviour (37).  Many of the quotes from this patient-
focused study illustrate the importance of these factors and are worthy of further discussion to 
help inform a CVD risk education programme. 
 
Patients’ inaccurate perception of risk may act as a barrier to implementing behaviour change.  
Understanding the concept of 10 year cardiac risk is difficult and, instead, patients tend to base 
their risk perception on emotions related to experiences of friends or family (31).  This may 
explain why many patients perceive their own CVD risk inaccurately.  Research has shown the 
majority of RA patients were incorrectly optimistic about their risk, and this could limit their 
motivation for behavioural change (38).  Although communicating risk is identified as a 
challenging task for healthcare professionals (39), effective risk communication will need to be 
an integral component of a CVD education programme for people with RA. 
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Depression may have a moderating effect on the impact of self-management training on patients’ 
self-efficacy (40), which in turn may affect their intentions to implement behaviour change.  
Unfortunately, patients with RA and co-morbid CVD show higher depression scores than RA 
patients without CVD (41), perhaps mediated through venting of emotions (42).  Thus, an 
important part of any educational programme addressing CVD risk in patients with RA should 
include the opportunity to screen for depression, and to refer for appropriate treatment where 
detected (43).  
 
A striking finding from this study was the variation in levels of personal responsibility that 
different individuals held.  Whereas some participants felt personally responsible for their health 
and were enthusiastic to engage in disease prevention, other participants took a more fatalistic 
view.  This is not uncommon (36).  Lay epidemiology includes personal theories whereby ill 
health is thought to be due to either luck or fate, factors beyond a persons control, or is 
unavoidable because of previous experiences, which could make personal behaviour change seem 
irrelevant (31;34;36).  Addressing such lay beliefs must, therefore, be a pre-requisite imperative; 
tailored patient education could achieve this.  
 
Lay beliefs may further affect behaviour through patients’ conception of ‘coronary candidacy’.  
Coronary candidacy describes the lay perception of ‘the type of person who gets heart trouble’ 
(44).  Such a perception will be informed by society, the media or anecdotal experiences of 
friends and family and may have a very powerful effect in terms of informing social norms and 
motivating people to implement behaviour change.  If a person does not believe that they fit the 
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description of a coronary candidate, even in the presence of several risk factors for CVD, they 
may not be motivated to make behavioural changes.   
 
Encouragingly, the participants were able to identify several factors that had facilitated 
appropriate behaviour changes.  Participant TH described stopping smoking having finally made 
a personal commitment to change, analogous to the preparation and action stages of the 
Transtheoretical Model of behaviour change (45).  For participant MW, simply receiving 
personal advice from a healthcare professional about the consequences of smoking was enough to 
make him stop smoking.  This is contrary to healthcare professionals’ perceptions that people 
with RA would not consider CVD a priority or would find it harder to implement lifestyle 
changes (10).  This should serve to remind healthcare professionals that their perceptions may be 
inaccurate and that they may underestimate the power and influence of their own advice to 
patients.  
 
Participants who had achieved behavioural change frequently referred to personal motivation, 
being proactive or taking the initiative as being key.  How does such motivation translate into 
action?  And what can we learn to help motivate others?  ‘Wellness motivation’ conceptions of 
the self are thought to be particularly important (46).  A study into the role of self knowledge and 
the modification of cardiovascular risk suggested the following useful framework to consider in 
future cognitive behavioural programmes: representing the issue (how do I desire myself to be? 
how would friends and family want me to be? what am I afraid of becoming?), evaluating the 
issue (creating short and long term goals and expectations for behavioural outcomes, gauging my 
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personal efficacy) and implementing behavioural action (creating behavioural strategies, 
negotiating the social context and creating self monitoring strategies) (46). 
 
These interviews generated a rich account of the factors that either motivated patients to 
undertake or inhibited them from undertaking lifestyle modification.  In contrast, healthcare 
professionals articulated far fewer reasons why patients may, or may not, modify their lifestyle 
(10).  This suggests that we, as healthcare professionals, have a lot to learn from patients, and the 
effectiveness of future education programmes may be less than optimal unless patients are truly 
‘heard’ as well as ‘listened’ to.  
 
With regard to the practicalities of designing a novel education programme, the timing of 
intervention appears to be critical.  There was uncertainty among healthcare professionals (10), a 
finding that has also been reported in designing lifestyle programmes for cancer survivors (47).   
On the other hand, patients were clear that optimal time for CVD risk intervention was once they 
had learned to cope with their RA diagnosis.  The form that such novel patient education should 
take was suggested by most participants to be small group work, with a small minority (often 
those in full-time employment) requesting internet or written material.  This is consistent with 
previous research (48).  The value that patients placed on learning from each other would also 
support a group intervention.  A group approach is integral to the ethos of the Arthritis Self-
Management Programme (49) and, indeed, was a key feature appreciated by patients when the 
Chronic Disease Self Management programme was qualitatively investigated (50). 
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In summary, the present study revealed a lack of awareness of increased CVD risk among 
patients with RA.  This reinforces the need to develop appropriate educational material and 
programmes to bring about relevant lifestyle modifications, which must be designed following 
careful consideration of the multitude of pertinent factors discussed above.  This study 
complements, and is complemented by, our accompanying paper addressing healthcare 
professionals’ perceptions (10).  Involving all stakeholders in a detailed examination of 
educational needs at the outset will result in the development of optimally effective patient 
education material. 
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CHAPTER 6: DEVELOPMENT AND INITIAL VALIDATION OF A HEART DISEASE 
KNOWLEDGE QUESTIONNAIRE FOR PEOPLE 
WITH RHEUMATOID ARTHRITIS 
 
Abstract  
 
Objective: To develop and validate two parallel versions of the Heart Disease Fact 
Questionnaire-Rheumatoid Arthritis (HDFQ-RA), a modified and RA-specific version of the 
HDFQ.   
Methods: The questionnaire was composed of generic questions from the original HDFQ with 
additional RA-specific questions added.  Cognitive interviewing was performed and the 
questionnaire piloted to generate two parallel questionnaires.  For psychometric validation, 130 
patients with RA completed the questionnaires at baseline and two weeks later.  
Results: Parallel form reliability of both questionnaires was established; the median score for 
both questionnaires was 9/13 with no statistical difference in scores.  Kuder-Richardson-20 
formula was 0.65 and 0.67 for both questionnaires.  Test-retest stability showed constant median 
scores of 9/13 and no statistical difference in scores between baseline and follow-up.  Known 
groups comparison revealed that patients who had self-educated themselves about heart disease, 
or who were taking CVD medications, had significantly higher scores on the questionnaires.  
Conclusion: The two parallel forms of the HDFQ-RA have been shown to be equivalent 
measures of CVD knowledge and evidence supporting their reliability and validity is presented.  
The HDFQ-RA is an appropriate tool for application in clinical and research settings, e.g., 
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assessing novel educational interventions or tracking participants’ progress on an education 
course.   
 
Introduction 
 
The most common cause of mortality in the western world is cardiovascular disease (CVD), and 
its prevention and management is a national health priority (1;2).  Identification and intensive 
management of risk factors for CVD is important, particularly in high risk groups of people such 
as those with diabetes mellitus.  People with rheumatoid arthritis (RA) are also at increased risk 
of CVD (3), thought to be due to both clustering of traditional risk factors as well as novel risk 
factors such as inflammation (4;5).  Traditional risk factors may be affected by both the disease 
itself and/or its treatments, for example, dyslipidaemia may relate to uncontrolled systemic 
inflammation (5), or hypertension may relate to ongoing use of non-steroidal anti-inflammatory 
drugs (6) or coxibs (7). The screening for CVD and its management (both relevant lifestyle 
changes and necessary pharmacological treatment) is therefore an important component of long 
term care of all patients with RA (5;8;9).  Underpinning such a CVD screening programme must 
be patient education; improving patients’ knowledge is fundamental to all treatment programmes 
(10) and is often a pre-requisite for initiating desired behaviour changes (11). 
 
Before implementing patient education programmes it is prudent to show their efficacy (12); the 
availability of a relevant valid knowledge questionnaire is an essential tool to evaluate a novel 
educational intervention.  In addition, such a questionnaire would also be useful in clinical 
practice to identify both patients who know little about CVD in general as well as to help tailor 
148 
 
educational opportunities to meet a patient’s specific needs within this vast field of knowledge 
(13). 
 
Validated knowledge questionnaires exist for use among patients with RA, but these are 
concerned with general knowledge about RA, signs and symptoms, as well as pharmacological 
management of joint pain and self-management techniques (14-17).  Use of these questionnaires 
has revealed a lack of knowledge among patients with RA, particularly about the aetiology of RA 
and its drug treatment (14), and that patient knowledge increases following a group educational 
intervention (15;17).  Currently available questionnaires, however, do not include questions about 
the CVD comorbidity associated with RA.  There is therefore a pressing need to construct a 
psychometrically sound questionnaire to measure heart disease knowledge in patients with RA, 
both to evaluate necessary cardiovascular patient education programmes and to identify patients’ 
particularly requiring education. 
 
Existing patient knowledge questionnaires about CVD and its risk factors have been validated in 
male patients with diagnosed coronary heart disease (18) as well as in high risk patients with 
diabetes (13).  This latter psychometrically validated questionnaire, the Heart Disease Fact 
Questionnaire (HDFQ), has 25 items; 15 questions concern the well-established risk factors of 
family history, age, gender, smoking, physical activity, lipids, blood pressure, weight and 
whether a person necessarily knows if heart disease is present; a further 10 questions address 
diabetes-related coronary heart disease risk factors.  The HDFQ employs closed questions with a 
dichotomous response format, supplemented by an ‘I don’t know’ option.  Dichotomous answers 
are suitable for factual questions, whereas scaled response formats may be less so (15).  
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Questions are worded to try to minimize acquiescence, which is appropriate (19).  Validation 
studies of the HDFQ showed a spectrum of item difficulty scores; it is important to have a 
balance and broad range of item-difficulty scores (17).  The HDFQ demonstrated adequate 
internal consistency, good content and face validity and criterion related validity in a sample of 
people with diabetes, and has been recommended for both clinical and research applications (13).  
Indeed, use of this questionnaire has not only highlighted groups of patients in greatest need of 
patient education but also identified timely opportunities where further education is required (20).  
This excellent patient knowledge questionnaire is therefore a very valuable resource but it is 
specific to patients with diabetes.  Patients with RA require disease-specific education to also 
address additional issues as exercise despite joint pain, (where they may have previously received 
conflicting advice (21)), the novel role of systemic inflammation as a risk factor for CVD, and 
the complex adverse effects on the vasculature of some medication used in RA such as non-
steroidal anti-inflammatory drugs or steroid medication.  It is therefore appropriate to modify the 
HDFQ to develop a RA-specific version, the Heart Disease Fact Questionnaire – Rheumatoid 
Arthritis (HDFQ-RA).  This will require re-validation among patients with RA.  Validation of the 
HDFQ did not include measuring test-retest reliability in a large sample and the authors propose 
this should be performed in the future (13).  To use a questionnaire as a tool to evaluate an 
educational intervention requires its stability over time (in the absence of intervention) to be 
shown (19).  Moreover, repeat administration of the same questionnaire may result in a 
respondent only ‘learning’ the answers to the questionnaire during the intervention in an 
artefactual nature.  It would therefore be optimal to develop parallel forms of the questionnaire 
(HDFQ-RA-1 and HDFQ-RA-2) to be used in a pre- and post-intervention fashion (17;22); these 
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must show parallel form reliability and both must be validated and shown to be stable over time 
in the absence of intervention. 
 
The purpose of this study was to develop and validate two parallel versions of the HDFQ-RA 
questionnaire which can be used clinically and in a research setting to measure knowledge of 
heart disease in patients with RA. 
 
Methods 
 
The present study used a multi-stage questionnaire development and validation process for which 
local research ethics committee approval was given. 
 
a) Questionnaire design 
The initial questions collected demographic data on the respondents, including sex, age, marital 
status, highest level of educational qualification, ethnicity and job/role.  Self-reported diagnoses 
of CVD and CVD risk factors, medication and attendance at different health education 
opportunities were also requested. 
 
Two domains of questions were generated; generic risk factors for CVD and risk factors for CVD 
specific to patients with RA.  Questions in the first domain were the initial 15 questions from the 
original HDFQ, including the transfer of the question on diabetes as a risk factor for CVD, which 
was originally in the diabetes-specific subscale.  Subsequent diabetes-specific questions in the 
HDFQ were not retained.  Nine questions in the second domain addressing CVD risk factors for a 
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person with RA were generated on the basis of face validity following group discussion amongst 
the authors (HJ, GJT, EDH).  A focus group of 5 consultant rheumatologists was next convened 
to discuss the questionnaire for content validity.  The panel felt the questions addressed the full 
spectrum of CVD risk factors for a patient with RA, both novel risk factors and traditional risk 
factors that may be adversely modified by systemic inflammation or the medications use to treat 
RA.  The panel did, however, suggest amending the language of the generic CVD risk factor 
questions into more lay language by changing “…you are at risk for developing heart disease…” 
to “…you are more likely to develop heart disease…”  Additionally, the language used in the 
questions collecting demographic data was simplified and any medical jargon minimized.   
 
This version of the questionnaire was then used for individual cognitive interviewing (‘think-
aloud’ interviewing).  This technique allows the interviewer to gain an understanding of how a 
participant perceives and interprets the questions and so is a valuable method of pre-testing a 
questionnaire (23).  Four patients with RA (two men and two women) gave informed consent for 
an audio-recorded individual cognitive interview, all of which lasted around 1 hour.  The 
participants both ‘read aloud’ the questions and ‘thought aloud’ their response.  Appropriate 
probing by the interviewer (HJ) was used to clarify any hesitancies in answering a question as 
well as identifying any ambiguities or omissions with the wording or problems with the layout of 
the questionnaire.  These interviews were used to identify questions that worked well (24) and a 
list of recommendations to improve the questionnaire was compiled and implemented (Table 1). 
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Table 1: Amendments to HDFQ-RA 1 and 2 following patient interviews  
 Clarifications Simplifications  Additions Formatting 
Amendments to 
demographic 
questions 
‘Divorced’ clarified 
to mean 
‘Divorced/Separated’ 
‘Caucasian’ changed 
to ‘White’ 
‘Other’ added as an 
option to question 
about level of 
qualifications 
obtained  
Font size increased 
 Clarified that the 
questionnaire wanted 
to know whether 
certain medications 
were taken, both 
prescribed by their 
GP or over the 
counter 
Statins described as 
‘cholesterol lowering 
tablets’ 
Instructions added for 
respondent to tick the 
boxes as appropriate 
Spacing between 
rows increased 
 ‘Employed’ changed 
to ‘Work’ (so to 
include the self 
employed)  
 Added a question 
‘Has anyone close to 
you, such as a relative 
or friend, ever had 
heart disease?’ 
Tick boxes aligned 
 Educational 
opportunities 
explained more 
clearly  
   
Amendments to 
HDFQ-RA-1 and 
2 
 ‘Undesirable’ used 
instead of 
‘unfavourable’ in 
HDFQ-RA-2 
‘Confidential’ added 
to the title 
 
   Examples of anti-
inflammatory 
medications added to 
the relevant question 
in HDFQ-RA-1 
 
 
This modified 24-item questionnaire was then piloted on 50 consecutive patients with RA 
attending an outpatient clinic.  Data analysis was performed using SPSS for windows version 
13.0.  Each response to each question was coded as correct or incorrect (‘I don’t know’ was 
coded as incorrect in reflection of the individual not knowing the correct answer).  The responses 
of one respondent gave an overall score more than three standard deviations away from the mean; 
this respondent was treated as an outlier and their answers removed from analyses.  Two further 
questions were added after this initial pilot; one question on generic risk factors for CVD and one 
question on RA-specific risk factors for CVD (see Table 3).  Within each of the two domains of 
questions, responses to items were compared (using percentage of respondents to score the 
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correct answer) to identify concordant pairs of questions, with similar levels of difficulty for the 
parallel forms of the HDFQ-RA.  Two parallel questionnaires were then developed by splitting 
the paired questions into two sets of questions, ensuring the question pairs were divided to ensure 
a sensible balance in question content between the two questionnaires; HDFQ-RA-1 and HDFQ-
RA-2.  Thus each questionnaire comprised 13 questions; eight questions from the original HDFQ 
on generic risk factors for CVD and five on CVD risk factors specific to a patient with RA.   
 
b) Psychometric validation of HDFQ-RA-1 and HDFQ-RA-2 questionnaires 
i) Participants 
Participants were recruited from a secondary care setting in a single rheumatology department.  
The inclusion criteria were a diagnosis of RA, being able to read and write English and 
consenting to complete two questionnaires 2 weeks apart.   
ii) Procedure 
Participants were consecutively recruited and each assigned a participant identification number 
for this study; the first group of participants completed the demographic questions, then HDFQ-
RA-1 and then finally HDFQ-RA-2.  A second group of participants completed the demographic 
questions, followed by HDFQ-RA-2 and then finally HDFQ-RA-1.  All participants were 
unaided in the completion of the questionnaires. Two weeks after completing the questions for 
the first time each participant was posted out the same questionnaires, but in the alternate order, 
i.e. a participant from the first group completed HDFQ-RA-2 then HDFQ-RA-1 in their second 
questionnaire pack and vice versa.  The questionnaires were returned in stamped addressed 
envelopes enclosed.  Repeat mailings were used to improve the response rate, until each group 
comprised 65 respondents with complete test/retest questionnaire results (130 respondents in 
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total); 100 has been suggested as a minimum sample size to validate a test (22) although others 
have advocated at least five participants are required per question being validated (25).  Data 
collection was conducted by one of the authors (HJ).  The questionnaires were produced in a 
scannable format using ‘Snap’ software; scanned results were entered into Microsoft Excel and 
transferred into SPSS for Windows version 13.0 for statistical analysis. 
iii) Statistical analysis 
The demographic data of the participants in the two groups were compared using two sample t-
tests for differences in means (or Mann-Whitney U tests for differences in medians) and chi-
squared tests or Fisher’s exact test for differences in proportions.   
 
The item ease scores for each question were calculated, that is, the percentage of participants who 
correctly answered that question, both for the pilot sample of people with RA, and the larger 
group of participants whose results were used for the psychometric validation (at baseline and at 
two-week follow-up).  A factor analysis of all 26 questions was carried out separately at the two 
time-points. 
 
Parallel form reliability was assessed by comparing descriptive statistics relating to HDFQ-RA-1 
and HDFQ-RA-2 (22), using Wilcoxon signed ranks tests to calculate the significance of the 
difference in the scores for each individual at one point in time, and using  Spearman’s 
correlation to compare each individual’s scores on HDFQ-RA-1 with HDFQ-RA-2.  Internal 
consistency of the HDFQ-RA-1 and HDFQ-RA-2 (for the total scores of each questionnaire as 
well as separate domain scores at both baseline and follow-up) were tested using the Kuder-
Richardson Formula 20 for dichotomously scored questions (26).  The test-retest stability for the 
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HDFQ-RA-1 and HDFQ-RA-2 was measured by comparing descriptive statistics for each form 
of the questionnaire when repeated two weeks later to the baseline descriptive statistics.  Also, 
Wilcoxon signed ranks test was used to calculate the significance of the difference in the scores 
at test and retest and Spearman’s correlation was used to compare test and retest scores.   Validity 
of the HDFQ-RA-1 and HDFQ-RA-2 was assessed in several ways.  As described above, face 
and content validity were subjectively established in the process of developing and revising 
items.  In addition, we conducted a known-groups analysis, using Mann-Whitney U tests, to 
examine discriminant validity; specifically by comparing scores among people who had self-
educated themselves by reading about CVD to those who had not, as well as people who self-
reported taking CVD medication versus those who did not.  We hypothesised that patients who 
had received some form of CVD education or whom were taking medications for CVD or CVD 
risk factors would have more knowledge about CVD than those without those characteristics.  
There are currently no other measures of the same concept available for us to test convergent 
validity of the HDFQ-RA. 
 
Results  
 
In order to have 130 participants in total with complete test/retest results, 151 participants were 
approached; all accepted to take part but 21 participants did not return the second questionnaire 
and so were excluded from analysis  
 
a) Demographic characteristics of respondents 
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The demographic details of the two groups of patients with RA who completed both 
questionnaires are listed in Table 2.  Overall, 78% of respondents were female and the mean age 
was 64 years.  This is representative of a typical sample of people with RA, which is three times 
more prevalent among women and shows greater incidence and prevalence among older adults 
(27).  No formal qualifications were held by 60% of respondents.  The mean duration of RA was 
16 years; in addition, 15% of the participants reported a previous CVD event and 42%, although 
they had not had a CVD event, reported risk factors for CVD.  The two groups of respondents 
were matched for all demographic variables. 
 
b) The questionnaires 
The two questionnaires (HDFQ-RA-1 and HDFQ-RA-2), each composed of 13 questions, are in 
Table 3.  The item ease score is given for each question as are factor loadings of the individual 
questions.  Factor analysis showed the questions generally load onto factors representing generic 
knowledge of CVD and RA-specific CVD risk knowledge, as predicted.  This factor analysis 
produces a fairly good fit, although a few questions did not load as expected; in particular, two 
RA-specific CVD questions from HDFQ-RA-1 (10 and 11) had consistently stronger loadings on 
the same factor that most of the generic knowledge questions also load most strongly on.  
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Table 2:  Demographic features of respondents to questionnaire (N = 130) 
Demographic factor Group 1 
n = 65 
Group 2 
n = 65 
p 
Age, years (mean ±sd)  64.45 ± 11.3  63.3 ± 11.2 0.564 
Sex; number of females  52 50 0.67 
Marital status 
   Married: 
   Living with a partner: 
   Single: 
   Divorced/separated: 
   Widow(er): 
 
38 
4 
3 
7 
13 
 
43 
3 
5 
3 
11 
0.614 
Highest qualification attained 
   No qualifications: 
   School qualifications gained at age 16:     
   School qualifications gained at age 18: 
   University degree: 
   Other: 
   Blank: 
 
35 
9 
10 
1 
8 
2 
 
43 
8 
6 
2 
3 
3 
0.454 
Ethnicity; number Caucasian 64 64 1.0 
Self-reported co-morbid CVD 
   CVD event: 
   Risk factors alone for CVD: 
   None: 
   Blank: 
 
12 
27 
24 
2 
 
8 
27 
29 
1 
0.532 
Duration of RA, years (median ± IQ range)    14.5 (5.25 – 24.75) 13.5 (4.0 – 23.0) 0.665 
Smoking status 
   Current smoker: 
   Ex smoker: 
   Never smoked: 
   Blank: 
 
12 
24 
29 
0 
 
11 
27 
24 
3 
0.733 
Self reported medications taken† 
   For CVD or risk factors: 
   Non steroidal anti-inflammatories: 
   Steroids: 
 
36 
31 
25 
 
34 
23 
18 
 
0.412 
0.228 
0.401 
Attendance at the following educational opportunities 
   Heart clinic at GP: 
   Well man / well woman clinic at GP: 
   Hospital cardiology appointment: 
   Combined rheumatology/cardiology clinic: 
   Rheumatology nurse: 
   Cardiac rehabilitation: 
   Expert Patient Programme: 
   Events about heart disease in the community: 
   Read articles/leaflets about heart disease: 
   Looked up information on heart disease on the internet: 
 
6 
8 
11 
9 
48 
2 
1 
1 
15 
2 
 
3 
17 
17 
8 
48 
3 
0 
0 
16 
3 
 
0.492 
0.045* 
0.201 
0.795 
1.0 
1.0 
1.0 
1.0 
0.837 
1.0 
IQ range = interquartile range 
*indicates p<0.05 
† patients were asked to self-report if they specifically took “aspirin, cholesterol lowering tablets, blood pressure  
tablets, tablets or insulin for diabetes, anti-inflammatories, such as ibuprofen or diclofenac, or steroids ie prednisolone”.   
We classified aspirin, cholesterol lowering tablets, blood pressure tablets and diabetes medication into ‘medications for  
CVD or its risk factors’.    
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Table 3: The HDFQ-RA-1 and HDFQ-RA-2 questionnaires with their question ease scores and factor loadings. 
Form Risk focus Question Item ease 
(% getting it correct) 
Factor loadings1 for N = 130 
N = 49  N = 130 Baseline 2 week follow-up 
Pilot Baseline 2 week 
follow-up 
Factor 1 Factor 2 Factor 1 Factor 2 
HDFQ-
RA-1 
General 1.1: A person always knows when they have heart 
disease 
75.5 73.8  86.9 0.31 -0.33 0.07 0.00 
General 1.2: A person who smokes is more likely to develop 
heart disease 
--
2 86.9 93.1 0.71 0.04 0.58 -0.06 
General 1.3: Keeping blood pressure under control will 
reduce a person’s chance of developing heart 
disease 
89.8 89.2 91.5 0.36 0.29 0.38 0.22 
General 1.4: A person with high cholesterol is more likely to 
develop heart disease 
87.8 90.8 83.1 0.69 0.22 0.71 0.18 
General 1.5: If your ‘good’ cholesterol (HDL) is high you 
are more likely to develop heart disease 
51.0 33.1 38.5 0.29 -0.03 0.37 0.18 
General 1.6: Only exercising in a gym or in an exercise 
class will lower a person’s chance of developing 
heart disease 
81.6 80.8 86.9 0.41 0.08 0.35 0.06 
General 1.7: Eating fatty foods does not affect blood 
cholesterol levels 
81.6 82.3 84.6 0.46 -0.13 0.52 0.16 
General 1.8: A person with diabetes is more likely to 
develop heart disease 
61.2 45.4 47.7 0.22 0.43 0.04 0.60 
RA-specific 1.9: A person with rheumatoid arthritis can reduce 
their chance of heart disease by keeping their 
weight under control 
87.8 89.2 86.9 0.13 0.28 0.47 0.09 
RA-specific 1.10: A person with rheumatoid arthritis can reduce 
their chance of heart disease by stopping smoking 
95.9 90.8 93.8 0.66 0.20 0.49 0.11 
RA-specific 1.11: People with rheumatoid arthritis should not 
exercise because it can damage their joints 
83.7 84.6 87.7 0.32 -0.06 0.25 -0.02 
RA-specific 1.12: Anti-inflammatory medications, such as 
diclofenac or ibuprofen, taken by patients with 
rheumatoid arthritis may increase the chance of 
heart disease 
12.2 12.3 13.8 -0.01 0.48 0.08 0.52 
RA-specific 1.13: Having lots of inflammation (‘flares’) of 
rheumatoid arthritis adds to the increased chance of 
heart disease 
18.4 23.1 22.3 0.03 0.63 0.11 0.68 
Continued over 
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Table 3 continued 
Form Risk focus Question Item ease 
(% getting it correct) 
Factor loadings1 for N = 130 
N = 49 N = 130 Baseline 2 week follow-up 
Pilot Baseline  2 week 
follow-up 
Factor 1 Factor 2 Factor 1 Factor 2 
HDFQ-
RA-2 
General 2.1: If you have a family history of heart disease, 
you are more likely to develop heart disease 
75.5 71.5 80.8 0.49 0.15 0.13 0.27 
General 2.2: Regular exercise will lower a person’s chance 
of getting heart disease 
91.8 90.8 92.3 0.42 0.01 0.40 -0.03 
General 2.3: A person who stops smoking will lower their 
chance of developing heart disease 
83.7 93.1 96.2 0.73 0.04 0.57 -0.12 
General 2.4: A person with high blood pressure is more 
likely to develop heart disease 
75.5 86.9 89.2 0.64 0.20 0.71 0.20 
General 2.5: If your ‘bad’ cholesterol (LDL) is high you are 
more likely to develop heart disease 
65.3 80.8 75.4 0.38 0.40 0.50 0.22 
General 2.6: Being overweight increases a person’s chance 
of developing heart disease 
98.0 95.4 96.9 0.25 0.12 0.09 0.09 
General 2.7: The older a person is, the more likely they are 
to develop heart disease  
44.9 33.8 40.8 0.04 0.53 0.24 0.31 
General 2.8: Walking and gardening are considered exercise 
that will help lower a person’s chance of 
developing heart disease 
87.8 86.9 90.0 0.24 0.24 0.19 -0.07 
RA-specific 2.9: Patients with rheumatoid arthritis are more 
likely to develop heart disease  
32.7 30.8 36.2 0.04 0.59 0.08 0.66 
RA-specific 2.10: Rheumatoid arthritis affects the balance of 
‘good’ and ‘bad’ cholesterol in the blood in an 
undesirable way 
14.3 16.2 12.3 -0.23 0.60 -0.05 0.57 
RA-specific 2.11: Long term or high dose steroids taken by a 
person with rheumatoid arthritis may cause diabetes 
--
2
 26.2 27.7 -0.02 0.36 -0.23 0.57 
RA-specific 2.12: A person with rheumatoid arthritis can reduce 
their chance of heart disease by keeping their 
cholesterol under control 
77.6 82.3 86.9 0.22 0.44 0.50 0.21 
RA-specific 2.13: A person with rheumatoid arthritis can reduce 
their chance of heart disease by keeping their blood 
pressure under control 
77.6 84.6 90.0 0.40 0.43 0.54 0.17 
Proportion of the variance explained 16.0% 11.6% 15.4% 10.4% 
1
 Principal components extraction of two factors with varimax rotation across all 26 questions; loadings in bold are > 0.20. 
2
 Question added after pilot phase. 
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c) Psychometric validation of the questionnaires 
Parallel form reliability was established: For HDFQ-RA-1, the median score was 9 (interquartile 
range 8 – 10).  For HDFQ-RA-2, the median score was also 9 (interquartile range 7 – 10). 
Wilcoxon signed ranks test confirmed that there were no significant differences in scores between 
parallel forms (z =-0.313, p=0.754).  Spearman’s correlation between scores to HDFQ-RA-1 and 
HDFQ-RA-2 showed r = 0.50. 
 
The internal consistency of the parallel questionnaires was adequate with a Kuder-Richardson-20 
formula of 0.65 for HDFQ-RA-1 and 0.67 for HDFQ-RA-2 (between 0.5 and 0.7 is considered 
the minimum acceptable level for internal consistency (19)) (Table 4). 
 
Table 4:  Internal consistency results (with 95% confidence intervals) of the two versions of the  
HDFQ-RA, including subscales, at baseline and follow up (N = 130). 
 
Question
naire 
Questions Number 
of 
questions 
Baseline questionnaire 
internal consistency (and 
95% confidence interval) 
Two-week follow up 
questionnaire internal 
consistency (and 95% 
confidence interval) 
HDFQ-
RA-1 
All  questions 13 0.65 (0.56 – 0.73) 0.66 (0.57 – 0.74) 
Generic CVD  
questions 
8 0.61 (0.50 – 0.70) 0.57 (0.45 – 0.67) 
RA-specific 
CVD questions 
5 0.34 (0.14 – 0.50) 0.37 (0.18 – 0.53) 
HDFQ-
RA-2 
All questions 13 0.67 (0.58 – 0.75) 0.58 (0.46 – 0.68) 
Generic CVD  
questions 
8 0.63 (0.52 - 0.72) 0.44 (0.28 – 0.57) 
RA-specific 
CVD questions 
5 0.51 (0.36 – 0.63) 0.41 (0.24 – 0.56) 
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In terms of test-retest, the median scores remained constant at 9 (HDFQ-RA-1 interquartile range 
8 – 11; HDFQ-RA-2 interquartile range 8 – 10).  In addition, Wilcoxon signed ranks test 
confirmed that there were no significant differences in scores between baseline and two weeks 
later (HDFQ-RA-1; z=-1.78, p=0.08: HDFQ-RA-2; z=-1.74, p=0.08).  Spearman’s correlation for 
test-retest showed r = 0.54 for HDFQ-RA-1 and r = 0.41 for HDFQ-RA-2. 
 
The parallel forms of the questionnaire demonstrated face and content validity in expert and 
patient investigations. The investigators and patients involved in cognitive interviewing agreed 
the questionnaire was well presented and the questions were relevant and clear.  The content was 
appropriate and addressed the full scope of the domains being tested.  Known groups comparison 
revealed that patients who had specifically received education about CVD (by virtue of reporting 
self-educating themselves by reading about CVD, both leaflets and on the internet, or attending 
community events on CVD) or who self-reported taking medication for CVD or CVD risk factors 
had statistically significantly higher scores in both questionnaires (Table 5).  There was no 
relationship between scores on both HDFQ-RA questionnaires and level of qualifications 
obtained, reflective of years in formal education.   
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Table 5: Discriminant validity of the HDFQ-RA-1 and HDFQ-RA-2; participants who had self- 
educated themselves, or who took medications for CVD or CVD risk factors scored higher on  
both questionnaires.  
Groups HDFQ-RA-1 HDFQ-RA-2 
Median 
score 
U 
value 
p value Median 
score 
U value p value 
Self educated about heart 
disease 
Yes 
n=32 
9.5 1215.0 0.05 10 1117.0 0.01 
No 
n=98 
9 9 
Taking medications for 
CVD or CVD risk factor 
Yes 
n=70 
9.5 1302.0 0.03 9 1312.5 0.04 
No 
n=48 
9 8 
 
 
 
Discussion 
 
The HDFQ-RA was developed in response to the clinical need to address the CVD risk 
associated with RA.  It is based on a well validated pre-existing questionnaire addressing the 
same issue in diabetic patients.  The present questionnaire will have applications in both clinical 
and research settings; the two parallel versions are appropriate to be used in a before-after fashion 
when assessing either a novel educational intervention or a participants’ progress on a patient 
education course.  Both parallel questionnaires have been shown to be an equivalent measure of 
CVD knowledge, and evidence supporting the reliability and validity of the scales has been 
shown in this sample. 
 
Psychometric validation was performed in a suitably large sample of patients with RA following 
appropriate cognitive interviewing to address its readability and acceptability.  The reliability of a 
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questionnaire is related to the variability between items and the length of the questionnaire (22).  
This questionnaire was designed to test knowledge about several issues, both classical risk factors 
for CVD as well as novel risk factors, and yet remain brief and convenient to use in practice.  The 
factor analyses revealed that the questions do indeed generally load onto these two factors, 
although some apparently RA-specific elements of knowledge (focusing on applied generic 
issues, such as exercise being important for managing CVD risk among people with RA) may 
relate more closely to other elements of generic CVD knowledge.  The internal consistency was 
satisfactory, and certainly better than an existing RA patient knowledge questionnaire (15).  
Increasing the length of the questionnaire, i.e. using all 26 questions, rather than two parallel 
questionnaires, yielded an internal consistency of 0.78 at baseline, identical to the original HDFQ 
(13).  However, there is a finite set of established CVD risk factors to write questions about and 
we did not want to expand the questionnaire with essentially repeated questions; indeed the two 
parallel shorter versions are more suitable for cross-over application to avoid artefactual learning.  
Based on the present study these two questionnaires should be used as described, not broken 
down into their two domains of questions as the internal consistency results of the individual 
domains of questions on each version of the questionnaires was sometimes less than adequate.  
Overall, one would not expect perfect factor structure or internal consistency for such factual 
knowledge questions because people will tend to only know certain facts (rather than knowing 
absolutely all or none of them), and the aim is to get a reasonable assessment of a complex aspect 
of patient knowledge.  Moreover, it is important to have a sensible balance of questions between 
the two questionnaires, which we achieved during the questionnaire design process, rather than 
react to the factor loadings and produce unbalanced questionnaires.  Similarly, during the 
development of the original HDFQ, the authors acknowledged they were seeking to measure 
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knowledge of a factorially complex set of items and so expected considerable variability between 
items and a lower internal consistency; they too declined to increase the number of items in their 
questionnaire (which would produce a more homogenous test) in order to keep the questionnaire 
user-friendly (13).   
  
Reproducibility was not included in the validation of the original HDFQ (13).  Test-retest 
stability with both the HDFQ-RA questionnaires was good with the median scores staying 
constant.  Again, there are factors which may affect test-retest stability; physical or emotional 
problems may lower test-retest reliability (22).  Our participants were recruited when attending a 
hospital appointment which may be relevant, but despite this the test-retest stability was 
maintained.  The spectrum of difficulty of the questions employed will also affect the test-retest 
correlation, for example, questions that are very easy should always be answered correctly 
leading to a high test-retest correlation (22).  However, for a knowledge questionnaire to be a 
useful tool requires it should be composed of questions of different levels of difficulty (17).  This 
was demonstrated by the HDFQ-RA, such that it can identify patients in need of further 
education or show progress following an education course.  Both HDFQ-RA questionnaires 
showed discriminant ability whereby meaningful groups of people scored differently on the scale 
as expected; specifically, respondents who had, or were more likely to have been educated about 
CVD (by virtue of having been commenced on relevant medications), scored higher scores on the 
HDFQ-RA than those who had not received CVD education.  A similar finding was observed 
with the original HDFQ; taking medications for CVD did predict heart disease knowledge in a 
sample of patients with diabetes, whereas having risk factors for CVD did not predict knowledge 
(20).  The lack of a relationship between respondents’ level of qualifications (reflective of their 
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years of formal education) and their scores on the HDFQ-RA may be influenced by the fact that 
many of respondents were elderly and so left school early, and that knowledge about CVD 
specifically pertaining to people with RA is comparatively ‘new’.  The important implication is 
that patient education addressing CVD in RA is required by all patients, regardless of how long 
they have been diagnosed.    
 
There are some limitations of this questionnaire.  The patients were recruited from one regional 
expert unit where annual review clinics to address co-morbidities, including CVD, are in place as 
recommended by the Arthritis and Musculoskeletal Alliance Standards of Care (28).  As such, the 
levels of heart disease knowledge may be higher in these respondents than in the general 
population of patients with RA.  It would be ideal to use the HDFQ-RA in a much larger national 
survey of patients’ knowledge which would both increase the geographical spread of respondents, 
as well as the number of respondents, although an adequate sample was recruited in the present 
study (25).  Another limitation is that the questionnaire has been validated only in English.  
People of South Asian origins are at increased risk of CVD compared to the general population 
(29) and patient education and supporting resources should be provided in relevant languages 
(30)  It would therefore be valuable for this questionnaire to be translated into other languages, 
which may require small adjustments to ensure it is culturally appropriate, and then re-validated. 
 
Other future studies with the HDFQ-RA could involve its use in a survey of health professionals’ 
knowledge about RA and CVD.  The results might be used to help inform local educational 
initiatives.  Having shown the HDFQ-RA is stable in the absence of an intervention, research is 
required to assess its sensitivity to change consequent on an education intervention. 
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In summary, the availability of a psychometrically validated questionnaire addressing knowledge 
of heart disease in patients with RA is a necessary and timely development, especially given the 
emphasis on managing CVD co-morbidity in RA (5).  Not only will the HDFQ-RA have 
important applications in current clinical practice, discussed below, but it will also be a 
particularly important measure to use in forthcoming research studies, including both educational 
and clinical research.  Current clinical research strategies are addressing the role of 
pharmacological therapies (31) on CVD risk in patients with RA but also need to address other 
non-pharmacological lifestyle measures such as regular exercise (21) and optimizing diet.  A 
valid score of heart disease knowledge will be an important measure in these trials, for example, 
to see if it affects adherence to the intervention.   
 
However, it is also important to consider, as with all health knowledge questionnaires, how these 
new gains in knowledge can be translated into behavioural change.  Therefore, we would 
emphasise the importance of using this questionnaire within the context of developing and 
delivering a CVD patient education programme whereby knowledge is conveyed to explain and 
underpin the rationale for implementing lifestyle modifications alongside the provision of 
appropriate resources to support such lifestyle changes.  
167 
 
 References 
 
 
 (1)  World Health Organization. Mortality Country Fact Sheet [online]. Available from: URL: 
http://www.who.int/whosis/mort/profiles/mort_euro_gbr_unitedkingdom.pdf 
 (2)  National Centre for Social Research, Department of Epidemiology and Public Health at 
the Royal Free and University College Medical School, Commissioned by Department of 
Health. Health Survey for England 2003; Volume 1. 
 (3)  Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. 
Increased Unrecognized Coronary Heart Disease and Sudden Deaths in Rheumatoid 
Arthritis. Arthritis Rheum 2005; 52: 402-11. 
 (4)  Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheum 2003; 
42: 607-13. 
 (5)  Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of 
the same coin? Rheum 2005; 44: 1473-82. 
 (6)  Morrison A, Ramey DR, van Adelsberg J, Watson DJ. Systematic review of trials of the 
effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. 
Curr Med Res Opin 2007; 23: 2385-404. 
 (7)  Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and 
arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296: 1619-332. 
 (8)  Symmons D, Bruce I. Hands On management of cardiovascular risk in RA and SLE.  
Hands on: arc reports on the rheumatic diseases 2006; Series 5: Number 8. 
 (9)  Kennedy T, McCabe C, Struthers G, Sinclair H, Chakravaty K, Bax D, et al. BSR 
guidelines on standards of care for persons with rheumatoid arthritis. Rheum 2005; 44: 
553-6. 
 (10)  Daltroy LH, Liang MH. Advances in patient education in rheumatic disease. Ann Rheum 
Dis 1991; 30(Suppl 3): 415-7. 
 (11)  Alm-Roijer C, Stagmo M, Uden G, Erhardt L. Better knowledge improves adherence to 
lifestyle changes and medication in patients with coronary heart disease. Eur J Cardiovasc 
Nurs 2004; 3: 321-30. 
 (12)  Hill J, Bird H. Patient knowledge and misconceptions of osteoarthritis assessed by a 
validated self-completed knowledge questionnaire (PKQ-OA). Rheum 2007; 46: 796-800. 
168 
 
 (13)  Wagner J, Lacey K, Chyun D, Abbott G. Development of a questionnaire to measure 
heart disease risk knowledge in people with diabetes: the Heart Disease Fact 
Questionnaire. Patient Educ Couns 2005; 58: 82-7. 
 (14)  Hill J, Bird H, Hopkins R, Lawton C, Wright V. The Development and Use of a Patient 
Knowledge Questionnaire in Rheumatoid Arthritis. Br J Rheumatol 1991; 30: 45-49. 
 (15)  Hennell S.L., Brownsell C., Dawson J.K. Development, validation and use of a patient 
knowledge questionnaire (PKQ) for patients with early rheumatoid arthritis. Rheum 2004; 
43: 467-71. 
 (16)  Lineker SC, Badley EM, Hughes A, Bell MJ. Development of an Instrument to Measure 
Knowledge in Individuals with Rheumatoid Arthritis: The ACREU Rheumatoid Arthritis 
Knowledge Questionnaire. J Rheumatol 1997; 24: 647-53. 
 (17)  Edworthy SM, Devins G.M., Watson M.M. The arthritis knowledge questionnaire.  A test 
for measuring patient knowledge of arthritis and its self-managment. Arthritis Rheum 
1995; 38: 590-600. 
 (18)  Smith MM, Hicks VL, Heyward VH. Coronary heart disease knowledge test: developing 
a valid and reliable tool. Nurse Pract 1991; 16: 28,31,35-8. 
 (19)  Bowling A. Research methods in health: investigating health and health services. 2nd ed. 
Buckingham: Open University Press; 2002. 
 (20)  Wagner J, Lacey K, Abbott G, de Groot M, Chyun D. Knowledge of heart disease risk in 
a multicultural community sample of people with diabetes. Ann Behav Med 2006; 31: 
224-30. 
 (21)  Metsios G, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten J, Treharne GJ, Panoulas 
VF, Douglas KM, et al. Rheumatoid arthritis, cardiovascular disease and physical 
exercise: a systematic review. Rheum 2008; 47: 239-48. 
 (22)  Kline P. The Handbook of Psychological Testing. 2nd ed. London: Routledge; 2000. 
 (23)  Drennan J. Cognitive interviewing: verbal data in the design and pretesting of 
questionnaires. J Adv Nurs 2003; 42: 57-63. 
 (24)  Murtagh FE, Addington-Hall JM, Higginson IJ. The value of cognitive interviewing 
techniques in palliative care research. Palliat Med 2007; 21: 87-93. 
 (25)  Tabachnick BG Fidell LS. Using Multivariate Statistics. 4th ed. New York: Addison 
Wesley Longman; 2000. 
 (26)  Nunnally JC. Psychometric Theory. 2nd ed. United States of America: McGraw-Hill 
Book Company; 1978. 
169 
 
 (27)  Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence 
and outcome. Best Pract Res Clin Rheumatol 2002; 16: 707-22. 
 (28)  Arthritis and Musculoskeletal Alliance. Standards of Care for Inflammatory Arthritis 
[online]. 2004. London. Available from: http://www.arma.uk.net/pdfs/ia06.pdf   
 (29)  British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, 
Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British 
Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 
2005; 91(Suppl 5): v1-v52. 
 (30)  Adebajo A, Blenkiron L, Dieppe P. Patient education for diverse populations. Rheum 
2004; 43: 1321-2. 
 (31)  McInnes IB, McCarey DW, Sattar N. Do statins offer therapeutic potential in 
inflammatory arthritis? Ann Rheum Dis 2004; 63: 1535-37. 
 
 
  
 
170 
 
CHAPTER 7: PATIENT EVALUATION OF A NOVEL PATIENT EDUCATION 
LEAFLET ABOUT HEART DISEASE RISK AMONG PEOPLE WITH  
RHEUMATOID ARTHRITIS  
 
Abstract  
 
Objective: People with rheumatoid arthritis require access to clear and consistent information 
about their condition and Arthritis Research UK produce a wide range of leaflets to meet this 
need.  There is no patient information leaflet about CVD in the context of having RA, despite the 
fact that CVD accounts for 50% of the mortality in RA. A leaflet was developed; this paper 
describes the patient evaluation of this novel education resource.  
Methods: A questionnaire was developed to evaluate the leaflets’ content, literacy, graphics, 
layout and ability to stimulate learning.  It was distributed, with the leaflet, to 500 NRAS 
members.   
Results: There was a 72.8% response rate.  Of the respondents: 96% agreed the purpose of the 
leaflet was clear; 78% agreed the leaflet was relevant to them; 96% agreed they understood the 
leaflet; 53% agreed the leaflet cover was appealing; 81% agreed that the size of the typing was 
suitable; 71% agreed the advice was appropriate for their lifestyle. Omissions included 
adequately describing any risks associated with its advice, what sources of information were used 
to compile the leaflet and when this information was produced.  84% of respondents would 
recommend this leaflet to other people with RA.  Qualitatively, many people felt more 
empowered as a result of reading the leaflet.  
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Conclusions: Patient evaluation of new educational resources is important and ensures materials 
meet patients’ needs and are presented in a user-friendly style.  Ultimately, the test of the 
effectiveness of the leaflet will be if patients change their behaviour appropriately. 
 
Introduction 
 
For people with a chronic disease, the provision of information and education should help them 
feel empowered to self-manage their condition, as well as make any necessary lifestyle changes 
that they wish based on professional advice and patients perceptions.   Specifically, providing 
appropriate and desired health-related information is a right all patients can expect under the UK 
Patient’s Charter (1).   
 
For people with rheumatoid arthritis (RA), the most common inflammatory arthritis, European 
guidelines consider patient information about the disease, its treatments and its outcome is 
important (2).  The Arthritis and Musculoskeletal Alliance Standards of Care state  patients 
should have access to clear and consistent information presented in a variety of formats (3).  
Educational preferences may vary from a one-to-one format to group work but certainly written 
material has been shown to be preferred by patients with arthritis for learning new information 
(4).  Certainly, to compliment the traditional clinical (verbal) consultation, written information is 
often provided for RA patients, including leaflets about specific medical conditions and 
medications, for example those produced by Arthritis Research UK (AR-UK).  Increased 
knowledge has been demonstrated in patients having read the AR-UK RA disease-specific leaflet 
(5;6) as well as a drug information leaflet (7).  The AR-UK leaflet range includes leaflets about 
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several co-morbidities associated with RA.  However, it is co-morbid cardiovascular disease 
(CVD) that accounts for 50% of the mortality in patients with RA (8) and there is currently no 
patient information leaflet available that discusses CVD in the context of having RA (9).  CVD 
risk management involves people making lifestyle changes such as increasing the amount of 
exercise they do or stopping smoking.  In order for patients to instigate such behaviour changes, 
they may need to be informed about the risk of CVD with RA and the rationale and practicalities 
associated with making behaviour change.  There is therefore a need to develop a patient 
education leaflet to address the cardiovascular co-morbidity that associates with RA. 
 
Mindful that the literature reports a potential incongruence between the information provided by 
health professionals and the information patients request (10), it was felt important to have 
patient input both in the development of the leaflet and in its evaluation. Hence, qualitative 
research with stakeholders was performed, namely individual interviews with patients with RA 
and focus groups with relevant healthcare professionals (11;12).  This revealed patients were 
mostly unaware of the association between RA and CVD, but were interested in learning what 
could be done to address their risk, requesting “common sense” advice taking into account their 
RA (11).  A leaflet was therefore developed by a steering committee of rheumatologists and 
psychologists.  It describes why there is an increased risk of CVD associated with RA and 
includes practical lifestyle advice on what patients can do to reduce their risk with specific 
examples.  User involvement was sought; the UK National Rheumatoid Arthritis Society (NRAS) 
distributed it to selected members for feedback which informed further iterations of the leaflet.  
The reading age of the leaflet was calculated using the Flesch-Kincaid readability test.  This 
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measure of comprehension difficulty can be calculated using a readability calculator available at: 
http://www.editcentral.com/gwt/com.editcentral.EC/EC.html.  The Flesch reading ease score was 
68.1%, that is, it is easily readable by someone with a reading age of an average 13 year old, a 
level which 89% of a sample of English RA patients achieved (7).  Permission was sought to 
reproduce graphics in the leaflet and copyright for the overall leaflet was obtained.  The leaflet 
was laid out in a style similar to the current AR-UK leaflets that are familiar to patients with RA, 
paying attention to checklists of factors suggested to enhance the quality of written patient 
information (13).  These include accuracy and reliability of material, acceptability, readability, 
style and attractiveness of presentation, references to sources of further information, and cultural 
appropriateness (13). The leaflet was formatted by a professional web developer and 
professionally printed; it is available on written request to our departmental secretary 
(Jaclyn.Griffiths@dgoh.nhs.uk). 
 
Patient feedback on resources is highly desirable (10;13) and so it was felt important to seek 
formal evaluation by patients on this new leaflet.  This paper describes the process and results of 
RA patients’ evaluation of this new patient education resource. 
 
Methods 
 
a) Questionnaire development 
A questionnaire was designed to seek patients’ evaluation of the leaflet.  This questionnaire was 
initially a synthesis of two existing questionnaires (14;15) as neither was entirely suitable on their 
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own.  Thirty four questions evaluated the content of the leaflet (questions 1- 15), its literacy 
(questions 16 - 19), the graphics (questions 20 - 24), the layout (questions 25 - 29) and the ability 
to stimulate learning (questions 30 - 34).  The response options were ‘yes’, ‘somewhat’ and ‘no’.  
The questionnaire was reviewed by all authors and amendments made to simplify the language.  
An AR-UK patient representative suggested further amendments as well as an additional question 
about whether the leaflet described who to turn to for further help and advice (question 7).  The 
opportunity for free text comments was provided.  Basic demographic questions were included at 
the end of the questionnaire.  The questionnaire was produced in a scannable format using ‘Snap’ 
software; scanned results were entered into Microsoft Excel™. 
 
b) Procedure 
Ethical approval was obtained from the Black Country Research Ethics Committee.  In February 
2010, the leaflet and questionnaire, together with a covering letter, were distributed by NRAS to 
500 of their volunteers and members with a stamped addressed envelope for replies to be returned 
anonymously to the researchers.  A total of 364 participants returned the questionnaire, a 72.8% 
response rate. 
 
Results 
 
a) Demographics of responders 
Most responders (299/364; 82%) were female.  The median age category was 50 -59 years old, 
most were married (246/364; 68%) and most were of white ethnicity (337/364; 93%).  The 
highest educational qualification obtained was GCSE/O-level by 49/364 (14%), A-
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level/diploma/vocational qualification by 143/364 (39%), degree by 78/364 (21%), post-graduate 
qualification by 58/364 (16%); 36/364 (10%) had no qualifications or did not respond to the 
question.   
 
b) Responses to the questionnaire 
Frequencies of responses to the 34 questions are provided in Figure 1.  Overall the responses to 
the content of the leaflet were positive with 96% of respondents agreeing the purpose of the 
leaflet was clear, 82% of respondents agreeing that the leaflet achieved its purpose and 78% of 
respondents agreeing the leaflet was relevant to them.  Only 10% of respondents found the 
content worrying or upsetting.  Whilst 82% of respondents felt the leaflet described the benefits 
of its advice, only 37% agreed that any risks associated with its advice were described.  Only 
41% and 52% of respondents respectively agreed it was clear what sources of information were 
used to compile the leaflet and when this information was produced.  Literacy factors relating to 
the leaflet scored well; 96% of respondents agreed they understood the leaflet and 89% of 
respondents reported understanding all the terms used.  The leaflets’ graphics were considered 
helpful with 78% of respondents agreeing the pictures were easy to understand and 77% agreeing 
the pictures made it easier to understand the text.  The cover graphics were less well received 
with 53% of respondents agreeing the leaflet cover was appealing.  The layout of the leaflet was 
agreed to be appropriate by 78% of respondents and 81% agreed that the size of the typing was 
suitable.  Questions to capture the leaflets ability to stimulate learning revealed that 76% of 
respondents agreed the leaflet’s advice seemed practical and achievable and 71% agreed the 
advice was appropriate for their lifestyle. Overall, 84% of respondents would recommend this 
leaflet to other people with RA.   
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The anonymous free text comments were analysed using a general thematic approach (16).  
Comments such as: “pictures are almost too graphic”, “ found leaflet quite frightening as I am a 
heavy smoker”,  “I found it a little disturbing because I have never been told there was any link 
between RA and heart disease” and “some anti-inflammatory tablets …may also contribute to 
developing high blood pressure…worrying to read this” suggest reasons why a small percentage 
of respondents found the content worrying or upsetting.  Many respondents felt that any risks 
associated with the leaflets advice were not described; the free text comments suggested that 
these risks, most commonly, were perceived to relate to exercise “if a person is very badly 
affected by RA or is having a long flare up, it is not always possible or advisable for them to 
exercise in the ways mentioned and this can add feelings of guilt” and “I certainly caused severe 
exacerbation when I tried cycling”.  Comments about the cover graphics (of an older couple 
walking along a beach) explain why it was less appealing:  “…bit dated”, “…brighter colours 
would be good”, “…rather ageist”, “I thought it looked like a brochure for holiday insurance!” 
and “I wouldn’t spot it in a rack of health info and think ‘that’s for me’”.   Additionally, the free 
text comments captured the notion that many people felt more empowered as a result of reading 
the leaflet.  Many felt confident to raise this topic with their rheumatologist or general 
practitioner (“I was not aware that the link between RA and heart disease was so strong…I now 
feel able to approach my consultant with this information”, particularly as “this leaflet provides 
an easier way to bring the subject up”) and others described valuing learning that there are things 
they can do themselves (“I found it very encouraging and left a feeling of ‘I can help myself’”).   
 
Discussion 
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This study describes the development and evaluation of a new leaflet for people with RA which 
broadly has been well received by a large group of NRAS members.  The excellent response rate 
to a non-requested survey suggests that NRAS members wanted to support it and saw it as a 
valuable resource.  Specifically, the leaflet was perceived to be relevant, its advice was practical 
for their lifestyle and respondents would recommend the leaflet to others with RA.  Moreover, 
qualitatively, the leaflet appears to have had an empowering effect on its readers.    
 
This quality-based evaluation methodology is in contrast to other studies of patient information 
leaflets.  Previous studies of patient information leaflets for people with RA have evaluated the 
effectiveness by patients completing subsequent knowledge questionnaires (5-7).  However, with 
increasing emphasis on the patients’ experience in the health service we believe that ensuring the 
quality of educational material is also important, paying attention to factors such as presentation, 
font size and suitability of graphics.  Other specialties have assessed the quality of their leaflets, 
but health professionals, rather than patients, have assessed them (17-19) often focusing on 
content and readability alone (17;19).  If the leaflet is designed for patients then it is logical that 
their opinion should be sought to ensure it addresses their questions and is presented in a user-
friendly style (13). 
 
The balance between content and readability is crucial.  It has been suggested that inadequate 
attention has been paid towards the content of patient leaflets (13) and certainly inaccuracies or 
omissions have been identified in leaflets (17-19).  Patients identified that our novel CVD-RA 
leaflet lacked detail about what sources of information were used to compile the leaflet, when this 
information was produced and what the risks associated with its advice are; similar findings were 
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observed in a review of 31 renal replacement therapy leaflets available nationwide (17).  The 
challenge is to convey all the necessary information, whilst maintaining readability; the review of 
renal leaflets revealed that 28/31 leaflets had readability scores ranging from fairly to extremely 
difficult with only 3/31 leaflets having a similar readability score to our leaflet (described as 
‘standard’ readability).  
 
A small proportion of our respondents were upset by the leaflet.  This may relate to the fact that it 
‘broke bad news’ about co-morbid CVD associated with RA (11;12).  The converse would be to 
adopt a more paternalistic view that patients couldn’t cope with bad news (13); however, this 
denies patients the opportunity to make informed decisions about their lifestyle (12).  Certainly 
the empowerment that respondents wrote about in the free text comments suggests that the 
information was appreciated and would be acted upon.   
 
The strengths of the study relate to the fact that a novel and urgently required leaflet has been 
developed following appropriate consultation with relevant stakeholders, including patients.  The 
anonymous evaluation of the leaflet by its target audience, and by a large number of people 
geographically dispersed across the UK increases the validity of the evaluation.   
  
Limitations of this study include the acknowledgement that NRAS members may be more 
enthusiastic to seek and receive information than other people with RA.  The questionnaire 
responses reflect those of a group of predominantly white females, who were well educated with 
the median having obtained A-levels/diploma or a vocational qualification.  How this leaflet is 
received by a more diverse group of people is unknown.  Also, the leaflet was only provided in 
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English, making it less helpful for people from ethnic minorities for whom English is not their 
first language.  This is particularly important as people of South Asian origin living in the UK 
have been found to be at increased risk of CVD (20).   
 
Future work will require further iterations of the leaflet, including correcting current omissions as 
well as improving the cover graphics to attract attention and highlight the leaflets importance.  
Producing versions in other languages will also be required ensuring cultural sensitivity and 
cultural competence (21).  Despite suggestions in this study that patients would be empowered to 
help themselves and discuss CVD with their doctor, ultimately the test of the leaflet will be if 
patients alter their behaviour having received this leaflet and if this in turn translates into real 
benefit for their well-being and longevity.   
 
In summary, people with RA require access to information and education about their chronic 
disease, its medications as well as relevant co-morbidities; currently no AR-UK leaflet is 
available discussing CVD in the context of having RA.  Patient evaluation of our leaflet 
addressing this unmet need has been broadly positive and has identified areas where 
improvements could be made.  We would encourage others to involve patients in the evaluation 
of patient education resources to ensure their information needs are met, their questions answered 
and it is presented in a user-friendly style. 
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CHAPTER 8: TRANSLATING PATIENT EDUCATION THEORY INTO PRACTICE: 
DEVELOPING MATERIAL TO ADDRESS THE CARDIOVASCULAR EDUCATION 
NEEDS OF PEOPLE WITH RHEUMATOID ARTHRITIS 
 
Abstract 
 
Objective: This paper describes the rationale and design of a theory-informed patient education 
programme addressing cardiovascular disease for people with rheumatoid arthritis (RA) to 
illustrate how theory can explicitly be translated into practice.   
Methods: A steering group of rheumatologists and psychologists was convened to design the 
programme.  The Common Sense Model, the Theory of Planned Behaviour and the Stages of 
Change Model were used to underpin the topics and activities in the programme.  User 
involvement was sought.  The programme was formatted into a manual and the reading age of the 
materials was calculated. 
Results: A small group 8 week programme was designed.  The structure of the patient education 
programme, including topics, underlying psychological theory as well as behaviour change 
techniques, is described.   
Conclusion:  This patient education programme addresses a currently unmet educational need for 
patients with RA and uses theory to design, not just evaluate, the programme.  This will allow 
both enhanced interpretation of the results when the programme is implemented and replication 
by other units if successful.  The actual design and detail of education programmes merit wider 
dissemination to facilitate progress in the process of development and application. 
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Introduction 
 
Patient education has been defined as “any set of planned educational activities designed to 
improve patients’ health behaviours and/or health status” (1).  In rheumatoid arthritis (RA), 
education interventions addressing articular symptoms are well established (2;3).   However, it is 
the co-morbidities of RA that mostly account for increased mortality, poor quality of life and 
work disability (4).  In particular, co-morbid cardiovascular disease (CVD) is evident early on (5) 
and accounts for ~50% of the mortality in RA (6).  Therefore, there is a need to educate RA 
patients about CVD prevention, particularly aiming to change modifiable CVD risk factors, such 
as smoking, sedentarity (7), obesity (8) and a high-fat diet (9).  No standard, widely available 
resources currently exist that are designed specifically for RA patients: new educational material 
is required to meet this currently unmet need (10).   
 
Patient education may involve information only, counselling or behavioural therapies.  Although 
many believe (11) and have shown (12) that improved knowledge is fundamental to behaviour 
change, such improvements alone do not necessarily translate into behaviour change (13).  
Behavioural-style education programmes have shown the best outcomes (3;14) in both secondary 
(15) and primary (16) CVD prevention by effecting improvements in lifestyle factors, cardiac 
risk factors and incidence of CVD events.  However, results are variable; interventions grounded 
in the theories of human behaviour seem more effective (17;18).  Health psychology models of 
human behaviour provide a theoretical framework on which behavioural interventions can be 
constructed or evaluated (19).  The Common Sense Model of Illness Perceptions has been used to 
understand how patients may (or may not) develop coping strategies, such as making appropriate 
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behavioural changes, when faced with new symptoms or illness (20); the model postulates this 
depends on an individuals representation of that illness, influenced by both their lay beliefs 
(based on the identity, perceived cause, timeline, consequences and control/curability) as well as 
emotional response to that illness (20). Social Cognition Theory postulates that behaviour 
critically depends on a person’s representations of their social world, as well as the expectations 
and consequences relating to behaviour; the concept of self efficacy lies at the centre of this 
theory and describes one’s belief in one’s ability to succeed in certain situations (21).  Several 
social cognition models have been developed e.g, the Theory of Planned Behaviour considers that 
a person’s attitude to a behaviour (based on beliefs of risk and evaluation of outcome), the 
socially determined norms and their perceived behavioural control predict behavioural intentions 
(22).  The Stages of Change Model (or Transtheoretical Model) describes the 5 stages (pre-
contemplation, contemplation, preparation, action and maintenance) a person may pass, and cycle 
through, in order to achieve behaviour change (23);  identifying what stage a person is at can 
allow an intervention to be tailored appropriately (24).   
 
Collectively, a set of factors can be identified from the literature as being associated with 
successful patient education interventions (Table 1). 
 
The Medical Research Council Framework for developing and evaluating complex (non-
pharmacological) interventions, advocates this theory-based approach (25); it recommends 
reviewing the evidence, then a modelling phase to identify components of the intervention, 
(suggesting qualitative research to define relevant components) and later a randomized controlled 
trial of the intervention (25).  There are some descriptions of these recommended phases (26-28),  
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Table 1: Recommendations for designing a patient education initiative 
• Conduct a problem analysis prior to developing an education programme (29). 
• Research both the patient’s health needs and beliefs (30) and the health 
professional’s agenda (31).  
• Use a theoretical model (29). 
• Design an intervention to deliver clinical benefits, as well as educational benefits 
(30).  
• Ensure the aims, content and endpoints of a patient education initiative are 
congruent (31). 
• Organise group education and involve partners (32). 
• Learn what are existing patient health beliefs and modify if necessary (32).  
• Include opportunities whereby patients can learn and develop the skills necessary 
to overcome adverse habits, in order to encourage behaviour change (11); these 
may be self-management techniques, problem-solving or self-efficacy techniques 
(30;33). 
• Encourage goal-setting and redefine unrealistic goals (32). 
• Provide feedback (32). 
• Evaluate the programme (29). 
 
but these are in the minority. Systematic reviews of behaviour change interventions suggest that 
theoretical models are used more to evaluate, rather than develop, interventions (18;34) and 
greater attention to theoretical development is required (34).  In addition, explicit description of 
behavioural interventions would allow replication of effective programmes by others (18).   
 
Mindful of these recommendations, background research was performed to: define the nature and 
magnitude of co-morbid CVD in RA (5); highlight current recommendations for CVD risk 
management as an integral component of the long term care of RA (10); reveal that no widely 
available RA-specific CVD patient education resources are currently available (10); identify the 
suppositions, agenda, health needs and beliefs of healthcare professionals and RA patients 
(35;36).  This supported developing a small group educational intervention and suggested three 
models were particularly pertinent: the Common Sense Model, the Theory of Planned Behaviour, 
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and the Stages of Change Model.  Interventions addressing cardiovascular risk factors using these 
models have effected significant change (24;37;38). 
 
This paper aims to illustrate how this background theory can be translated into practice by 
describing the rationale and design of a theory-informed patient education programme. 
 
Methods 
 
A steering group was convened to design the education programme consisting of 2 
rheumatologists with special interests in patient education (HJ) and CVD in RA (GDK), 1 
rheumatology chartered health psychologist (EDH), and 2 academic psychologists specialising in 
cardiovascular psychophysiology (DC) and coping with the threat of ill health (PB).   There was 
consensus that the above three models were appropriate and would help participants identify the 
most suitable CVD risk factor for them to modify first.  Techniques relating to these models were 
inserted into an outline for the educational programme.  Other topics were identified, including 
accurate estimation of 10-year CVD risk, promoting personal responsibility for one’s health (39), 
challenging perceptions of the type of person likely to get heart trouble (coronary candidacy (40)) 
and screening for depression (36).  Different cognitive behavioural therapy techniques were 
discussed; graded goal setting was agreed to be particularly important in supporting and 
achieving behaviour change (24;32;41).  EDHs’ clinical experience offered valuable insight into 
which techniques have proved helpful in RA. The structure of weekly meetings was chosen as 
this format has proved successful for the Arthritis Self Management Programme (42), a 
multifaceted education programme based on the principles of self-efficacy, pioneered by Lorig in 
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the 1970s in the USA and now successfully delivered in Australia and Europe (43).  After several 
cycles of discussion/evolution of the programme, led by HJ, the educational content and activities 
were formatted into a patient manual, with a chapter per weekly meeting; identical interactive 
written and web versions were produced.  User involvement was provided through the 
membership of the National Rheumatoid Arthritis Society; most feedback was specific 
suggestions to simplify the language in the manual and appropriate amendments were made.   
One respondent said he did not like group work, contrary to previous research (36;44) but this is 
perhaps inevitable; most respondents commented favourably on the benefits of group work. The 
reading age of the manual was calculated using the Flesch-Kincaid readability test (45).  This 
score, which measures comprehension difficulty, is calculated using a readability calculator 
available at: http://www.editcentral.com/gwt/com.editcentral.EC/EC.html.  The Flesch reading 
ease score was 73.4% overall (i.e. it is easily readable by someone with a reading age of a 13 year 
old).     
 
The steering committee agreed that external input on the course would be very helpful.  A person 
with RA was recruited (modelling by other patients may be very powerful and is the principle 
behind the use of lay leaders on the Arthritis Self Management Programme (42)), as well as a 
dietician, exercise physiologist and smoking cessation advisor to provide tailored expert advice 
and resources as appropriate.  All steering group members agreed on the final version of the 
programme. 
 
Results 
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The educational intervention has been developed as a small group (eight participants) eight week 
programme, involving weekly 2 1/2 hour meetings in weeks 1-4 and week 8 with the opportunity 
to practice behaviour changes in weeks 5, 6 and 7. The course is led by a health professional and 
works through the corresponding 8 chapters of the manual; the interactive nature gives lots of 
opportunities for group discussion and peer support.  Table 2 summarises the content and 
activities of the course in chronological order, and relates this to the underpinning psychological 
theory.  The full manual, subject to copyright law, is available by contacting the first author. 
 
The Common Sense Model of Illness Perceptions particularly underpins the first weeks’ meeting.  
Some patients with RA have previously described incorrect aetiological models of disease (36), 
which Leventhal posits will (incorrectly) inform their representations of CVD .  Therefore, 
currently-held lay beliefs are explored and challenged in small group discussions; accurate 
knowledge about the symptoms of CVD, its cause, chronic nature and consequences is imparted, 
which provides the rationale, and explains the importance of making lifestyle changes, or 
adopting ‘active coping’ techniques.  A patient, who has recently made remarkable improvements 
in these health behaviours, then describes their personal story. This programme will support 
participants similarly develop and maintain their coping efforts so their experiences feedback 
constructively into their controllability representations of CVD.   
 
The Theory of Planned Behaviour and the Stages of Change models are translated into practice in 
week 2.  Participants are asked to rate the importance, their intention, confidence, perceived 
ease/difficulty and readiness to: stop smoking, increase exercise, eat heart-healthy low-fat diet 
and achieve a normal weight.  This makes manifest patients’ readiness to change behaviour,  
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Table 2: CVD patient education programme for people with RA 
 
Week Topic Theoretical 
model/concept 
Activity and behavioural techniques 
employed 
1 Introduction    
Current beliefs about CVD Common Sense 
Model 
Group discussion 
CVD and RA; CVD risk 
factors  
Common Sense 
Model 
Information giving, group discussion 
Reaction to learning about 
CVD 
Common Sense 
Model 
Encouraging coping rather than avoidance 
techniques 
Lifestyle modifications  Common Sense 
Model 
Concept of personal responsibility for health  
Self management 
Patient example 
2 Risk factors for CVD 
 
Common Sense 
Model 
Calculating personal risk for CVD, 
including a BMI calculation 
Consideration of which 
CVD lifestyle risk factor is 
most appropriate for them 
to modify 
Theory of 
Planned 
Behaviour 
Importance, intention, perceived 
behavioural control over CVD lifestyle 
factors (46),  
Stages of Change Readiness to change lifestyle risk factors for 
CVD 
Motivational interviewing (39) 
3 Identification of CVD risk 
factor to be modified  
Stages of Change Target goal identified in writing for each 
participant 
Graded goal setting Stages of Change Identification of first goal, using modelling 
by other participants, examples from 
relevant health professionals, setting 
SMARTS goals (47) and identification of 
relevant organisations  
4 Review  Stages of Change Comparison of performance against initial 
goal set 
Graded goal setting Stages of Change Further SMARTS goals (47) including 
rewards and contingency plan to cope with 
setbacks 
5-7 Graded goal setting and 
weekly review 
Stages of Change Skills mastery (42) 
Regular practice 
Practicing positive health behaviours 
Self monitoring  
Self management (19) 
8 Review of progress  Theory of 
Planned 
Behaviour 
Comparing intention and perceived 
behavioural control for lifestyle 
modifications against Week 2 scores (46) 
The future Stages of Change Identification of which cognitive 
behavioural techniques they have found 
most helpful personally 
 BMI = Body mass index;  SMARTS = Specific, Measurable, Action-orientated, Realistic, Time-
orientated with contingency plans in case of Sabotage. 
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permitting them to identify which CVD risk factor would be the most suitable to modify first.  
Activities such as identifying the advantages and disadvantages of making, or not making, this 
change as well as considering what friends or family would want them to do, spring from both 
these theories and may be powerful triggers for behaviour change.   
 
The Stages of Change Model is further translated into practice in weeks 3 to 7.  In week 3, 
participants commit to the behaviour they wish to modify and identify their target goal.  Graded 
goal setting is introduced (41), subdividing stages of the  model, eg, setting several stages of 
preparation and action goals gradually increasing in intensity or duration.  Experience from other 
participants and advice from a visiting dietician, exercise physiologist and smoking cessation 
advisor may help identify useful resources.  Participants commit to their first graded goal and 
ensure it is ‘SMARTS’; Specific, Measurable, Action-orientated, Realistic, Time-orientated with 
contingency plans in case of Sabotage (47).  In week 4 the participants review their performance 
against their first graded goal set.  The group provide praise, constructive feedback and 
contingency planning as appropriate.  Each participant now commits to a series of graded 
(SMARTS) goals for the forthcoming weeks when the group does not meet.  In this way, weeks 
5, 6 and 7 give participants the opportunity to practice their new behaviour, self monitor, master 
skills necessary for long term behaviour change and gain confidence in their ability to implement 
lifestyle changes.   
 
The Theory of Planned Behaviour underpins the activities in week 8.  Each participant reviews 
their progress over the course and re-evaluates their intention, confidence and perceived 
ease/difficulty in making lifestyle changes.  Testing out the experience of making behaviour 
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change, seeing the response of  family/friends, gaining confidence in their mastery of a behaviour 
and reflecting back on their progress should, according to the Theory of Planned Behaviour  
affect their attitude towards behaviour change and predict improved behavioural intentions for 
the future.   
 
Discussion 
 
This article describes the translation of health behaviour theory into practice, through a process 
underpinned by relevant stakeholder involvement, background research and theoretical models 
(as recommended by the Medical Research Council framework (25)), in order to develop novel 
educational material.  This process and product meets all the recommendations described in 
Table 1; evaluating the programme is described below. 
 
The specific use of the Common Sense, Theory of Planned Behaviour and Stages of Change 
Models in this programme allows each participant to personally determine which CVD risk factor 
they should aim to modify first, based on which risk factor they believe they are most likely to 
succeed at modifying; advice from health professionals to modify a risk factor that the patient has 
no intention or readiness to change undermines self-efficacy skills and may be futile (48).   
Whilst intention does not always translate into action, the flexible nature of this programme and 
the different cognitive behavioural techniques it uses should optimise the process that individuals 
go through in their decision making.  In this way, the content of the programme is congruent with 
the aims and endpoints of the programme.   
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The reading age of the manual accompanying the programme is appropriate.  Many RA patients 
have limited health literacy (49); however, 89% of an English sample of RA patients had a 
reading age of 13 years or above (50), suggesting that our intervention manual, despite focusing 
on complex health issues, should be accessible to the majority of patients. 
 
Other studies of complex patient behavioural modification interventions often simply report the 
results of their programme, furnishing only limited details of its precise nature.  This makes 
interpretation or replication harder.  This intervention is currently being compared, in a 
randomized controlled trial, to a control group receiving a small factual leaflet about CVD and is 
due to report in late 2011.  Outcome measures address educational (knowledge), behavioural and 
clinical endpoints.  This detailed description of the programme will allow replication by other 
researchers if the trial shows the intervention to be effective.  Should, however, the trial fail to 
show improvements then a detailed analysis will be possible, knowing the components of the 
intervention.  This information can inform future patient education initiatives and minimise the 
cost (both time and money) and ethical implications in repeating research studies.   
 
 
In summary, this paper describes the development of a theoretical and research based patient 
education programme.  The requirement for patient education programmes is increasing due to 
recognition of their impact in managing chronic disease (51) and the increasing complexities and 
co-morbidities of chronic disease (4).  Understanding the effective components of patient 
education will allow theory to successfully be translated into practice for the ultimate benefit of 
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patients.  We would advocate further groups describe the education programmes they develop as 
individual research papers. 
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CHAPTER 9: A RANDOMISED CONTROLLED TRIAL OF A COGNITIVE 
BEHAVIOURAL PATIENT EDUCATION INTERVENTION VERSUS A 
TRADITIONAL INFORMATION LEAFLET TO ADDRESS THE CARDIOVASCULAR 
ASPECTS OF RHEUMATOID DISEASE. 
 
Abstract 
 
Objectives: Cardiovascular disease (CVD) is responsible for 50% of the excess mortality for 
patients with rheumatoid arthritis (RA).  This study aimed to evaluate a novel 8 week cognitive 
behavioural patient education intervention designed to effect behavioural change with regard to 
modifiable CVD risk factors in people with RA. 
Methods: This was a non-blinded randomised controlled trial with a delayed intervention arm.  
Participants were randomised 1:1 to receive the education intervention or a control information 
leaflet.  The primary outcome measure was knowledge of CVD in RA; secondary measures were 
psychological measures relating to effecting behaviour change, actual behaviour changes and 
clinical risk factors.  Data were collected at baseline, 2 and 6 months.  
Results: 110 participants consented (52 in intervention group; 58 in control group).  At 6 months, 
those in the intervention group had significantly; higher knowledge scores (p<.001); improved 
behavioural intentions to increase exercise (p<.001), eat a low fat diet (p=.01) and lose weight 
(p=.06); lower mean diastolic blood pressure (DBP) of 3.7mmHg, whereas the control groups’ 
mean DBP increased by 0.8mmHg.   
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Conclusion: Patient education has a significant role to play in CVD risk factor modification for 
patients with RA; the detailed development of the programme likely contributed to its successful 
results. 
 
Introduction 
 
Rheumatoid arthritis (RA) is the commonest inflammatory arthritis and is a chronic, disabling 
condition (1).  As with all chronic diseases, patients require access to information about the 
condition, its medications and associated co-morbidities; this is re-inforced by RA-specific 
European and national guidelines (2-4).  Such information may be presented in a variety of ways, 
including written (leaflets, mind maps, internet resources) or interactive (individual or group; 
information giving, counselling or behavioural) formats.  However, systematic reviews of the 
patient education literature in RA have shown that successful interventions, that is, having 
significant effects on health outcomes, are behavioural (rather than information or counselling 
alone) (5) or psycho-educational (rather than education alone) programmes (6).  Moreover, 
incorporating a psychological theoretical underpinning to an education programme is thought to 
be instrumental to its success (7).  Educationalists should be mindful of these conclusions when 
developing future resources for people with RA. 
 
A currently unmet educational need for patients with RA is information regarding associated 
cardiovascular disease (CVD)  (8); this is particularly relevant as CVD is responsible for 50% of 
the excess mortality in RA, due to both clustering of traditional CVD risk factors and the role that 
systemic and local inflammation plays in driving the development and instability of the 
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atherosclerotic plaque (9).  Existing generic resources addressing modifiable CVD factors are 
likely to be inadequate for people with RA as their advice about exercise and weight control is 
not set in the context of the physical and psychosocial constraints associated with having RA (8).  
Novel education  resources are therefore required both to inform people with RA about the CVD 
risk and to effect behaviour change with regard to modifiable traditional CVD risk factors such as 
smoking cessation, increasing physical activity, adoption of a healthy low fat diet and weight 
control in order to achieve subsequent benefits on CVD risk factors such as lipid profiles, blood 
pressure and insulin resistance (8;10); concurrently, rheumatologists must aim to achieve control 
of the systemic inflammation (11).   
 
We have designed a novel education resource to address the CVD co-morbidity in RA, informed 
by the Medical Research Councils’ (MRC) recommendations for designing and evaluating 
complex interventions (12).  During the theoretical phase we reviewed the literature; this revealed 
considerable theoretical common ground between successful RA education programmes and 
primary and secondary CVD prevention programmes which could be integrated to provide a 
framework from which to develop our intervention (13).  Using a behavioural approach, 
underpinned by social cognition models (14) and stages of change theory (15) we developed a 
small group programme lasting two months, which should theoretically confer the greatest 
benefit (13).  The modelling phase involved qualitative research with relevant stakeholders, both 
health professionals and patients (16;17), to provide further guidance on how such a novel 
intervention should be developed and implemented in practice.  Theory was translated into 
practice in the exploratory trial phase and an eight week small group cognitive behavioural 
education programme was developed with accompanying patient manual; specific details about 
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the process of programme development and the details of the final programme, including specific 
weekly topics, underlying theoretical models and the activities and behavioural techniques 
employed are described elsewhere (18).   
 
The next stage of the MRCs framework requires the novel intervention to be tested in a definitive 
randomised controlled trial (RCT).  This paper describes this trial whereby the cognitive 
behaviour patient education programme about CVD designed for people with RA (18) is 
compared to a control group who receive a small factual information leaflet about CVD, akin to 
the information- giving component of the first week of the programme (19).  
  
Methods 
 
Ethical approval was obtained from the Black Country Research Ethics Committee.   
 
a) Participants 
Participants were recruited from a secondary care setting from a single rheumatology centre.  The 
inclusion criteria were aged over 18, a diagnosis of RA, the ability to speak, read and write in 
English, agreeing to participate in an eight week small group education programme and to attend 
a research clinic to collect outcome data at baseline and two and six months later.  
 
b) Trial design  
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The trial was a non-blinded randomised controlled trial with a waiting list delayed intervention 
arm.  Participants were randomised 1:1 to the intervention immediately or the control group.  
After completing the six months follow up, those in the control group could subsequently attend 
the intervention programme should they wish, although this was not included as part of the trial.  
 
c) Procedure 
Consecutive patients attending outpatient clinics were approached by the chief investigator (HJ) 
and the study explained.  Those interested in the study were given a patient information leaflet 
and contacted 48 hours later to identify if they would like to participate.  Patients were 
randomised to the intervention or control group; a computer programme generated a 
randomization list which was applied to our list of recruits by an independent member of the 
research team.  All participants provided informed consent and signed a consent form.  Baseline 
data were collected; age, gender, ethnicity, employment and number of years in full time 
education.  Medical records were used to confirm duration of RA, past medical history of a CVD 
event or diabetes, and whether patients currently received treatment for hypertension or 
dyslipidaemia.  Biologic, disease modifying, steroid and non-steroidal treatments for their RA 
were documented and disease activity was scored in 28 joints (DAS 28).  Control participants 
were given a copy of the control information leaflet to read at home.  Intervention participants 
subsequently attended the small group cognitive behavioural education programme held in the 
hospital research unit.  Follow up data were collected on all participants at two and six months.  
 
d) Outcome measures 
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At baseline, two and six months follow-up, outcome data were collected.  The primary outcome 
measure was knowledge of heart disease in rheumatoid arthritis using the Heart Disease Fact 
Questionnaire-Rheumatoid Arthritis (HDFQ-RA), a validated self-completion questionnaire, 
where scores range from 0 (no knowledge) to 13 (maximum knowledge) (20).  Secondary 
outcomes measures were: 
i) Psychological measures relating to effecting specific behaviour changes, namely smoking 
cessation, increasing exercise, eating a healthy low fat diet and losing weight. 
Specifically, these were: 
a. Attitudes to each individual behaviour change, measured by the mean response to 
six items rated on bipolar scales (-3 to +3) (21). 
b. Perceived behavioural control over each individual behaviour change, measured 
by the mean response to four items, measured on unipolar scales +1 to +7 (21). 
c. Behavioural intention towards each individual behaviour change, measured by the 
mean response to two items rated on bipolar scales (-3 to +3) (21). 
ii) Behavioural outcomes  
a. Smoking status; categorised as current or ex/never smoked 
b. Participation in physical activity; the International Physical Activity Questionnaire 
(IPAQ) was used (22), a validated self-complete questionnaire from which total 
weekly physical activity can be expressed as weighted metabolic equivalent of 
task (MET) minutes per week  
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c. Dietary modifications; the short semi-quantitative food group questionnaire was 
used (23), from which questions pertaining to fruit and vegetable consumption, 
type of milk used, use of salt and removing fat from meat were used. 
iii) Clinical outcomes 
a. Body mass index  
b. Blood pressure 
c. Lipid profile, including total cholesterol to high density lipoprotein (TC:HDL) 
ratio (lipid levels are inversely associated with inflammation; this ratio has been 
shown to be a more robust measure in patients with RA (24;25)) and low density 
lipoprotein (LDL) levels. 
 
e) Sample size 
The sample size was based on the primary endpoint, i.e. evaluating for changes in knowledge of 
heart disease in RA, using the Heart Disease Fact Questionnaire-Rheumatoid Arthritis (20).  This 
was set at 50 per group to provide 80% power at the 5% significance level.  Therefore, 55 
patients were recruited per group (110 in total) to allow for 10% attrition. 
 
f) Statistical analysis 
All data were collected and entered into SPSS software version 17 (SPSS, Chicago IL).  The 
database was audited and cleaned for out of range values.  Baseline characteristics for the 
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intervention and control group were compared using analysis of variance (ANOVA) for 
continuous data and chi-square for categorical data.  An intention-to-treat analysis was 
performed.  Continuous outcome data were compared between the intervention and control 
groups using analysis of covariance (ANCOVA), whereby the differences in outcome variables 
could be compared at two and six months follow up, with baseline values serving in each case as 
the covariate.  The F statistic, degrees of freedom (df), probability and partial eta squared (ŋ2), an 
estimate of effect size, are reported.  Probability values less than 0.05 are considered statistically 
significant.  Categorical outcomes between groups were compared at the different time points 
using chi-square.   
 
Results 
 
One hundred and ten patients with RA consented to participate in the study, with 52 patients 
randomised to the intervention arm and 58 to the control arm.  Figure 1 shows the flow of recruits 
through the study.  Comparison of the baseline characteristics of the intervention and control 
groups is shown in Table 1.  The only significant difference between the groups was that the 
participants in the intervention were more likely to be on biologic therapy. 
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Figure 1: Study design, number of participants and their progress through the study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reasons included did not have the time, could not fit it in, other commitments, could not get time off work, do not 
want to make any more visits to hospital and not interested. 
 
 
 
 
 190 people met inclusion criteria 
and interested in study 
52 people randomised to intervention 
group 
58 people randomised to control group 
49 people completed 
6 months follow up 
3 people lost to 
follow up 
48 people completed 
6 months follow up 
10 people lost 
to follow up 
80 people declined to 
participate* 
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Table 1: Comparison of baseline characteristics between the intervention and control groups 
Characteristic Intervention group 
n = 52 
Control group 
n = 58 
Test statistic p value 
Continuous data: 
 
Mean (SD) Mean (SD) F statistic (df)  
Age 62.19 (10.59) 60.81 (10.67) (1,108) = .46 .50 
Years in full time education 11.27 (2.06) 11.18 (2.23) (1,96) = .04 .85 
Duration of RA 11.6 (11.35) 14.09 (13.91) (1,106) = 1.03 .31 
BMI 29.34 (6.87) 29.09 (5.17) (1,107) = .05 .83 
Waist circumference 98.19 (17.51) 97.42 (12.11) (1,107) = .07 .79 
SBP 143.50 (15.58) 141.48 (19.14) (1,106) = .36 .55 
DBP 83.60 (11.28) 82.14 (10.83) (1,106) = .47 .50 
Total cholesterol 5.00 (0.94) 5.24 (0.95) (1,108) = 1.86 .18 
HDL cholesterol 1.56 (0.41) 1.56 (0.34) (1,108) = .01 .93 
LDL cholesterol  2.79 (0.78) 3.05 (0.86) (1,104) = 2.71 .10 
Triglycerides 1.49 (0.83) 1.45 (0.63) (1,108) = .06 .81 
TC:HDL ratio 3.37 (0.96) 3.51 (0.89) (1,108) = .64 .43 
Glucose 4.83 (0.85) 4.85 (0.86) (1,108) = .02 .89 
DAS 28 score 3.27 (1.55) 2.93 (1.23) (1,106) = 1.65 .20 
Categorical data: 
 Number (%) Number (%) χ2 (df) p value 
Number of females 37(71.15) 43(74.14) (1)= 0.12  .73 
Number of caucasians 50 (96.15) 57 (98.28) (1)=0.47 .50 
Employment 
• Retired 
• Full time work 
• Part time work 
• Unemployed 
• Homemaker 
 
38 (73.08) 
6 (11.54) 
5 (9.62) 
1 (1.92) 
2 (3.85) 
 
39 (69.64) 
7 (12.5) 
8 (14.29) 
0  
2 (3.57) 
(4)=1.64 
 
.80 
PMHx CVD event 6 (11.54) 10 (17.24) (1)=0.72 .40 
PMHx treated hypertension 24 (46.15) 24 (41.38) (1)=0.25 .61 
PMHx treated dyslipidaemia 19 (36.54) 24 (41.38) (1)=0.27 .60 
PMHx DM 4 (7.69) 2 (3.45) (1)=0.96 .33 
Current biologic Rx 24 (46.15) 13 (22.41) (1)=6.92 .01 
Current DMARD RX 41 (78.85) 51 (87.93) (1)=1.65 .20 
Current steroid Rx 13 (25) 13 (22.41) (1)=0.10 .75 
Current NSAID Rx 12 (23.08) 17 (29.82) (1)=0.63 .43 
Smoking status 
• Current 
• Never or ex  
 
8 (15.38) 
44 (84.82) 
 
11 (18.97) 
47 (81.03) 
(1)=0.25 .62 
Abbreviations: (df) = degrees of freedom, RA = rheumatoid arthritis, BMI=body mass index, SBP=systolic blood 
pressure, DBP=diastolic blood pressure, TC:HDL=total cholesterol to high density lipoprotein ratio, DAS 
28=disease activity score in 28 joints, PMHx=past medical history, CVD=cardiovascular disease, DM=diabetes 
mellitus, DMARD=disease modifying anti-rheumatic drug, NSAID=non-steroidal anti-inflammatory, Rx=treatment 
 
 
 
 
210 
 
a) Primary outcome measure; effect of intervention on knowledge 
The intervention group had a statistically significant higher knowledge score measured using the 
HDFQ-RA immediately after the intervention and this difference was maintained at the final 
follow-up at six months.  This is shown in Table 2. 
 
Table 2: Comparison of the intervention and control groups' knowledge at two and six months, 
adjusting for knowledge at baseline. 
HDFQ-RA 
score 
 
Intervention group 
n=52 
Mean score (SD) 
Control group 
n=58 
Mean score (SD) 
F statistic 
(df) 
p value partial ŋ2 
• 0 
• 2 
• 6 
9.41 (2.50) 
10.93 (2.18) 
10.16 (2.41) 
9.24 (2.71) 
9.34 (2.84) 
9.08 (2.75) 
(1,79)=13.73 <.001 .148 
HDFQ-RA=Heart Disease Fact Questionnaire-Rheumatoid Arthritis 
 
 
b) Secondary outcome measures;  
i) Effect of intervention on psychological measures 
Attitudes, perceived behavioural control and behavioural intentions towards effecting specific 
behaviour changes are compared between the intervention and control groups in Tables 3, 4 and 5 
respectively.  The intervention group showed significant improvements in all psychological 
measures with regard to increasing exercise and in two out of the three measures with regard to 
adopting a healthy low fat diet when compared to the control group.  However, there was no 
difference between groups with regard to stopping smoking; indeed, smoking was the only 
behaviour where both groups showed negative intentions towards changing throughout the study.   
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Table 3: Comparison of the intervention and control groups' attitudes at two and six months, 
adjusting for attitudes at baseline. 
Attitude to: Intervention group 
n=52 
Mean score (SD) 
Control group 
n=58 
Mean score (SD) 
F statistic 
(df) 
p value partial ŋ2 
Stopping smoking 
• 0 
• 2 
• 6 
 
0.48 (2.24) 
0.32 (2.23) 
0.03 (1.63) 
 
1.11 (1.75) 
0.91 (1.64) 
1.58 (1.57) 
(1,9) = 1.40 .27 .134 
Increasing exercise 
• 0 
• 2 
• 6 
 
1.46 (1.37) 
1.71 (1.35) 
1.71 (1.20) 
 
1.17 (1.28) 
0.94 (1.38) 
1.07 (1.08) 
(1,67) = 7.44 .01 .100 
Healthy low fat eating 
• 0 
• 2 
• 6 
 
1.36 (1.22) 
1.66 (1.33) 
1.78 (1.15) 
 
1.5 (1.02) 
1.45 (1.19) 
1.35 (1.33) 
(1,77) = 7.57 .01 .089 
Losing weight  
• 0 
• 2 
• 6 
 
2.06 (1.13) 
2.27 (0.88) 
2.21 (1.06) 
 
2.09 (1.03) 
2.06 (1.06) 
2.08 (1.13) 
(1,75) = 2.48 .12 .032 
 
 
Table 4: Comparison of the intervention and control groups' perceived behavioural control at two 
and six months, adjusting for perceived behavioural control at baseline. 
Perceived behavioural 
control over: 
Intervention group 
n=52 
Mean score (SD) 
Control group 
n=58 
Mean score (SD) 
F statistic 
(df) 
p value partial ŋ2 
Stopping smoking 
• 0 
• 2 
• 6 
 
2.46 (1.95) 
3.13 (2.13) 
2.88 (2.00) 
 
2.96 (1.00) 
3.36 (1.52) 
3.32 (1.83) 
(1,10) = .01 .92 .001 
Increasing exercise 
• 0 
• 2 
• 6 
 
4.32 (1.69) 
4.79 (1.71) 
4.73 (1.79) 
 
4.03 (1.55) 
4.06 (1.80) 
3.99 (1.71) 
(1,75) = 4.30 .04 .054 
Healthy low fat eating 
• 0 
• 2 
• 6 
 
5.14 (1.53) 
5.52 (1.51) 
5.54 (1.71) 
 
5.41 (1.33) 
5.42 (1.28) 
5.61 (1.20) 
(1,83) = 1.86 .18 .022 
Losing weight  
• 0 
• 2 
• 6 
 
5.21 (1.47) 
5.51 (1.34) 
5.49 (1.35) 
 
5.41 (1.41) 
5.15 (1.39) 
5.21 (1.47) 
(1,78) = 4.60 .04 .056 
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Table 5: Comparison of the intervention and control groups' behavioural intentions at two and six 
months, adjusting for behavioural intentions at baseline. 
Behavioural intentions 
to: 
Intervention group 
n=52 
Mean score (SD) 
Control group 
n=58 
Mean score (SD) 
F statistic 
(df) 
p value partial ŋ2 
Stopping smoking 
• 0 
• 2 
• 6 
 
-1.00 (2.63) 
-0.75 (2.42) 
-0.17 (2.34) 
 
-0.57 (2.16) 
-0.43 (2.55) 
-0.36 (2.48) 
(1,10) = .51 .49 .048 
Increasing exercise 
• 0 
• 2 
• 6 
 
0.42 (1.95) 
1.28 (1.61) 
1.01 (1.64) 
 
0.40 (1.70) 
0.32 (1.66) 
0.32 (1.76) 
(1,72)=14.11 <.001 .164 
Healthy low fat eating 
• 0 
• 2 
• 6 
 
1.16 (1.88) 
1.70 (1.62) 
1.71 (1.61) 
 
1.64 (1.35) 
1.54 (1.43) 
1.63 (1.27) 
(1,82) = 7.27 .01 .082 
Losing weight  
• 0 
• 2 
• 6 
 
1.84 (1.35) 
2.26 (0.87) 
2.14 (1.05) 
 
1.99 (1.15) 
1.86 (1.12) 
1.91 (1.11) 
(1,79) = 3.73 .06 .045 
 
 
ii)  Effect of intervention on behavioural outcomes 
There was no difference between groups on smoking status at the different time points.   Analysis 
of dietary questionnaires showed no difference between the intervention and control groups on 
quantity of fruit and vegetables consumed, type of milk used, use of salt or removing fat from 
meat, at 0, 2 and 6 months.  There was no significant difference between the groups at the three 
different time points on physical activity undertaken. 
iii) Effect of intervention on clinical outcomes 
A significant effect on diastolic blood pressure (DBP) was observed; over the 6 month follow up 
period the intervention groups mean DBP fell by 3.7mmHg, whereas the control groups’ mean 
DBP increased by 0.8mmHg.  The group effect on LDL was close to the conventional criterion 
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for statistical significance.  The control groups’ mean LDL levels increased during the trial by 
0.25 mmol/l whereas the intervention groups mean LDL only increased by .09mmol/l.  Table 6 
shows the results of all clinical outcomes measured and compares them between the two groups.  
 
Table 6: Comparison of the intervention and control groups' clinical outcomes at two and six 
months, adjusting for clinical variables at baseline. 
 Intervention group 
n=52 
Mean score (SD) 
Control group 
n=58 
Mean score (SD) 
F statistic 
(df) 
p value partial ŋ2 
BMI 
• 0 
• 2 
• 6 
 
29.08 (6.55) 
29.09 (6.64) 
28.99 (6.51) 
 
29.04 (5.32) 
29.05 (5.52) 
29.09 (5.65) 
(1,93) = .17 .68 .002 
SBP 
• 0 
• 2 
• 6 
 
143.48 (15.73) 
139.50 (15.78) 
139.96 (16.01) 
 
142.26 (19.71) 
135.35 (15.55) 
139.83 (20.97) 
(1,91) = .36 .55 .004 
DBP 
• 0 
• 2 
• 6 
 
83.04 (10.75) 
78.81 (9.56) 
79.31 (9.50) 
 
81.93 (11.18) 
81.63 (10.27) 
82.72 (10.66) 
(1,91) = 5.97 .02 .062 
TC:HDL ratio 
• 0 
• 2 
• 6 
 
3.38 (0.99) 
3.47 (1.02) 
3.57 (0.98) 
 
3.47 (0.87) 
3.66 (0.97) 
3.84 (1.04) 
(1,92) = 2.33 .13 .025 
LDL 
• 0 
• 2 
• 6 
 
2.75 (0.79) 
2.72 (0.85) 
2.84 (0.87) 
 
2.98 (0.84) 
3.02 (0.80) 
3.23 (0.85) 
(1,84) = 3.38 .07 .039 
Abbreviations: BMI=Body mass index;SBP=systolic blood pressure; DBP=diastolic blood 
pressure;TC:HDL=total cholesterol to high density lipoprotein ratio; LDL=low density 
lipoprotein 
 
 
Discussion 
 
214 
 
Patient education is widely accepted as an integral part of patient care; benefits such as effecting 
positive patient behaviours and improving compliance with medication are essential to 
compliment the clinical decisions made by healthcare professionals (26).  However, changing 
people’s behaviour is a particularly challenging task, especially in a primary prevention setting 
(27).  The positive outcomes that emerge from this study, therefore, give strong encouragement to 
the present approach to patient education.  Not only have we shown significant improvements in 
knowledge, our primary outcome measure, but this has also translated into changing participants’ 
psychological views, particularly their intentions, to make behaviour change.  In turn, we have 
reported improvements in clinical risk factors, namely DBP.  This concurs with  Ajzens Theory 
of Planned Behaviour (28), which posits that attitudes and perceived behavioural control, 
alongside subjective norms, to a specific behaviour drive behavioural intentions which in turn 
translate into actual behaviour change.  This theory is underpinned by the prerequisite of 
adequate knowledge and information provision and, in turn, the consequence of this theory is that 
behaviour change should translate into tangible benefits, namely changes in clinical CVD risk 
factors in this case. The improvement in DBP we observed is particularly relevant as the impact 
of hypertension on cardiovascular outcome in patients with RA is similar to those who do not 
have RA, that is, the risk of CVD increases in parallel with systolic or diastolic blood pressure, 
approximately doubling for every 20/10mmHg incremental increase in blood pressure that occurs 
within the  range of 115–185/75-115mmHg (29).  Pertinently, the prevalence of hypertension in 
secondary care cohorts of RA patients may be as high as 70% (30).  Furthermore, the 
improvements we achieved in DBP were similar to or better than improvements in DBP observed 
longitudinally in patients commencing treatment with anti-tumour necrosis factor α (anti-TNFα) 
medication, where reductions in DBP of 5mmHg (31) and up to 2.8mmHg were observed (32). 
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These results are comparable with other ‘Healthy Heart’ programmes aiming to modify multiple 
CVD risk factors; some delivered improvements in behaviours, such as nutrition and exercise 
(33), whereas others have, similar to our study, achieved some clinical benefits (34;35).  It is 
particularly relevant to note that our study participants were an unstratified group of all ages and 
with a varying number of CVD risk factors, other than RA, from zero to several.  Our results 
cannot, therefore, be directly compared to other primary prevention trials where the inclusion 
criteria required participants to have a specified cluster of CVD risk factors, such as diabetes, 
hypertension and dyslipidaemia (36).  Further, this is the first programme to aim to modify CVD 
risk factors in an RA population where there are specific additional challenges participants may 
face in trying to modify adverse CVD behaviours; exercise despite joint pain, weight loss despite 
corticosteroid medication, blood pressure control despite the need for non-steroidal anti-
inflammatory medication (13). 
 
It is helpful to consider why this trial has delivered successful results, to inform future patient 
education initiatives.  Reasons may relate to both the trial design and methodology, such as 
ensuring it was adequately powered and a sensible choice of outcome variables was used 
appropriate to the duration of the follow- up period. Over a six month period and with this sample 
size it would be unrealistic to aim to show differences in subsequent CVD events, particularly 
with a predominantly primary prevention intervention; much longer follow up would be required, 
such as the 8-year follow up period used by Rachmani et al where a significant reduction in CVD 
events was demonstrated (36). Further, the detailed and careful development of the actual 
cognitive behavioural patient education programme likely contributed to its successful results.  
Interventions developed specifically for purpose and their target audience are more likely to be 
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successful (8) and the MRCs framework reinforces the importance of thorough theoretical, 
modelling and exploratory phases to develop a complex intervention, prior to moving onto a RCT 
(12); completing these stages (13;16-18) ensured the intervention developed was truly focused on 
the specific needs of people with RA with regard to modifying their CVD risk.   
 
Interestingly, there was a discrepancy between intentions to modify the different CVD risk 
behaviours, in particular smoking cessation appeared to be resistant to this intervention as 
measured by both psychological measures and actual changes in smoking habits.  This may relate 
to the fact that there were only 19 smokers recruited to this study so the numbers were small, but 
may also reflect the public health challenge in getting people to quit this addictive behaviour;  
recent public health/government strategies have encouraged many to give up (37) so those 
remaining may represent a particularly resistant group.  In contrast, the intervention group 
showed improved psychological parameters across all measures with regard to increasing 
exercise.  People with RA have previously described both physical and psychological factors as 
barriers to exercise (38) as well as concerns that exercise could further damage their joints (17), 
whereas tailored advice from health professionals has consistently been identified as an exercise 
enabler (39).   This study, where people in the intervention group received specific exercise 
advice from health professionals set in the context of having RA, provided as part of an 
interactive discussion, appears to be more effective in encouraging people with RA to increase 
their physical activity levels than the didactic written information provided to the control group. 
 
This study is not without its limitations.  First, despite randomisation, there were significantly 
more patients in the intervention group than the control group taking biologic medication and 
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biologic medications may have effects on the lipid profile and blood pressure.  The anti-TNFα 
medication infliximab has been shown to increase TC and HDL but with no overall change in the 
atherogenic index (TC:HDL ratio), and tociluzimab, an interleukin-6 receptor antagonist, has also 
been shown to significantly increase components of the lipid profile, namely TC, HDL, 
triglycerides and LDL, although the impact on the atherogenic index is currently unclear (40).  
However, a comparison of TC:HDL ratio results of those not on biologic medications versus all 
subjects concluded that biologic therapy was not masking any change.  Recent evidence also 
suggests that biologic treatment may decrease blood pressure (31;32); these results were observed 
comparing blood pressure readings pre and post commencement of biologic therapy.  However, 
in this study, participants were on stable long-term treatment with biologic medication and so this 
is unlikely to provide an explanation for the decreases in DBP observed.  Second, the study 
would have undoubtedly benefitted from a longer term follow-up, both to investigate whether 
currently observed benefits of the intervention are maintained longer term, as well as to test 
whether there are subsequent effects of the intervention on other clinical outcomes.  We have 
previously discussed, in the context of the timing of a patient education programme, the concept 
of a ‘golden moment’, that is, a specific point in time when a patient will objectively self-assess 
their health and commit to a behaviour change (16).  This golden moment will not necessarily 
happen during an education programme, especially a research education programme where 
consecutive patients are invited to attend, although the course may act as a trigger later on.  
Anecdotally, participants have reported modifying their behaviours but the golden moment which 
prompted them to act came after the six months follow-up had been completed.  Longer term 
follow-up, over a period of years, would then be suitable to include CVD events as an outcome 
measure, although the study was not powered originally to detect a difference here.  Lastly, 
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another limitation is that health economics data were not collected; this information would be 
useful for the future in deciding whether to implement this existing CVD education programme 
or whether changes are needed to improve its cost-effectiveness.   
 
Future research should also include further analysis to identify predictors of successful outcomes 
from the cognitive behavioural patient education programme.  Hypothesised possibilities could 
include baseline CVD risk factor profile; baseline knowledge of CVD; levels of anxiety and 
depression; health locus of control; self-efficacy measures, and number of sessions attended.   If 
future education programmes were made available the imperative of cost-effectiveness would 
require physicians to pre-select participants most likely to benefit from the intervention.  The 
identification of predictors of success would be a valuable tool here. 
 
In conclusion, this cognitive behavioural education programme has effected significant changes 
in knowledge, and intentions to modify adverse CVD behaviours, as well as clinical 
improvements in diastolic blood pressure.  These successful outcomes are thought to relate to the 
careful design of the education programme, informed by extensive theoretical and qualitative 
research with stakeholders.  We would advocate the integration of patient education about CVD 
risk in RA into the standard care of patients with RA, as well as further research into developing 
and delivering effective patient education programmes. 
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CHAPTER 10: DISCUSSION 
 
Guidelines for the management of rheumatoid arthritis (RA) clearly state the importance of 
patient education to encourage patients to be active partners in the management of their disease, 
capable of self- management and implementing appropriate behaviour change as necessary (1;2).  
In addition, guidelines also emphasise the importance of addressing the cardiovascular co-
morbidity for patients with RA, recommending that individuals should be screened and relevant 
risk factors medically managed (1-3).  However, until now, these two principles have not been 
integrated to develop suitable and tailored patient education resources about cardiovascular 
disease (CVD) in RA.  We identified this gap in our existing provision of care for patients with 
RA and this thesis has described our efforts to highlight this unmet need, as well as to develop 
and evaluate an education programme to fulfil this need.   
 
Summary 
 
We explicitly used the Medical Research Council (MRC) framework for developing complex 
interventions and the Chapters of this thesis chronologically relate to their recommended phases.  
Relevant stakeholder qualitative research identified important themes and health psychology 
behaviour change models which were employed to inform the design of the complex intervention 
(Chapters 4 and 5).  Patients seemed unaware of their risk of CVD co-morbidity and few 
displayed extensive and accurate knowledge of CVD.  Information about CVD was therefore 
required to accurately inform patients’ illness cognitions (Common-Sense Model) and to provide 
the rationale for adopting approach-coping strategies, such as adopting appropriate lifestyle 
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behaviours. However, health professionals presumed that patients would not consider CVD a 
priority and perceived that they would be poorly motivated to adopt suitable lifestyle behaviours; 
in contrast, patient interviews revealed that patients were interested in learning about preventative 
strategies.  Moreover, patients could identify factors that had specifically motivated them 
previously to change behaviour, for example, stopping smoking, and gave examples of changes 
in their attitude, social norms and perceived behavioural control, that is, self-efficacy, which had 
driven such behaviour change (Theory of Planned Behaviour).  Additionally, patients identified 
inaccurate perception of risk, depression or fatalism as barriers to implementing behaviour 
change.  Both health professionals and patients agreed that a personal ‘golden moment’ of 
realisation was needed to drive behaviour change, analogous to the preparation and action stages 
of the Transtheoretical Model.  Accordingly, as well as providing accurate information, the 
education intervention needed to provide the opportunity to explore the breadth of social 
cognitive factors relating to behaviour change, enhance patients’ self-efficacy, and signpost 
patients to resources supporting their commitment to change.  Health professionals were unsure 
when CVD should be discussed with patients; patients revealed that they felt information about 
CVD would be both overwhelming but also seem irrelevant at diagnosis but, given time to adapt 
to their diagnosis, they would be able to cope with information about CVD.   Practical issues 
relating to the development of an education programme included a majority request for a small 
group format and for secondary care health professionals to communicate with primary care so 
that patients are provided with a consistent message.   
 
The next phase of the MRC framework required all components of the forthcoming trial to be 
defined.  This included defining outcome measures, as well as determining the nature of the 
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control arm of the trial.  Our primary outcome measure was knowledge of CVD in RA.  
However, no questionnaire existed to measure this.  Therefore the Heart Disease Fact 
Questionnaire (HDFQ), designed to measure CVD knowledge in people with diabetes mellitus, 
was modified and a RA-specific version was developed (HDFQ-RA) (Chapter 6).  Aware that 
repeat administration of a questionnaire may result in a respondent only learning the answers to 
the questionnaire, two parallel versions of the HDFQ-RA were developed.  Parallel form 
reliability, internal consistency and test-retest stability of the questionnaires were established, as 
was face, content and discriminant validity.  Thus, it was assured that the HDFQ-RA had robust 
psychometric properties and was a suitable measure to use to assess our novel education 
intervention.   
 
The control arm of our intervention would need to receive some basic information about CVD in 
RA.  Standard information leaflets for people with RA are produced by Arthritis Research-UK, 
but there is no existing leaflet addressing CVD in RA.  Therefore, an information leaflet was 
developed for the control group (Chapter 7); it was akin to the information-giving component at 
the beginning of the novel education intervention, but without the subsequent discussion or open 
questions to explore the complex web of social cognitive factors that underlie patients’ 
behaviours.  Evaluation by members of the National Rheumatoid Arthritis Society (NRAS) 
revealed that the leaflet was well received, perceived to be relevant and provided practical 
lifestyle advice; a majority of respondents indicated that they would recommend it to a patient 
with RA.   
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The last component of the intervention to be defined was the nature of the education programme 
itself.  The theoretical models identified by the qualitative research were translated into practice 
and a small group, eight-week programme was developed (Chapter 8).  The exact topics covered 
each week were defined, as was the underlying health psychological model and activities and 
behavioural techniques employed.  The content was formatted into an interactive manual, with a 
chapter per weekly meeting, for each participant to keep; identical written and web versions were 
available.   
 
The MRC then recommend a definitive randomised controlled trial of the intervention developed.  
Participants were randomised to the intervention immediately or the control group and were 
followed-up for six months (Chapter 9).  Those in our intervention group showed significant 
improvements in knowledge, which translated into changing participants’ psychological views, 
particularly behavioural intentions, and in turn we observed improvements in clinical risk, 
namely reduced diastolic blood pressure; this is particularly relevant as the prevalence of 
hypertension in RA may be as high as 70% and the risk of CVD events increases in parallel with 
increases in blood pressure (4).  The positive outcomes from this trial suggest that patient 
education has a significant and important role to play in CVD risk factor modification for people 
with RA. 
 
Strengths of this study 
 
There are many strengths of this thesis as a whole; the strengths of individual Chapters have been 
previously described.  Fundamentally, this thesis directly addresses an important and highly 
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prevalent co-morbidity for patients with RA where, previously, education and information 
resources were lacking.  This thesis has not just hypothesised about what education resources 
would be ideal, neither has it developed education resources spontaneously.  Instead it has 
followed a recommended structured framework to fully research the health beliefs and needs of 
the target population and, combined with what has been learnt from previous published education 
studies, produced and robustly evaluated a novel education intervention.  The positive outcomes 
from the randomised controlled trial are a strong endorsement of this approach.  Further, the 
materials produced can be used in routine patient care, so there is an immediate and direct clinical 
application from the research in this thesis. 
 
Implications of this study 
 
The implications of this study are twofold; firstly, that patient education has a significant role to 
play in CVD risk factor modification for patients with RA; secondly, that a rigorous and 
theoretically-driven process of development of patient education materials is the approach most 
likely to yield dividends. 
 
Regarding the first implication, current guidelines for patients with RA recommend, in relation to 
their CVD risk, lifestyle advice to encourage smoking cessation, dietary modification, weight 
control, and exercise (1;2); this study adds to the evidence base for the benefits of this 
recommendation.  How to provide this advice effectively to patients with RA, however, is not 
discussed by these guidelines and remains a challenge.  A previous education intervention to 
address CVD risk factors in patients with RA used a one-to-one approach with a specialist nurse 
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who provided generic smoking and dietary booklets and invited patients to a weekly swimming 
group  specifically for patients with arthritis; only modest benefits were observed (5).  The 
benefits observed in our study may relate to one or, more likely, the interaction of several of the 
following strategies that were used; group education; eight-week course duration; advice 
provided within the context of having RA, rather than generic advice; cognitive behavioural 
approach; explicit use of techniques aimed to modify behaviour; role modelling using a 
‘successful’ patient; supporting written and internet resources.  Further research into the 
dynamics of these individual components may allow future guidelines to make more explicit 
recommendations about providing CVD lifestyle advice for people with RA. 
 
With regard to the second implication, the process employed in developing these educational 
resources is transferable both to other RA co-morbidities and other chronic diseases where there 
is a lack of effective educational material.  Indeed, others have also called for a theoretical 
approach to be used in the design of patient education materials in order to improve the efficacy 
of education programmes (6).  Currently, such practice is only reportedly used in a minority of 
published interventions.  Other examples include a patient education programme to encourage 
increased physical activity in those at risk of type 2 diabetes, whose design was underpinned by a 
causal modelling approach (7), a stroke secondary prevention programme (8) or a physician and 
patient education intervention aiming to improve the management of osteoporosis (9), informed 
by qualitative research (10),  and described in detail (11).  The diabetes education and self-
management for ongoing and newly diagnosed (DESMOND) trial is a large UK multicentre 
cluster randomised controlled trial of a structured group education programme; its design and 
development, including explicit use of specific theoretical psychological models, has been 
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described in depth (12).  At 12 months, the intervention participants showed significantly greater 
improvements in weight loss and smoking cessation as well as in illness beliefs (13).  Inevitably, 
some would argue that adopting this advocated rigorous approach to the development of patient 
education resources is both time-intensive and expensive.  However, a cost-effectiveness analysis 
of the DESMOND programme suggested it is likely to be cost-effective compared with usual 
care, even under the more modest assumptions that include the effects of the intervention being 
lost after one year (14). 
 
Limitations of this study   
 
Inevitably, there are limitations associated with the present research.  Many of the limitations 
have already been identified in the individual Chapters.  Overall, this was a single centre study in 
a predominantly Caucasian population.  All the patients involved in the qualitative research phase 
were Caucasian; consequently the education intervention was developed to suit Western lifestyles 
and all educational resources were provided in English in a written format.  While it is possible to 
conceptually generalise from qualitative research and comparisons can be made between similar 
people in similar circumstances (15), the findings of this study cannot be assumed to apply to 
those from a minority ethnic background.  Further, the educational resources may need to be 
adapted to be culturally relevant to minority ethnic groups and their approaches to diet and 
exercise (16); the Chronic Disease Self-management Programme, run in the UK as the Expert 
Patient Programme, was adapted by a local community group before it was delivered to a 
Bangladeshi population (17).  Additionally, educational resources would need to be provided in 
other languages or as an audio compact disc as a significant proportion of people from minority 
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ethnic groups cannot read the script of their spoken language (18).  There may be a particular 
need for this as CVD risk is further increased in people of South Asian origin (19).   
 
Future research 
 
This thesis lends itself to a wealth of future studies.  Initially, the programme could be applied on 
a larger scale to determine whether current results can be replicated.  In the present study, a single 
person led all the educational meetings, which controlled for operator-dependent effects.  
However, to translate this from a research study into an accurate evaluation of the programme in 
a ‘real-world’ setting, a multi-centre study is needed which will require several course 
leaders/facilitators.  Employing allied health professionals to deliver this course is a sensible 
option; using lay people to deliver the course could also be considered.  Training the facilitators 
would be a priority, to ensure adequate knowledge and understanding across both the disciplines 
of rheumatology and cardiovascular medicine; provision of a script for the facilitators would help 
to optimise consistency.  Indeed, the multicentre DESMOND education course provides two days 
of education for their healthcare professional educators (12). The programme could be delivered 
in a more ethnically diverse geographical area, but where participants can still speak and read 
English, or the course could be culturally and linguistically adapted to be delivered to minority 
ethnic groups of people.  Future replications of the course could involve health economists at the 
outset so appropriate data are collected to allow a subsequent cost-effectiveness analysis.   
 
If necessary, another future option would be to modify and shorten the course to improve its cost-
effectiveness.  Existing data could be analysed to identify if attending a critical number of 
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sessions is predictive of a successful outcome.  If so, could the programme be truncated to this 
critical number of sessions?  Could CVD education be a module of a general RA patient 
education programme? If the programme were to become shorter, some content would need to be 
sacrificed; qualitative research with ‘successful’ participants could help identify which aspects of 
the programme were pertinent and helpful and should be retained.  Moreover, the identification 
of these particularly influential factors would be helpful in general for other patient education 
initiatives. 
 
More broadly, future research will also need to include other formats for delivering CVD 
education to patients with RA, as, inevitably, some patients do not like attending group meetings 
(20) or cannot attend them due to other commitments.  In principle, all interactions with 
healthcare professionals provide the opportunity for education (21) but this often needs to be 
supplemented with specific additional resources.  Individual appointments could be available to 
discuss CVD risk management.  For those that prefer a written format (22), the existing education 
course manual (Chapter 8) could be adapted to be used as a hand-out, rather than alongside group 
discussions; the manual can then still pose questions to the reader to prompt deeper thinking 
about their personal lifestyle behaviours which would offer a more cognitive-behavioural 
approach than the information leaflet in Chapter 7 currently does.  For less able readers, Arthritis 
Research-UK currently provides information as ‘mind maps’ whereby information is presented 
more diagrammatically (23); this could be complemented by additional audio-visual resources to 
provide a more complete educational resource.   
 
Conclusion 
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This thesis chronologically describes the identification of a highly prevalent co-morbidity for 
patients with RA, identifies the lack of existing patient education resources necessary to address 
it, and describes an attempt to systematically design, develop and evaluate a complex educational 
programme to meet this need.  The positive outcomes that emerged from the intervention endorse 
the approach taken, and also highlight the beneficial role that patient education can play in the 
long term care of patients with RA.  Future research could evaluate this novel education 
intervention in a larger scale and more ethnically diverse setting, with the ultimate goal of 
integrating the programme into a routine care package for patients with RA.   
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